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ABSTRACT
Parkinson’s disease (PD) is, after Alzheimer’s disease, the second most common 
neurodegenerative disorder. It is characterized by a slow and gradual loss of neurons in specifi c 
brain regions and subsequent loss of neurotransmitter dopamine in the movement-related 
brain tracts. This causes symptoms of PD, which are resting tremor, rigidity and slowness of 
movement. Genetic and environmental factors are linked to PD, but its etiology is still largely 
unknown. Current drug therapies can only relieve the symptoms of PD but treatment to stop or 
delay the disease progression does not exist at the moment. 
The main fi ndings in neuropathological characterization of the brain regions that are infl uenced 
in PD, are abnormal intraneuronal protein inclusions, called Lewy bodies. Insoluble, aggregated 
α-synuclein (aSyn) protein is the most abundant component of Lewy bodies. Pathological 
aggregation and accumulation of aSyn is associated with neuronal death in PD and some other 
brain diseases, named α-synucleinopathies. Therefore, approaches to target aSyn as a potential 
disease-modifying treatment for PD have been under investigation. 
The aim of this study was to examine the role of prolyl oligopeptidase (PREP) and 
pharmacological inhibition of its enzymatic activity by KYP-2047 in aSyn aggregation. 
In the fi rst part, direct protein-protein interaction between PREP and aSyn and its effect on 
aSyn aggregation was studied using purifi ed proteins and cell culture models. We showed that 
PREP interacts with aSyn, thus enhancing its aggregation. PREP inhibition reduced the PREP-
mediated aSyn aggregation in cell culture. 
The second and third parts concentrated on studying the effects of PREP inhibition on aSyn 
aggregation in vivo. The purpose was to fi rst characterize a genetic mouse model, carrying 
mouse A30P mutated aSyn, which is linked to early-onset PD in humans, in order to fi nd out 
if the mutated mouse aSyn is more prone to aggregate; and to cause PD-like phenotype or to 
sensitize the mice for toxicity of 6-hydroxydopamine. Thereafter, the effects of KYP-2047 
treatments were assessed in the model. The main fi ndings were that the A30P mutation in mouse 
aSyn protein caused minor hyperactive behaviour in mice but did not change the brain dopamine 
levels, and A30P aSyn accumulated in the brain more than wildtype (WT) aSyn by age. KYP-
2047 treatment reduced the amount of A30P aSyn in immunohistochemical and Western blot 
analysis. Western blot analysis revealed that the reduction was more specifi c for high-molecular 
weight aSyn oligomers. Furthermore, we observed elevated dopamine levels in the striatum and 
increased autophagy markers in brain tissue. Therefore, PREP inhibition was further studied in 
cell culture, where it was shown to enhance macroautophagic protein clearance pathway, which 
is an important pathway in the degradation of high-molecular weight aSyn forms. 
In the fourth study, the effects of KYP-2047 were examined in a mouse model of PD that was 
based on lactacystin-induced inhibition of ubiquitin-proteasome protein degradation pathway. 
Proteasome inhibition was shown to induce rapid PD-like neurodegeneration recapitulating the 
cardinal features of PD. KYP-2047 treatment partially protected dopaminergic neurons in the 
brain and had benefi cial effect on motor behaviour, but did not have an effect on aSyn amount in 
immunohistochemical analysis.
 
Taken together, the fi ndings of this study have provided new insights into the role of PREP 
in aSyn aggregation and suggest that PREP inhibition has benefi cial effects on reducing the 
aggregation process via two different mechanisms. PREP inhibition could be promising and 
further assessed in the treatment of PD, other α-synucleinopathies and possibly other protein 
accumulation diseases. 
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Parkinson’s disease (PD) was originally described by James Parkinson (Parkinson, 1817) in an 
Essay on the Shaking Palsy. The defi ning symptoms of the patients he observed were muscle 
weakness, resting tremor, bent trunk and abnormal shortened gait. He also  noticed that the 
intellectual and sensory abilities of these patients remained unaltered. PD is the most common 
neurodegenerative movement disorder, and is a slowly progressive disease (Fahn, 2003). It also 
encompasses a variety of other, non-motor, symptoms; mood disorders, sleep disturbances, 
hyposmia and autonomic nervous system dysfunctions (Simuni and Sethi, 2008). Lack of the 
neurotransmitter dopamine (DA) in the striatum (STR) is cause for the symptoms of PD as 
a result of selective and gradual destruction of DAergic neurons in the substantia nigra (SN) 
(Fearnley and Lees, 1991). The symptoms will manifest when approximately 30 % of the 
neurons in the SN pars compacta (SNc) are lost. Surviving neurons in the SN usually contain 
intracytoplasmic proteinaceous inclusions called Lewy bodies (LB), which are important 
neuropathological fi ndings of PD.
Genetic mutations and exposure to environmental toxins, such as pesticides and herbicides, 
have been linked to PD etiology (Wirdefeldt et al., 2011). At the cellular level, mitochondrial 
dysfunction, oxidative stress, protein aggregation, dysfunctional protein degradation and 
infl ammation are thought to be the key mechanisms in PD pathology, but their relations 
remain largely to be elucidated (Fahn, 2003). The characterizing feature of PD pathology is 
the presence of LBs that contain a variety of proteins, of which fi brillar α-synuclein (aSyn) is 
the most abundant (Spillantini et al., 1998). In recent years, the involvement and the role of 
aSyn in PD pathology has been extensively studied. Point mutations, like A30P and A53T, in 
aSyn coding gene (SNCA), and SNCA duplications and triplications are associated with PD 
(Polymeropoulos et al., 1997, Krüger et al., 1998, Singleton et al., 2003, Chartier-Harlin et al., 
2004). aSyn aggregation is a process where its native soluble monomeric form changes into 
oligomeric and fi brillary species and fi nally into aggregates. In addition, the neurotoxicity of 
oligomeric species of aSyn has been proven and many factors affecting the aggregation of aSyn 
have been identifi ed. Currently, LBs themselves are not considered to be the toxic aSyn species 
to the cells but rather represent an end stage of the aSyn pathology. Furthermore, cellular protein 
clearance systems, which participate in degradation of aSyn, are thought to have a potential role 
both in toxic accumulation and benefi cial clearance of aSyn.
A serine protease, prolyl oligopeptidase (PREP), has also been associated with aSyn aggregation 
(Brandt et al., 2008). PREP is expressed in various tissues, it takes part in neuropeptide cleavage 
and potentially has a role in cognition and mood, but its physiological role has remained partly 
unknown. The size of aSyn is too large for it to be digested by PREP, which cleaves small 
peptides on the C-terminal side of proline residue (Gass and Khosla, 2007). However, PREP has 
been shown to enhance in vitro aggregation of aSyn (Brandt et al., 2008) and inhibition of PREP 
enzyme activity reduced the aggregation in cell culture and in vitro models. 
This literature review focuses on the role of aSyn in PD pathophysiology, factors affecting the 
aggregation and deposition of aSyn as well as possible treatment strategies against the formation 
of toxic aSyn species and their accumulation. In order to study this, both good PD cell culture 
Introduction
2and in vivo models are required, and mouse models that are based on aSyn will be overviewed 
here. The experimental part of this thesis concentrates on elucidating the role and mechanisms 
of PREP inhibition in aSyn cellular aggregation in vitro and in the clearance of aSyn in vivo. 
Furthermore, a transgenic aSyn mouse line and a proteasome inhibition-based lesion model will 
be characterized as PD mouse models. 
Introduction
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2  REVIEW OF THE LITERATURE
2.1  α-synuclein
aSyn, together with β- and γ-synucleins belongs to the family of synuclein proteins (Surguchov, 
2008). aSyn was fi rst purifi ed from cholinergic vesicles of Torpedo californica and thereafter 
from rat neuronal tissue in the late 1980s (Maroteaux et al., 1988). aSyn proteins from different 
species were shown to have highly homologous sequences and localization in the presynaptic 
nerve terminal. In birds, a homologous protein, named synelfi n, shares high sequence similarity 
(George et al., 1995). In the early 1990s a precursor protein for non-amyloid-β component 
(NAC) of Alzheimer’s disease (AD) amyloid was identifi ed in human brain (Ueda, 1993), which 
was sequenced and verifi ed to be aSyn (Jakes et al., 1994). The initial fi nding of NAC-fragment 
of aSyn in AD pointed to a possible role of aSyn in AD pathophysiology and led the study 
towards its involvement in neurodegenerative diseases.
2.1.1  Physiological functions of α-synuclein
In immunohistochemical (IHC) and electron microscopy (EM) studies, aSyn has been found to 
be highly expressed in cortex, entorhinal cortex, STR and hippocampus (Hc), and it localizes in 
vesicles in presynaptic nerve terminal areas (Jakes et al., 1994, Iwai et al., 1995). In songbirds, 
synelfi n mRNA and protein expression are shown to increase during critical periods of song 
learning, where in situ hybridization and immunofl uorescence stainings point to a role for 
aSyn in neuronal plasticity (George et al., 1995, Jin and Clayton, 1997). Moreover, songbird’s 
synelfi n localizes in nerve terminals. The fi nding of highly conserved sequence similarity 
between species and prominent neuronal tissue localization highlights the physiological role for 
aSyn in synaptic functions.
aSyn inhibits phospholipase D2 function (Jenco et al., 1998) which has a role in membrane 
organization, vesicle traffi cking and secretion (Colley et al., 1997). It also interacts with acidic 
phospholipid vesicles, which induces aSyn’s alpha-helixity (Davidson et al., 1998, Perrin et al., 
2000, Jo et al., 2000), suggesting a role in cellular processes involving lipid binding, such as 
regulation of synaptic vesicles. aSyn associates with synaptic vesicles (Jensen et al., 1998) and 
regulates the presynaptic vesicular pool in hippocampal neuronal culture (Murphy et al., 2000), 
where knocking down aSyn expression reduced the size of the vesicular pool. Study with aSyn 
knock-out (KO) mice supports the role for aSyn in synaptic maintenance (Abeliovich, 2000). 
aSyn KO mice have normal expression of tyrosine hydroxylase (TH) and vesicular release-
associated proteins; synaptophysin and ras-related protein Rab3a as well as normal morphology 
of neurotransmitter vesicles, suggesting that aSyn is not required for normal neurogenesis of 
DAergic neurons. α-, β-, and γ-synuclein triple-KO mice develop age-associated neurological 
defi cits which highlight the protecting and maintaining function of synuclein family in synaptic 
homeostasis (Burré et al., 2010).
In cell culture experiments aSyn associates with microtubules, it binds to tubulin and 
overexpression of aSyn inhibits microtubule formation suggesting that aSyn also regulates the 
microtubular network (Zhou et al., 2010). Although the results of another study by Chen et al. 
(Chen et al., 2007) do not support the direct interaction between aSyn and tubulin, their results 
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are otherwise similar indicating that aSyn oligomers can disturb tubulin polymerization into 
microtubules.
In the light of current evidence, aSyn seems to be a regulator of neuronal activity and synaptic 
homeostasis but in general the physiological role of aSyn is not yet very well understood.
2.1.2  α-synuclein and dopaminergic neurotransmission
DA homeaostasis in the synapse is regulated by enzymes, transporters and other proteins that 
participate in DA synthesis, metabolism, release and vesicular packing (Nestler et al., 2009). 
aSyn is the main component of LBs, aggregates found in the areas of a PD patient’s brain where 
DAergic cell loss occur (Spillantini, 1997, Spillantini et al., 1998). The role of aSyn in DAergic 
neurotransmission has therefore been studied extensively.
Studies with aSyn KO mice have shown that the striatal DA content as well as response to 
amphetamine-induced locomotion were reduced, while the study showed enhanced recovery of 
DA release after multiple stimuli (Abeliovich, 2000). In another study, where DA release was 
stimulated and burst fi ring was measured by voltammetry, aSyn KO mice showed enhanced DA 
release and enhanced facilitation of DA release between repeated stimuli compared to WT mice 
(Yavich et al., 2004). This data indicates a regulatory role for aSyn in synaptic DAergic balance.
Dopamine transporter (DAT) is the main regulator of synaptic DA content in the STR, and it 
terminates the DA action by reuptaking it from the synapse back to the presynaptic terminals 
(Reith et al., 1997). Several studies indicate a role for aSyn in DAT activity and traffi cking, which 
may be disturbed due to mutated aSyn or its aggregated forms. aSyn interacts with DAT and 
inhibits DAT activity on the cell surface causing a decrease of the magnitude and rate of DAT-
substrates uptake in neuronal cell cultures (Wersinger and Sidhu, 2005, Swant et al., 2011). The 
mutant form A53T aSyn is unable to alter DAT-function (Wersinger and Sidhu, 2005). Higher 
extracellular DA levels in aSyn KO mice have been associated with reduced amount of DAT 
expression and consequently reduced re-uptake of DA (Chadchankar et al., 2011). Aggregation 
of aSyn is associated with increased DAT expression and it causes DAT-redistribution away 
from the plasma membrane in a mouse model expressing truncated aSyn(120) (Bellucci et al., 
2011). The modulatory effects of aSyn on DAT are at least partially mediated by microtubules 
which are important mediators of cellular traffi cking (Wersinger and Sidhu, 2005). Microtubular 
network may be regulated by aSyn and disrupted by its oligomerization (Chen et al., 2007, Zhou 
et al., 2010). 
Soluble N-ethylmaleimide-sensitive-factor attachment protein receptor (SNARE) proteins are 
the major regulators of vesicle endocytosis and intracellular membrane fusion (Südhof, 1995). 
Complexes formed by these proteins are crucial for rapid release of the reserve vesicle pool 
and subsequent fast neurotransmission. SNARE complex assembly is regulated by several 
proteins, one of which is aSyn (Chandra et al., 2005). In cell culture and transgenic (TG) 
mouse studies, aSyn promotes SNARE complex assembly by interaction with synaptobrevin-2/ 
vesicle-associated membrane protein 2 and simulatenously binding to phospholipids (Burré et 
al., 2010). In aSyn overexpressing rat neuronal cell culture, exocytosis of synaptic vesicles is 
reduced as a consequence of a reduced readily releasable vesicle pool size (Nemani et al., 2010). 
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These observations are made with WT aSyn and A53T and E46K mutants, whereas A30P aSyn 
did not inhibit neurotransmitter release. Yet, reduced DA release, suggested to be related to 
reduced amount of dopamine vesicles, has been identifi ed in a TG mouse line expressing A30P 
aSyn (Yavich et al., 2005).
aSyn also has a regulatory role in DA biosynthesis, which is mainly rate-limited by TH enzyme, 
that is responsible for converting tyrosine into dihydroxyphenylalanine (L-DOPA). aSyn 
interacts with TH in brain and aSyn overexpression inhibits its activity via increased protein 
phosphatase 2A-dependent dephosphorylation and subsequently reduces DA in MN9D cell 
culture (Perez et al., 2002, Peng et al., 2005). In the BE2-M17 neuronal cell line, microarray 
and quantitative reverse transcription-PCR study have revealed that overexpression of aSyn 
modulates the expression of many genes related to DA synthesis (Baptista et al., 2003). This 
could be linked to downregulation of Nurr1 (Baptista et al., 2003), an important transcription 
factor in the maintenance of DAergic homeostasis (Jankovic et al., 2005). In MN9D cells, aSyn 
overexpression decreased the activity and phosphorylation of aromatic amino acid decarboxylase 
(AADC), which converts L-DOPA to DA (Tehranian et al., 2006).  
These fi ndings indicate that aSyn is not only an important regulator of normal DAergic 
neurotransmission but its overexpression or aggregation as well as mutated forms most likely 
result in dysregulation of DA homeostasis.
2.2  α-synuclein in pathophysiology of neurogenerative 
diseases
The discovery of the NAC-fragment of aSyn from AD plaques generated interest towards the 
role of aSyn in the pathogenesis of AD. Sequencing techniques and generation of specifi c 
antibodies against aSyn soon revealed that aSyn is the major component in LBs of PD. As 
the antibodies and detection methods evolved, the presence of NAC fragment of aSyn in the 
AD plaques has even been questioned. Evidence linking aSyn in PD pathophysiology will be 
reviewed in the next paragraphs.
2.2.1  α-synuclein in Lewy bodies of Parkinson’s disease and 
other synucleinopathies
Neuropathological characterization of post-mortem PD brain samples has revealed that LBs 
are ubiquitinated intraneuronal fi lamentous inclusions (Goldman et al., 1983, Kuzuhara et al., 
1988). Lewy neurites (LN) that are also associated with the pathology, are abnormal neurites 
containing fi lamentous aSyn, like LBs. Similar inclusions are also present in dementia with 
Lewy bodies (DLB) and multiple system athropy (MSA) (Galvin et al., 2001). In DLB, LBs are 
found in the cortical and subcortical brain regions and the disease is characterized by late-onset 
memory impairment and is often associated with hallucinations or behavioural disturbances 
(Spillantini and Goedert, 2000, Galvin et al., 2001), in the MSAs inclusions are present in 
the oligodendrocytes and they are termed glial cytoplasmic inclusions (Tu, 1998, Spillantini 
and Goedert, 2000). MSAs are clinically characterized by various symptoms from PD-like 
movement defi cits to cognitive decline and cerebellar and autonomic problems. 
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In 1997, IHC stainining revealed that aSyn is the main component of the protein aggregates, LBs, 
in the SN of PD and cingulate cortex of DLB patients’ post-mortem brain samples (Spillantini, 
1997). In immune-EM, aSyn antibody labeled 9-12 nm-thick fi laments of LBs in PD and DLB 
(Spillantini et al., 1998, Arima, 1998). Then, aSyn was shown to exist as a full-length form 
but also in truncated and insoluble forms in the inclusions of PD and DLB (Baba et al., 1998). 
In double label IHC, LBs were more intensively immunoreactive with aSyn antibodies than 
ubiquitin, which had earlier been the most sensitive detection for LB pathology (Spillantini et al., 
1998). aSyn positive inclusions were also shown to be specifi c for neurodegenerative diseases 
exhibiting LB formation, whereas in diseases where intracellular microtubule-associated protein 
tau (Tau) inclusions occur, aSyn did not co-localize with Tau in double label immunofl uorecense 
staining (Takeda et al., 1998). The possible role of aSyn in AD pathogenesis was also questioned 
when new specifi c NAC targeted antibodies failed to stain extracellular AD plaques and aSyn 
was shown only to be present in intracellular LB-like inclusion in mixed DLB/AD and PD cases 
(Culvenor et al., 1999, Bayer, 1999).
During the year when aSyn was identifi ed in IHC analysis of PD brain, the fi rst genetic analysis 
was published, revealing a point mutation A53T in the aSyn coding gene connecting this 
mutation to the familial early-onset form of PD (Polymeropoulos et al., 1997). Since then, other 
genetic missense mutations (A30P, E46K, H50Q and G51D) have been associated with familial 
Parkinsonism, and also duplications and triplications of the SNCA have been discovered from 
other families with PD (Krüger et al., 1998, Singleton et al., 2003, Chartier-Harlin et al., 2004, 
Zarranz et al., 2004, Proukakis et al., 2013, Lesage et al., 2013). The aggregation of aSyn has 
been thereafter extensively studied as a pathological mechanism of PD and other diseases 
displaying LB pathology.
2.3  Mechanisms of α-synuclein aggregation, 
accumulation and toxicity
Structurally aSyn is a natively unfolded protein (i.e. it is intrinsically disordered) (Weinreb 
et al., 1996). It also has a hydrophobic core, which makes it unstable. Conformation of aSyn 
has minor secondary structure making the hydrophobic parts of the protein exposed and more 
prone to form protein-protein interactions, to misfold and self-aggregate. Three regions in 
aSyn contribute to the aggregation; 1) the N-terminal, amphipathic region, which contain the 
PD linked mutations, 2) the hydrophobic NAC-region in the central part, which is required for 
fi brillogenesis and 3) the acidic C-terminal region, which reduces the aggregation (El-Agnaf 
et al., 1998b, Giasson et al., 2001, Bisaglia et al., 2009), (Figure 1). In solution, aSyn forms 
dimers and higher molecular weight conformers as shown with incubation of 125I-labeled aSyn 
(Jensen et al., 1997). Moreover, immunoblotting assay, atomic force microscopy and EM 
studies have shown that fi brils and aggregates form in both a concentration and time-dependent 
manner (Jensen et al., 1997, Hashimoto et al., 1998, El-Agnaf et al., 1998b, Giasson et al., 
1999, Conway et al., 2000a). Prolonged incubation of recombinant aSyn results in a formation 
of 8-10 nm width amyloid-like fi brils which stain positive in thiofl avine-S staining, similarly to 
LBs taken from cortical brain areas (Hashimoto et al., 1998). Similar to aggregation processes 
of other amyloid-like proteins, aSyn undergoes a conformational change from random coil 
structure to βl-sheet conformation during fi bril formation (Serpell et al., 2000). Fibril formation 
7is a nucleation-dependent process, where aSyn may seed its own fi brillogenesis (Wood, 1999), 
but self-oligomerization may occur also in the presence of amyloid beta (Aβ) fragement (25-
35) (Paik et al., 1998). The aggregation process, where soluble aSyn folds, dimerizes, further 
oligomerizes and forms fi brils and aggregates, is illustrated in Figure 2. Although aSyn self-
oligomerizes in solution in time, there are multiple factors that are found to enhance the 
aggregate formation and accumulation of aSyn (Figure 2), which may lead to its toxicity (Figure 
3), and they will be reviewed in more detail in the next paragraphs. 
2.3.1  Genetic mutations and α-synuclein gene duplication and 
triplication
Point mutations, A30P, A53T, E46K, H50Q and G51D, which are associated with PD pathology, 
enhance the aggregation propensity or toxicity of human aSyn (Conway et al., 1998, El-Agnaf 
et al., 1998a, Conway et al., 2000b, Li et al., 2001, Choi et al., 2004, Proukakis et al., 2013, 
Lesage et al., 2013). A30P, A53T and H50Q mutants enhance the fi bril-formation of aSyn as 
shown in atomic force and EM, while A53T and E46K mutations accelerate the fi bril formation 
more signifi cantly than A30P (Conway et al., 1998, El-Agnaf et al., 1998a, Conway et al., 
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Figure 1: α-synuclein regions and structure.  α-synuclein consists of three regions; the N-terminal 
amphipathic region where aggregation accelerating mutations are located (amino acids that are 
known to have PD-associated mutations are marked), the non-amyloid-β component (NAC)-region is 
a hydrophobic part of aSyn and is required for fi brillation and aggregation, whereas the C-terminal 
acidic region protects from aggregation. Phosphorylation of serine at position 129 is a post-
translational modifi cation which is relevant for aSyn fi brillation and associated with PD pathology. 
The schematic representation of the biochemical structure of α-synuclein (bottom) shows α-helical 
N-terminal and NAC- region, whereas the C-terminal region is unstructured (structure of micelle-
bound α-synuclein was determined by solution NMR spectroscopy ID: 1XQ8, was downloaded from 
RCSB Brotein Data Bank and rendered in JMol).
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2000a, Li et al., 2001, Choi et al., 2004, Rutherford et al., 2014). Secondary structure analysis 
with fourier transform infrared spectroscopy of WT, A30P and A53T aSyn proteins has revealed 
that mutated aSyn exists in a more ordered β-sheet fold instead of an unfolded structure, which 
may increase their aggregation potency (Li et al., 2001). 
The E46K mutation enhances the phospholipid binding of aSyn, which could contribute to 
the fi bril formation (Choi et al., 2004). In contrast to other pathogenic mutations, the G51D 
mutation, which is linked to the early-onset rapidly progressing form of PD, does not enhance 
aSyn aggregation, but it has been shown to enhance aSyn toxicity under cellular stress in vitro 
(Lesage et al., 2013, Rutherford et al., 2014). Also C-terminally truncated aSyn (1-120), which 
is present in LBs of PD brain, accelerates the fi bril formation (Crowther et al., 1998, Baba et 
al., 1998, Serpell et al., 2000, Li et al., 2005). Duplications (Chartier-Harlin et al., 2004) and 
triplications (Singleton et al., 2003) of the SNCA gene are associated with familial PD. In the 
cases of triplication, the onset of PD is early whereas duplications are more similar to sporadic 
PD, implicating a dose-dependent aSyn aggregation-tendency.
2.3.2  Post-translational modifi cations
Many posttranslational modifi cations that possibly affect aSyn aggregation and/or accumulation 
have been identifi ed. In LBs aSyn is extensively phosphorylated at position Ser129 (pS129 
aSyn), which also enhances the aSyn fi brillization in vitro (Okochi, 2000, Fujiwara et al., 2002, 
Anderson et al., 2006).  aSyn and phosphorylated aSyn have been found to be ubiquitinated 
in LBs (Hasegawa et al., 2002, Sampathu et al., 2003). Therefore, aSyn ubiquitination may 
have a role in fi bril-formation or is merely a sign of a defective degradation pathway because 
ubiquitination targets proteins for proteasomal clearance. However it has been suggested that 
ubiquitination is more likely to be an event occurring after fi bril and aggregate formation and not 
to directly enhance the aggregation process (Sampathu et al., 2003). It has also been proposed 
that aSyn phosphorylation has a role in its targeting for proteasomal degradation. Using mutant 
S129A aSyn, which does not undergo S129 phosphorylation, Tenreiro et al. (Tenreiro et al., 
2014) showed that cellular clearance of unphosphorylated mutant aSyn inclusions is reduced. 
S129A aSyn also failed to activate the autophagy pathway, which was activated upon WT aSyn 
accumulation. In contrast to aggregation enhancing posttranslational modifi cations, sumoylation 
of aSyn by small ubiquitin-like modifi ers reduces aSyn aggregation by increasing aSyn solubility 
(Krumova et al., 2011, Abeywardana and Pratt, 2015).
Cellular oxidative stress enhances the formation of reactive oxygen species (ROS) and 
consequent formation of reactive nitrogen species (Jenner, 2003, Ischiropoulos, 2009). Reactive 
oxygen and nitrogen species may, among other toxic cellular effects, cause posttranslational 
modifi cations that promote fi brillization of aSyn. Nitrated aSyn species are found in aSyn 
positive inclusions in synucleinopathies in IHC and Western blot (WB) experiments using 
antibodies against nitrated aSyn (Giasson, 2000). Nitration of tyrosine residues of aSyn has 
been shown to induce aSyn folding and secondary structure formation leading to enhanced 
oligomerization, stabilization of oligomeric form and inhibition of fi brillation (Duda et al., 
2000, Uversky et al., 2005). Iron-catalyzed oxidation of aSyn induces aggregation, as shown 
with peroxide in the presence of ferric ion (Hashimoto et al., 1998 and 1999a) or cytochrome c 
or hemin (Hashimoto et al., 1999b). The phenomena can be blocked in vitro by iron chelators 
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or anti-oxidant N-acetyl-L-cysteine. Other metal ions are also linked to enhanced oxidative self-
oligomerization of aSyn (Paik et al., 1999, Rasia et al., 2005). Copper(II)-mediated aggregation 
is dependent on the C-terminus of aSyn (Paik et al., 1999) and is enhanced via acidic lipids, like 
phosphatidylinositol (Lee et al., 2003). Binding of Fe(II). Cu(II) and Pb(II) metal ions to aSyn is 
also enhanced via aSyn phosphorylation (Lu et al., 2011). Although methionine group oxidation 
has been reported to reduce fi brillation (Uversky et al., 2002), this effect is hampered in the 
presence Zn(II) (Hokenson et al., 2004) and may contribute to aSyn toxicity by inhibiting aSyn 
proteasomal degradation (Alvarez-Castelao et al., 2014).
2.3.3  Interactions
DA causes conformational changes in aSyn secondary structure, which promotes its oligomeric 
state (Outeiro et al., 2009). DA has also been shown to stabilize the protofi bril conformer of aSyn 
and prevent the fi bril formation, which prolongs the availability of neurotoxic aSyn conformer 
(Conway et al., 2001). At physiological pH, DA may be oxidized into reactive intermediates 
which promotes the oxidative stress effect and aSyn aggregation (Pham et al., 2009, Chan et al., 
2012).  
Lipid- and protein-protein interactions between lipids or proteins and aSyn may enhance 
the aggregation of aSyn. Acidic lipids such as phosphatidic acid, phosphatidylinositol, 
phosphatidylserine, phosphatidylethanolamine, and arachidonic acid enhance the self-
oligomerization of aSyn (Lee et al., 2003). The lipid or protein binding partner may act 
as a nucleation point or facilitate aSyn folding. Vesicle and lipid rafts-associated protein, 
synphilin-1, interacts with aSyn and enhances its aggregation and toxicity in yeast model 
(Engelender, 1999, Büttner et al., 2010). Therefore, synphilin-1 may facilitate the membrane 
toxicity of aSyn. FK506 binding proteins, which are peptidyl-prolyl isomerases, have also 
been shown to accelerate aSyn aggregation and their inhibition has been shown to reduce aSyn 
aggregation (Gerard et al., 2010). Their infl uence on the aggregation enhancement is facilitated 
via C-terminal prolyl residues of aSyn. Tissue transglutaminase 2, an enzyme that catalyzes 
protein cross-linking, enhances the formation of aSyn aggregates in vitro and in cell culture 
(Junn et al., 2003). Furthermore, PREP enhances aggregation of aSyn in vitro (Brandt et al., 
2008), suggesting that it acts as a seeding point for aggregation. A PREP inhibitor also reduces 
the aSyn aggregate formation in cell culture (Myöhänen et al., 2012).
Heat shock proteins (Hsp) are chaperones that participate in protein quality control, have a role in 
protein folding and reduce protein-protein interactions, which makes them potential drug targets 
for protein aggregation diseases (Feder and Hofmann, 1999). Hsp104 have been shown to inhibit 
aSyn fi brillation and resolve formed aSyn fi brils in vitro and also to reduce A30P aSyn mediated 
neurodegeneration in an aSyn-lentivirus rat model (Lo Bianco et al., 2008). Overexpression of 
Hsp70 together with human aSyn in a TG mouse was shown to have a benefi cial effect on aSyn 
aggregation (Klucken et al., 2004), but overexpression of Hsp70 together with A53T-aSyn in 
double TG mice failed to protect neurons from aSyn accumulation or death (Shimshek et al., 
2010). Similarly, inhibition of Hsp90 causes subsequent induction of Hsp70, which in other 
studies failed to protect against aSyn positive inclusion formation and DAergic cell loss in rat 
aSyn adeno-associated virus (AAV) model (McFarland et al., 2014). However, Hsps increased 
striatal DA content suggesting some positive modulatory effects (McFarland et al., 2014). Of 
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other factors affecting aSyn aggregation, its close relative, β-synuclein inhibits aSyn aggregation 
and toxicity in a double TG mouse line and in double-transfected cell lines, suggesting that 
β-synuclein is an endogenous negative regulator of aSyn aggregation (Hashimoto et al., 2001).
2.3.4  Factors affecting α-synuclein accumulation
Because the missense mutations in the SNCA gene comprise only a small part of PD cases, 
other cellular events over the genetic component most likely lie behind the disease pathology. 
If aSyn is transcribed more than the protein degradation systems are able to handle, it is 
likely that it starts to accumulate. aSyn genetic duplications and triplications are known to 
cause hereditary PD, which suggests that overexpression of aSyn leads to its dose-dependent 
accumulation (Singleton et al., 2003, Chartier-Harlin et al., 2004). In mouse and rat models, it 
has also been shown that TG overexpression of human aSyn together with endogenous murine 
aSyn gene (Snca) or using viral vector-mediated aSyn overexpression causes accumulation of 
aSyn (Chesselet et al., 2012, Decressac et al., 2012b, Oliveras-Salva et al., 2013), but as stated 
already, genetic overexpression of aSyn can explain only a minority of PD cases. Multiple 
protein-clearance pathways in the cell degrade aSyn. Once aSyn starts to aggregate as a result 
of one or many of the above mentioned factors, the cellular protein clearance pathways may be 
Figure 2: α-synuclein aggregation and clearance. In its native form, α-synuclein (aSyn) exists in an 
unfolded monomeric state. Folded aSyn may undergo dimerization and subsequent oligomerization. 
Pore-like oligomers are formed upon membrane-interactions. Fibril-formation eventually leads 
to aggregation. Factors that enhance the aggregation process are written in green. Two protein 
clearance pathways, ubiquitin-proteasome and autophagy-lysosome, participate in α-synuclein 
degradation. α-synuclein-mediated factors that may compromise its own clearance pathway are 
marked with ├. HSP, heat shock protein; LAMP-2A, lysosome-associated membrane protein 2A
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compromised. Decline in the activity of protein clearance systems could also contribute to the 
cellular deposition of aSyn and further promote the aggregation. Therefore, the relevance of 
protein degradation systems in aSyn accumulation will be reviewed next. Relevant pathways in 
aSyn degradation are illustrated in Figure 2.
Ubiquitin-proteasome system
UPS consists of the 26S proteasome, which degrades proteins that are targeted for degradation 
via poly-ubiquitination (Pickart, 2000). Ubiquitinylation of UPS substrates is carried out in 
cycles and is initiated by ubiquitin-activating enzyme E1, followed by ubiquitin-conjugating 
enzyme E2 and fi nalized by ubiquitin-ligase E3 (Haas and Siepmann, 1997). Poly-ubiquitinated 
proteins should have at least four ubiquitins linked to them in order to be targeted to the 26S 
proteasome. The 26S proteasome is formed of two parts, the 19S subunit, which recognizes, 
unfolds and deubiquitinates its substrates, and the 20S core part, which has proteolytic activity. 
Proteins may also undergo proteasomal degradation ubiquitin-independently by the 20S or 26S 
subunit (Jariel-Encontre et al., 2008).
Several studies have shown that aSyn is degraded via UPS. In SH-SY5Y cell culture, UPS 
degrades aSyn after transient transfection and this was blocked with proteasome inhibitor 
β-lactone (Bennett et al., 1999). A53T aSyn was shown to have slower degradation kinetics 
of clearance, suggesting an explanation for its enhanced toxicity and aggregation propensity. 
In vitro, aSyn interacts with the α7 subunit of the 20S proteasome, and aSyn and pS129 
aSyn undergo UPS degradation ubiquitination-independently in aSyn overexpressing or 
pS129aSyn transfected SH-SY5Y cell lines, respectively (Tofaris et al., 2001, Machiya et al., 
2010). Whereas, high-molecular weight (HMW) forms of aSyn, which represent oligomeric 
or larger aSyn species, are not degraded via UPS (Alvarez-Castelao et al., 2014). In rat 
ventral mecencephalic neuronal culture, proteasome inhibition using lactacystin (LC) and 
subsequent immunocytochemistry analysis revealed aSyn positive inclusion bodies (McNaught 
et al., 2002). There are some controversial results about the role of UPS in aSyn clearance. 
Proteasome inhibition in PC12 cell line failed to increase aSyn levels in WB analysis although 
ubiquitin and aSyn positive inclusions were formed when analysed using immunocytochemistry 
(Rideout et al., 2001). Accumulation of aSyn in transfected PC12 cells after LC treatment 
was suggested to be dependent of LC-induced transcriptional activation, which enhances 
aSyn expression (Biasini et al., 2004). It is also suggested that aSyn is not degraded by the 
proteasome in HEK293 cells or TSM1 neurons; Ancolio et al. (Ancolio et al., 2000) showed 
that the amount of soluble monomeric aSyn is not affected by proteasome inhibitors, and it 
does not undergo ubiquitinylation in those cell cultures. Controversial results of different studies 
may be explained by the fact that aSyn is not degraded solely by one protein clearance pathway 
(Ebrahimi-Fakhari et al., 2011) and other clearance pathways may be upregulated when one is 
inhibited. Furthermore, the contribution of different protein degradation pathways for cellular 
protein turnover seems to be cell type specifi c (Klionsky et al., 2008).
Other lines of evidence supporting the role of UPS in aSyn accumulation and PD is from 
post-mortem SN samples of sporadic PD patients where proteasomal activity is shown to be 
decreased (McNaught and Jenner, 2001, McNaught et al., 2003, Tofaris et al., 2003) and of 
IHC and WB experiments, showing the loss of proteasomal 20S α-subunit in the same area 
(McNaught et al., 2002 and 2003). When the effect of aSyn overexpression was studied in cell 
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cultures, aSyn overexpression reduced the activity of UPS in BE-M17 neuroblastoma cells 
(Snyder et al., 2003). Moreover, monomeric (Snyder et al., 2003) or aggregated (Snyder et 
al., 2003, Alvarez-Castelao et al., 2014) forms of aSyn were shown to inhibit 20S proteasomal 
activity. Aggregated aSyn also inhibited ubiquitin-independent and -dependent 26S proteasome 
pathways. Monomeric and aggregated aSyn forms bind to the 19S region of the proteasome. In 
cell culture studies, overexpression of A30P (Tanaka et al., 2001) and A53T (Smith et al., 2005) 
aSyn inhibits proteasomal activity and A30P aSyn enhances LC-mediated apoptotic cell death 
(Tanaka et al., 2001). 
UPS function seems to experience an age-dependent decline in its capacity, since aged aSyn TG 
mice accumulate more aSyn under proteasome inhibition (Ebrahimi-Fakhari et al., 2011). Most 
LBs in human brain usually immunostain positively with ubiquitin (Spillantini et al., 1998, 
Sampathu et al., 2003), which suggests that defects in proteasome function could contribute to 
PD. But ubiquitinated aSyn is found only in the brain tissue fractions, which contain insoluble 
aSyn, and in a normal situation aSyn undergoes ubiquitin-independent UPS degradation 
suggesting that the ubiquitin-dependent aSyn degradation pathway may be important in disease 
states (Tofaris et al., 2003). Sampathu’s (2003) characterization of ubiquitination patterns of 
aSyn in human brain LBs and in vitro suggested that aSyn is aggregated in inclusions before 
ubiquitination. Furthermore, not all aSyn positive inclusions immunostain with ubiquitin in the 
brain areas exhibiting PD and DLB pathology. It is also shown that phosphorylated aSyn in LBs 
(Sampathu et al., 2003, Tofaris et al., 2003) and glycosylated aSyn in normal brain (Shimura 
et al., 2001) are ubiquitinated, suggesting that only some disease-associated posttranslationally 
modifi ed forms of aSyn undergo ubiquitin-dependent degradation.
In summary, this data indicate that ubiquitin-independent proteasomal degradation is important 
for the clearance of monomeric aSyn whereas HMW aSyn does not undergo UPS degradation. 
Overexpression and aggregation of aSyn as well as mutations in aSyn may inhibit UPS, and thus 
contribute to cellular protein accumulation. Furthermore, decline of UPS activity and reduced 
amount of proteasome subunits in the brain is associated with PD, but the relationship of aSyn 
accumulation and UPS dysfunction in the pathogenesis of PD is not yet fully understood.
Autophagy-lysosome pathway
Autophagy-lysosome pathway (ALP) consists of multiple pathways, which degrade proteins in 
the lysosomal compartment of the cell. Two of them are especially relevant for aSyn cellular 
clearance: chaperone-mediated autophagy (CMA) and macroautophagy (hereafter, autophagy). 
CMA substrates are targeted for lysosomal degradation by KFERQ-like peptide sequences 
(reviewed in Dice, 2007, Cuervo and Wong, 2014). Hsp70 is a chaperone protein, which takes 
part in substrate recognition by consensus motif and translocation across lysosomal membrane. 
In order to cross lysosomal membrane, substrate-Hsp70 complex interacts with lysosome-
associated membrane protein (LAMP-2A) receptor, which is localized on the membrane of the 
lysosome. The CMA-substrates need to be unfolded before they are sequestered into lysosomes. 
Ammonium chloride specifi cally inhibits lysosomal protein clearance irrespectively of the 
pathway targeting substrates to ALP. Ammonium chloride treatment in cell culture signifi cantly 
increases aSyn half-life indicating that lysosomal clearance is important for its degradation 
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(Paxinou et al., 2001, Cuervo et al., 2004). There is a specifi c peptide sequence in the aSyn gene 
which targets it for CMA-mediated lysosomal clearance. WT aSyn carrying mutated consensus 
motif or lacking the consensus sequence for CMA targeting exhibits slower cellular turnover 
than WT aSyn in the PC12 cell line (Cuervo et al., 2004, Vogiatzi et al., 2008), the SH-SY5Y 
cell line and in primary cortical neurons (Vogiatzi et al., 2008). A53T aSyn was shown to impair 
CMA-dependent lysosomal clearance in SH-SY5Y and rat-derived PC-12 cell lines (Xilouri 
et al., 2009), which was followed by compensatory induction of autophagy. In differentiated 
SH-SY5Y cells, it produced more generalized ALP impairment and enhanced cell death, which 
could be blocked using autophagy inhibition with 3-methyladenine (3-MA) or silencing of 
autophagy-related gene 5 (Atg5), which is required for autophagosome formation. 
Moreover, silencing of LAMP-2A expression induces aSyn deposition into cells (Vogiatzi et al., 
2008), implicating an important role of CMA degradation of aSyn. A30P and A53T mutations and 
DA-modifi ed aSyn have been shown to have higher affi nity towards LAMP-2A receptor but they 
have reduced translocation into the lysosome thus having reduced CMA degradation (Cuervo et 
al., 2004, Martinez-Vicente et al., 2008). Furthermore, they enhance the accumulation of other 
cellular CMA substrates, which means that they block overall CMA function. S129E aSyn, 
mimicking pS129 aSyn, also has reduced lysosomal translocation capacity as does nitrated, 
oligomeric aSyn (Martinez-Vicente et al., 2008). This could implicate that aSyn mutations and 
posttranslational modifi cations play a role in causing defects in the cellular clearance. 
In aSyn TG mice, CMA is induced under elevated aSyn burden as shown with LAMP-2A 
upregulation (Mak, 2010). LAMP-2A overexpressing cells have higher CMA activity and 
enhanced aSyn turnover in a stably overexpressing SH-SY5Y cell line (Xilouri et al., 2013). 
LAMP-2A overexpression protects cells against AAV-aSyn-mediated toxicity in SH-SY5Y and 
rat cortical neuronal cultures. To support the compensatory roles of different protein clearance 
pathways this study shows reduced macroautophagy activity in the presence of CMA induction. 
In the rat SN, AAV-LAMP-2A protects nigral cells against AAV-aSyn-mediated neurotoxicity.
Autophagy is a conserved pathway in eukaryotes. It usually has low bulk degradation activity 
in basal conditions but it can be highly induced by various stimulations, such as nutrient 
starvation or cellular stress. Autophagy is regulated by different, complex pathways depending 
on starvation conditions of the cell (Yorimitsu and Klionsky, 2005). In autophagy, cellular 
compartments are sequestered into double membrane vesicles, called autophagosomes, which 
are then fused into the lysosome to form the autolysosome for degradation. Mammalian target 
of rapamycin (mTOR)-dependent and independent pathways are important players in autophagy 
induction; inhibition of mTOR induces autophagy (Laplante and Sabatini, 2009) whereas Atg7 
is an important factor in induction of autophagosome formation (Komatsu et al., 2005). 
Pharmacological inhibition of autophagy by Bafi lomycin A1 or 3-MA increases aSyn 
accumulation only minorly whereas autophagy induction with rapamycin markedly increases 
its clearance in inducible WT, A30P or A53T aSyn expressing PC12 cell lines (Webb et al., 
2003). These results suggested that in normal cellular conditions autophagy does not have major 
contribution to clearance of aSyn, but when autophagy is induced, it markedly reduces cellular 
aSyn levels (Webb et al., 2003). In other studies 3-MA has been shown to signifi cantly decrease 
aSyn clearance (Vogiatzi et al., 2008) or not to have an effect on it (Lee et al., 2004).
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In analysis of DLB cortical neuronal samples (and in aSyn TG mice), increased mTOR and 
decreased Atg7 levels together with abnormal appearance of autophagosomes and lysosomes 
indicate that autophagy seems to be impaired in the affected brain areas (Crews et al., 2010). 
Overexpression of WT, but not mutant aSyn, has been shown to impair autophagosome 
formation in the SKNSH cell line and in aSyn TG mouse brain (Winslow et al., 2010). 
In mouse brain, UPS and ALP both have a role in aSyn degradation and there seems to be some 
level of crosstalk between the systems (Ebrahimi-Fakhari et al., 2011). There is also evidence 
that UPS acts as the main degradation pathway in normal as well as with increased aSyn burden 
but autophagy seems to be recruited only under increased aSyn load, as shown with WT and 
aSyn TG mice. The role of lysosomal clearance of oligomeric aSyn intermediates has also 
been studied in COS-7 and SH-SY5Y cell cultures, where inhibiting lysosomal clearance with 
Bafi lomycin A1 reduced the clearance of rotenone-induced aSyn oligomers, whereas proteasome 
inhibition did not alter their clearance (Lee et al., 2004).
Autophagy was shown to be induced after introduction of pre-formed aSyn fi brils (Pff) in the 
HEK293 cell line, while rapamycin enhanced the clearance of these aSyn inclusions, indicating 
the role of macroautophagy in the clearance of fi brils/aggregates (Watanabe et al., 2012). 
Using aSyn Pffs and pharmacological inhibition or induction of autophagy or proteasome in 
HEK293 stably expressing aSyn cell culture, Tanik et al. (Tanik et al., 2013), showed that 
macroautophagy and proteasomes are not able to degrade insoluble aSyn aggregates that were 
seeded by exogenous aSyn Pff’s. They also show that autophagy function is impaired in Pff 
treated cells while aggregated aSyn associates with autophagosome-like structures in cells 
together with impaired degradation of other autophagy substrates. 
In summary, these studies indicate that autophagy has a role in aSyn clearance depending on the 
cellular conditions. It also seems that autophagy could contribute to the clearance of aSyn fi brils 
but not insoluble aggregates.
2.3.5  α-synuclein toxicity
Several pathways are involved in aSyn-associated toxicity, which most likely occurs due to aSyn 
conformational changes, accumulation of toxic aSyn species and fi nally degradation-resistant 
aggregates. Toxic conformations of aSyn disturb normal cellular functions and homeostasis. 
Mechanisms associated with aSyn toxicity are illustrated in Figure 3.
Membrane destabilizing pore-like oligomers
A number of studies have suggested that the prefi brillar or oligomeric form of aSyn is the toxic 
species of aSyn (Gosavi et al., 2002, Schmidt et al., 2012). To support this, A30P and A53T 
aSyn mutants are both shown to have enhanced oligomerization capacity whereas they differ 
in the later stages of the aggregation process; A53T is more prone to fi brillize whereas A30P 
aSyn aggregates more easily, suggesting that the oligomeric form of aSyn is toxic for the cell 
(Conway et al., 2000b).
WT, A30P and A53T aSyn form ring-like protofi brils in vitro, which have been shown to bind 
cellular, vesicular and mitochondrial membranes more tightly than the monomeric form (Ding 
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et al., 2002). A30P and A53T aSyn were shown, by using EM, to promote formation of pore-like 
(A30P) and annular, tubular (A53T) protofi brils (Lashuel et al., 2002). The membrane-bound 
aSyn has also been shown to adopt ring-like/annular structure, which resembles pore-forming 
conformation that has been observed in some bacterial toxins (Ding et al., 2002). In molecular 
modeling, molecular dynamics simulations and biochemical and ultrastructural analysis of 
aSyn, it has been found to undergo a conformational change into a dimer form which may be 
“propagating” in nature, thus facilitating the formation of octameric pore-like protofi brils on the 
membrane surfaces (Tsigelny et al., 2007 and 2012). aSyn protofi brils that have pore forming 
activity are shown to affect membrane conductance of the artifi cial lipid bilayer in ion channel 
measurement (Kim et al., 2009). In cell culture, overexpression of WT and A53T aSyn increased 
cell permeability as measured with the calcein assay (Tsigelny et al., 2012). The cells also had 
increased intracellular Ca(II) levels, and these results are consistent with computer models that 
suggest increased membrane permeability by aSyn. Taken together, these studies propose that 
annular membrane-bound aSyn has membrane permeabilizating properties that contribute to its 
toxicity.
ER stress, mitochondrial dysfunction and apoptosis
Endoplasmic reticulum (ER) stress is induced by incompletely synthetized proteins and buildup 
of misfolded proteins in the ER (Doyle et al., 2011). It induces an activation of different 
pathways, collectively called unfolded protein response, which promote cell survival and quality 
Figure 3: Mechanisms of α-synuclein toxicity. Oligomers and aggregates of α-synuclein may disturb 
normal cellular functions in various ways leading to induction of apoptosis-promoting cascades 
and fi nally cell death (modifi ed from Lashuel et al., 2013, Gallegos et al., 2015). ER, endoplasmic 
reticulum; ROS, reactive oxygen species
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control; autophagy could be one example of an activated quality control pathway. If ER stress 
is prolonged and survival mechanisms fail this may induce apoptotic cell death pathways via 
cytochrome c and caspase-activation. Mitochondrial dysfunction and oxidative stress have been 
linked to PD and toxicity of aSyn (Abou-Sleiman et al., 2006). Mitochondrial outer membrane 
permeabilization and cytochrome c and pro-caspase release into cytoplasm are markers of early 
apoptosis (Kroemer and Reed, 2000, Ott et al., 2002). 
In A53T aSyn TG mice, overexpression of mutated aSyn causes accumulation of toxic aSyn 
oligomers in the ER resulting in pathological ER stress, which is similar to what is observed 
in human PD cases (Colla et al., 2012a and 2012b). In mice, the accumulation of oligomers 
in the ER was reported to precede the onset of the disease symptoms. In cell culture studies, 
overexpressed WT, A30P and A53T aSyn aggregates colocalize with mitochondria in 
immunocytochemistry and immune-EM (Parihar et al., 2009). In addition, aSyn overexpression 
is associated with mitochondrial dysfunction, ER stress, increased levels of ROS, NO and Ca2+ 
and decreased UPS activity (Smith et al., 2005, Parihar et al., 2008 and 2009). Inducible A53T 
aSyn overexpression was shown to promote cell death via caspase 3 and 9- activation (Smith et 
al., 2005).
aSyn interferes with protein secretion which is a sign of defect in ER-Golgi transport (Winslow 
et al., 2010). aSyn overexpression (Winslow et al., 2010) or oligomers (Gosavi et al., 2002) 
have also caused Golgi fragmentation in cell culture, which led to subsequent cellular traffi cking 
impairment as noted with reduced cell surface expression of DAT (Gosavi et al., 2002). 
Impairment of cellular traffi cking has also been reported to be associated with aSyn oligomer-
mediated disturbances in the microtubular network (Wersinger and Sidhu, 2005, Chen et al., 
2007, Zhou et al., 2010).
Dysfunction of protein degradation pathways
Different aggregation states of aSyn may also cause dysfunction of autophagy-lysosome and 
ubiquitin-proteasome protein clearance pathways, potentially leading to enhanced accumulation 
of aSyn itself as well as other substrates of these pathways (Betarbet et al., 2005, Ebrahimi-
Fakhari et al., 2011, Lynch-Day et al., 2012). Compromised degradation of misfolded and 
damaged proteins in the cell harms cellular functions and homeostasis (Vilchez et al., 2014). 
aSyn degradation pathways were reviewed more thoroughly in the previous chapter.
2.4  Propagation of α-synuclein pathology
Neuropathological characterization of aSyn immunostained PD and DLB patients’ brain and 
incidental LB cases, the latter representing non-symptomatic or early stage of PD, has revealed 
that the amount of LBs and LNs increases during disease progression (Del Tredici et al., 2002, 
Braak et al., 2003 and 2004, Jellinger, 2004). The LB pathology seems to proceed anatomically 
from the dorsal IX/X motor nucleus and intermediate reticular zone towards the lower brainstem 
and eventually reaching up to the cerebral cortex. Clinical PD symptoms usually fully manifest 
at Braak stages 5-6 (Figure 4) (Braak et al., 2003 and 2004).
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Figure 4. Progression of α-synuclein pathology in the human brain. Braak stages 1-6 represent 
different phases of pathology, which starts from the lower parts of the brain and slowly progress 
towards cortical areas. The darkness of the color represents the amount of pathology observed in 
the areas at different time points (Adapted by permission from Macmillan Publishers Ltd: Nature 
Reviews Neurology, Doty, 2012).
Although there is a substantial amount of evidence that aSyn LB formation and DAergic neuron 
loss correlate, there seems to be variation between the cases, especially in subjects with a 
LB-presenting condition other than PD. LB accumulation was shown to be more pronounced 
in the cortical areas of the patients with non-tremor dominant PD, suggesting a variation of LB 
spread and load between types of PD (van de Berg et al., 2012). It has also been reported that 
DAergic neuron loss may occur before aSyn pathology in cases of incidental LBD (Dijkstra et 
al., 2014). Although this was not the case with PD brains in the same study, where the authors 
confi rmed the earlier fi ndings that DAergic neuron loss occurs as the aSyn-containing inclusions 
appear in the SNc. 
Transplantation of fetal nigral grafts into putamen to replace loss of DA of the PD patients 
proved to improve motor function in short term studies (Kordower et al., 1995, Hauser et al., 
1999). The interest towards the progressive and propagating nature of aSyn pathology was 
initiated when aSyn and ubiquitin positive LBs and LNs were found in the 10 - 16-years old 
striatal neuronal grafts in post-mortem PD patients (Li et al., 2008, Kordower et al., 2008a and 
2008b, Chu and Kordower, 2010). The accumulation of aSyn in the grafts also correlated with 
decreased DAT function and worsening of PD symptoms (Chu and Kordower, 2010).
In the studies exploring aSyn cell-to-cell transmission, it is shown to be released from aSyn 
overexpressing cells (Desplats et al., 2009, Hansen et al., 2011, Kisos et al., 2012) and 
transferred into cocultured cells in cortical neuronal stem cell culture, in SH-SY5Y derived 
cells (Desplats et al., 2009) and in HEK293 and SH-SY5Y cell lines (Hansen et al., 2011), but 
also in the oligodendrocytic cell lines Oli-neu and OLN93 (Kisos et al., 2012). Extracellularly 
introduced synthetic Pffs are taken up from culture medium into cortical neurons (Lee et 
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al., 2008), mouse cortical neuronal stem cells (Desplats et al., 2009), primary neuronal cells 
(Volpicelli-Daley et al., 2011) and in HEK-293 cells (Luk et al., 2009), where they are able 
to form LB-like inclusions. The pathology also recapitulates posttranslational modifi cations 
observed in PD, aSyn phosphorylation and ubiquitination (Luk et al., 2009). Oligodendocytic 
cell lines, Oli-neu and OLN93, primary oligodendrocyte cultures from rat brain (Kisos et al., 
2012) and astrocytes, microglial cells and BV2 microglial cells (Lee et al., 2008) also take up 
extracellular aSyn (Kisos et al., 2012). 
In primary neuronal cell culture, Pffs recruit endogenous aSyn to form insoluble PD-like LB 
and LN inclusions. Fibrils derived from either mouse or human full-length aSyn or truncated 
aSyn forms 1-120, 58-140 or 61-95 (NAC domain) were all able to seed the pathology/
insoluble aggregate formation, which occurs time-dependently (Volpicelli-Daley et al., 2011). 
aSyn cellular uptake seems to be endocytosis-dependent because it is blocked or reduced by 
inhibitors of clathrin-mediated endocytosis, dynasore and monodansylcadaverine, respectively 
(Hansen et al., 2011). Clathring silencing, which also inhibits chlathrin-mediated endocytosis, 
reduces aSyn uptake (Kisos et al., 2012). This data indicates that aSyn can be internalized into 
cells where it may act as a nucleation core to recruit endogenous aSyn for further aggregate 
formation. Moreover, cytochalacin D, an inhibitor of clathrin-independent endocytosis did not 
have an effect on aSyn internalization supporting the role of clathrin-mediated endocytosis in 
aSyn cellular translocation (Ahn et al., 2006). However, there might also be other routes for 
aSyn translocation into cells, because endocytosis inhibition under reduced temperature did not 
reduce its cellular penetration. 
Seeding of LB/LN pathology and aSyn spreading to connected brain areas is observed in 
mouse models. In human aSyn overexpressing mouse brain, human aSyn propagates into 
hippocampally (Desplats et al., 2009) and striatally (Hansen et al., 2011) grafted mouse 
neurons, which do not express human aSyn endogenously. Additionally, tissue homogenates 
derived from brainstem and spinal cord from symptomatic (aged over 12 months) human A53T 
aSyn overexpressing mice (line M83), which were stereotactically injected into the neocortex 
or STR of non-symptomatic mice, were able to induce bilateral LB/LN pathology 3 months 
after injection (Luk et al., 2012b). The pathology spread distally from the injection sites in 
cortex, thalamus, brainstem and major whitematter tracts. Host aSyn expression is required for 
the pathology to occur because injection of Pffs into aSyn KO mice did not result in inclusion 
formation. In non-TG mice, striatally injected recombinant aSyn Pff spread into interconnected 
brain areas within 30 days post-injection and LB/LN pathology was visible at 90 to 190 days 
post-injection (Luk et al., 2012a). Spreading of LB/LN-like pathology is also seen after injection 
of aSyn Pffs or homogenate from DLB brains into the SN of C57BL/6J mice (Masuda-Suzukake 
et al., 2013). Recombinant pre-formed aSyn monomers, oligomers and fi brils are taken up by 
oligodendrocytes in vitro and in vivo after injection into mouse cortex (Reyes et al., 2014). aSyn 
also transferred into grafted oligodendroglial cells in rat brains. This may have relevance in 
MSA pathology, which is associated with aSyn accumulation into oligodendrocytes. 
Altogether, aSyn transmission from neuron to neuron and neuron to glia has been demonstrated 
in vitro and in vivo. Once introduced into cell culture or brain, exogenous PD-associated species 
of aSyn are able to recruit endogenous aSyn into pathological species. When triggered, aSyn 
pathology has been shown to propagate throughout the brain.
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2.5  α-synuclein as a drug target
There is a considerable amount of evidence suggesting that the neurotoxic form of aSyn is the 
oligomer (Feng et al., 2010, Winner et al., 2011, Rockenstein et al., 2014), which is able to 
propagate throughout the brain via prion-like mechanisms (Desplats et al., 2009, Crews et al., 
2010, Danzer et al., 2012). Although there is no evidence of over-production of aSyn in sporadic 
PD, aSyn overexpression caused by SNCA duplications and triplications (Singleton et al., 2003, 
Chartier-Harlin et al., 2004) enhances its accumulation in neurons. Another signifi cant factor in 
aSyn buildup are defects in protein degradation systems (McNaught et al., 2003, Crews et al., 
2010, Winslow et al., 2010, Metcalf et al., 2012, Tanik et al., 2013). Furthermore, aSyn cellular 
deposition is thought to lead to secretion and pathological spreading of aSyn (Lee et al., 2010b, 
Alvarez-Erviti et al., 2011, Danzer et al., 2012, Lee et al., 2012, Luk et al., 2012a). Therefore 
the disease-modifying treatment options targeting aSyn in synucleinopathies aim to reduce the 
amount and formation of oligomeric aSyn in the neurons and/or to prevent the extracellular cell-
to-cell transmission of aSyn (Outeiro and Kazantsev, 2008, Masliah et al., 2011, Lashuel et al., 
2013, Valera and Masliah, 2013). Possible treatment strategies targeting aSyn are illustrated in 
Figure 5.
Figure 5: Drug targets against α-synuclein toxic oligomer formation, cellular accumulation and 
cell-to-cell propagation. I) reduction of protein expression, II) enhancing the proteolytic clearance, 
III) reduction of oligomer and aggregate formation, IV) inhibiting aSyn secretion and pathological 
spreading, V) inhibition of aSyn uptake into neighboring cells, VI) modulation of aSyn-induced 
infl ammatory responses. CMA, chaperone-mediated autophagy
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aSyn overexpression or expression when aSyn degradation is compromised could be 
suppressed by RNA interference, which is a tool to silence gene expression by preventing the 
protein synthesis. RNA interference promises to be a feasible way to reduce aSyn amount and 
consequently reduce its aggregation potential. Small interfering RNAs against aSyn have been 
tested in the monkey brain where they provided effective aSyn reduction and were proved to 
be safe (McCormack et al., 2010). AAV-mediated aSyn silencing also proved to be effective in 
rat, but the silencing vector had some neurotoxic effects, questioning the safety of AAV-vector-
mediated drug delivery (Khodr et al., 2011 and 2014).
An approach to prevent oligomer formation and aggregation are molecular stabilizers of the 
native conformation, such as chaperones and small molecules. At least in theory, chaperones 
participate in protein unfolding, reduce aggregation and target proteins for degradation, and 
Hsps have been under investigation for the treatment of PD but the results of their effi cacy in 
animal models have been controversial (Auluck et al., 2002, Ono et al., 2009, Shimshek et al., 
2010). 
Approaches to promote the cellular proteolytic clearance of aSyn include 1) modulation of 
endogenous factors that have been shown to directly cleave aSyn, like neurosin (Iwata et al., 
2003) and matrix metalloproteinases (Sung et al., 2005) 2) proteasome or autophagy activators, 
3) enhancers of lysosomal storage-associated protein, glucocerebrosidase, activity (Schapira, 
2015), and 4) active and passive immunization against aSyn (Masliah et al., 2005 and 2011). 
Active immunization induces an immune reaction against aSyn and has been proposed as an 
option to reduce intracellular aSyn accumulation (Masliah et al., 2005). Mice expressing human 
aSyn (Masliah, 2000) were vaccinated with human aSyn. They developed antibodies against 
human aSyn, and showed sequential reduction of neuronal aSyn accumulation. In passive 
immunization, antibodies targeted against a specifi c sequence of the protein are introduced 
into an organism. It is proposed that the antibodies could recognize the secreted form of aSyn 
or membrane-bound aSyn therefore reducing the toxic form of aSyn. Passive immunization 
was tested in the above mentioned mouse line, where it was proved to reduce neuronal aSyn 
accumulation and associated with improved performance in behavioural tests (Masliah et 
al., 2011). Passive immunization was also shown to induce microglial aSyn clearance and 
reduce cell-to-cell transmission of aSyn (Bae et al., 2012). PD vaccinations have further been 
developed commercially under a company, AFFiRiS, and their vaccination intended for active 
immunization against aSyn have been shown to reduce aSyn and have benefi cial effects related 
to aSyn pathology in multiple aSyn overexpressing mouse models (Schneeberger et al., 2012, 
Mandler et al., 2014 and 2015).
2.6  α-synuclein-based mouse models in the modeling of 
Parkinson’s disease
In the previous chapters I have reviewed aSyn pathology, fundamental fi ndings in human PD 
and other α-synucleinopathies, and mechanisms of aSyn aggregation and propagation. To study 
these phenomena, it is essential to build disease models, which recapitulate the human condition 
as closely as possible including pathological hallmarks and measurable behavioural features 
(face validity of the model) (Beal, 2010, Chesselet and Richter, 2011)). A model should also be 
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based on a known cause of the disease, such as triplication of SNCA gene (construct validity) 
(Chesselet and Richter, 2011). Furthermore, predictive validity of the animal model would tell 
that it is responsive for a treatment that has been proven to also be effective in human – the model 
predicts symptomatic effi cacy. Current therapeutic focus is also largely on neuroprotective effect 
of new drugs, but predictive validity of a model on neuroprotection cannot be established until 
the therapy is validated in clinic.
In the sense of cost-effective drug discovery, it would be important to generate a model with a 
short disease course (Beal, 2010). A suitable PD animal model should aim to produce progressive 
and selective DAergic neurodegeneration, with loss of striatal DA and SNc cell bodies. 
Accumulation of ubiquitin, aSyn and phosphorylated aSyn into LB-like fi brillar inclusions, at 
least in the brainstem and SN, should be the distinguishing feature of the model. Behavioural 
observations should include reduced grip strength, shortened gait, hypolocomotion, postural 
instability and tremor. Using pharmacological tools, altered responses to pharmacological 
challenging of DAergic system or reduction of the behavioural symptoms with levodopa 
could be observed. Other behavioural measures could monitor non-motor symptoms, like 
sleep-wake rhythm, hyposmia and constipation assuming that relevant brain or other areas 
are affected. Although many models have been established in order to mimic aSyn pathology 
and neurodegeneration in mice, the challenge has been to comprehensively recapitulate the 
above-mentioned characteristics. Next chapters will review PD mouse models that are based on 
transgenic or viral vector-mediated aSyn overexpression or toxin-induced aSyn accumulation.
2.6.1  α-synuclein transgenic mice
Since aSyn gene duplications, triplications and mutations have been linked to PD, it is reasonable 
to use TG overexpression of aSyn as a genetics-based approach to study the role of aSyn in PD 
pathogenesis. There are many fundamental differences in the used models which will affect the 
mouse phenotype; is the type of used aSyn mutated, truncated or WT, expression promoters and 
homozygous or heterozygous expression will all have their infl uence. Different TG aSyn mouse 
lines are collected into Table 1. The expression promoters guide the transgene expression to 
desired cell types that should be brain neurons in PD models. The expression pattern between 
different promoters varies markedly. Commonly used promoters are mouse brain neuron specifi c 
elements from Thy1.2 glycoprotein (Thy1), mouse prion promoter (PrP) and platelet-derived 
growth factor β (PDGFβ). In a study comparing Thy1 and PDGFβ promoters, Thy1-driven 
expression was higher and seen in Hc, neocortex, olfactory system, brainstem and SN, whereas 
PDGFβ-driven expression was observed to be highest in the Hc, neocortex and olfactory system 
but low in SN and brainstem  (Rockenstein et al., 2002). PDGFβ-driven aSyn expression was 
also observed in glial cells and therefore it could resemble some aspects of MSA pathology. PrP-
driven expression was observed in spinal cord, brainstem, deep cerebellar nuclei, white matter 
and thalamic areas but not in SN (Lee et al., 2002). aSyn expression using calcium/calmodulin-
dependent protein kinase IIα (CaMKIIα) promotor resulted in an expression in olfactory bulb 
(OB), cortex, STR, Hc, thalamus, ventral tegmental area (VTA) and SN (Nuber et al., 2008). 
In the same study, PrP promoter was compared, and it resulted in much weaker expression in 
those areas. Thus, it is not only the promoter which will affect the expression pattern and level, 
but also the method of how the TG mouse is produced. In order to target DAergic neurons more 
specifi cally, pituitary homeobox3 (PITX3), TH and DAT promotes have been used in TG mouse 
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models (Tofaris et al., 2006, Bellucci et al., 2011, Lin et al., 2012, Chen et al., 2015). They 
produce high to moderate expression in SN, VTA, STR and OB. In conclusion, distinct mouse 
strains exhibit differentiating expression patterns and levels of aSyn, which may be explained 
by the expression promotor and method of making the transgenic strain. This may infl uence the 
face validity of the model.
Usually human aSyn is overexpressed in the mouse background strain, which either has or does 
not have endogenous aSyn expression. The A30P mutation has also been inserted in the mouse 
Snca gene (Plaas et al., 2008). Several mouse lines are made to express WT, A30P or A53T 
mutated aSyn, and also a double mutated mouse line has been developed. In some studies they 
have been compared, and A53T seems to produce more toxicity than WT or A30P (Lee et al., 
2002, Giasson et al., 2002, Kurz et al., 2010), while A30P accumulates at the same level as 
WT (Kahle et al., 2001, Lee et al., 2002). Mouse lines expressing C-terminally truncated aSyn, 
aSyn(120) (Tofaris et al., 2006) and A53T aSyn(130) (Wakamatsu et al., 2008), which has been 
shown to be part of the LBs in human, have also been generated. They both express truncated 
aSyn under TH promoter, and show aSyn accumulation in TH+ SNc neurons associated with 
SNc neuron loss. In addition, both models showed hypolocomotion in locomotor activity test. 
In the model of Tofaris et al (Tofaris et al., 2006), there were aSyn and Thiofl avin S-positive 
LB-like inclusions present in SN neurons, which were shown to be insoluble aggregates by urea 
extraction and aSyn WB. 
The toxicity of aSyn seems to be dependent both on the expression level of aSyn which is 
guided by the promoter, as well as on gene dosage by homozygosity versus hemi/heterozygosity. 
Homozygous animals show more severe and earlier pathology (Neumann et al., 2002). When 
aSyn was expressed at the normal level relative to endogenous mouse aSyn expression, no 
toxicity or abnormalities were observed in mice homozygous to human S129AaSyn or S129D 
aSyn (Escobar et al., 2014). 
In order to recapitulate human PD characteristics, the mouse line should show age-dependent 
accumulation of aSyn and LB pathology in the SN. Various mouse lines show high or moderate 
aSyn expression throughout the brain, and accumulation is seen in the SN (Tofaris et al., 2006, 
Lim et al., 2010, Chesselet et al., 2012, Lin et al., 2012), but quite often the expression seems 
to be minor or absent in the SN area (Masliah, 2000, van der Putten et al., 2000, Giasson et 
al., 2002, Neumann et al., 2002, Rockenstein et al., 2005). aSyn pathology is generally seen 
in cortical and hippocampal brain areas, which resembles DLB pathology. aSyn accumulation 
in the Hc results in minor to moderate memory and learning impairment (Nuber et al., 2008) 
whereas accumulation in OB is connected with olfactory defi cit (Farrell et al., 2014). Some 
models also show gross spinal cord motor neuron aSyn pathology associated with motor neuron 
disease which leads to fast paralysis and death in a few weeks from the onset of the symptoms 
(van der Putten et al., 2000, Martin et al., 2006). This is not a phenotype associated with PD 
pathology in humans, which is slow-progressing and does not have an effect on motor neurons, 
although it provides information about aSyn toxicity.
The LB-like aSyn pathology, characterized by proteinase K (PK)-resistant aSyn inclusions 
observed in IHC or detergent-insoluble aSyn in WB, aSyn phosphorylation and possible 
ubiquitination seem to associate with neuronal loss in different brain areas (van der Putten et 
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al., 2000, Neumann et al., 2002, Martin et al., 2006, Freichel et al., 2007, Ikeda et al., 2009, 
Clark et al., 2010, Lim et al., 2011, Chesselet et al., 2012, Farrell et al., 2014). Some of the 
studies have shown fi ndings of reduced TH staining in the SN and striatal DA content associated 
with aSyn pathology (Masliah, 2000, Tofaris et al., 2006, Ikeda et al., 2009, Ono et al., 2009, 
Chesselet et al., 2012), whereas some fail to show any effect or the effect is mild on nigral TH 
positive neurodegeneration, as may be expected if no major aSyn pathology exists in the area 
(Neumann et al., 2002, Nuber et al., 2008, Kurz et al., 2010). 
Studies comparing A53T aSyn to WT and/or A30P aSyn TG models did not generally fi nd motor 
behavioural defi cit in WT and A30P aSyn expressing mice whereas A53T has more pronounced 
pathology (Lee et al., 2002, Giasson et al., 2002, Lim et al., 2011, Chen et al., 2015). In some 
models hyperactive and anxiety-like behaviours were observed (Bellucci et al., 2011, Lin et al., 
2012, Chesselet et al., 2012, Farrell et al., 2014), which indicates the imbalance of DAergic 
system of the brain and is suggested to be related to impaired DAT traffi cking and dysregulation 
of DAergic signaling. In TG mice, typical fi ndings of impaired motor performance are diffi culties 
in challenging motor tests: rotarod, beam walk and pole test, and reduced activity in horizontal 
and vertical movement test (Tofaris et al., 2006, Chesselet et al., 2012). These usually develop 
in mice over 12 months old. 
aSyn overexpression produces varying pathology depending on gene dosage, expression site 
in the brain and type of aSyn. Common challenges with the TG expression of aSyn seem to be 
to direct the expression in the SN, recapitulate the LB-like inclusion formation and progressive 
neurodegeneration in the SNc. Although the models overexpress moderate to high levels of 
aSyn, the disease phenotype progression in mice is not always comparable to human; phenotype 
of motor decline may not present itself as it does in human or it is not progressive, and in some 
cases it may present itself as a motor neuron degeneration. Moreover, the TG aSyn models 
usually overexpress either WT or mutated human aSyn, whereas most of the sporadic PD cases 
do not have pathophysiological overexpression of aSyn.
2.6.2  Viral vector-mediated α-synuclein gene-delivery
An approach to target the gene expression more locally in the brain is to use stereotactic injection 
to deliver the viral vectors containing the desired gene directly in the brain. Viral vector is 
utilized to transduce the gene of interest in the desired neurons without being toxic to neurons 
themselves. Lentiviruses (LV) and AAV are most commonly used as gene delivery systems. The 
overall difference appears to be that LVs have longer-lasting expression capacity than AAVs, but 
in AAV vectors the overexpression starts quicker.  Nowadays, AAV is preferred over LV because 
it is considered to be a safer option. The transduction effi cacy of viral vector preparations is 
defi ned, in addition to vector origin, by promoter elements, which have different strengths and 
may vary on the cell type specifi city, and the titer of the purifi ed vector. AAVs have a variety of 
serotypes, which are shown to have different transduction capacities in mice (Korecka, 2010). In 
mice, neutralizing antibodies against viral vectors have been detected, which could decrease the 
transduction and therefore prevent the expression of the gene (Rapti et al., 2012). 
Much greater number of TG mouse models than viral vector-based models exist. An explanation 
could be that the TG models are more common in mice whereas a lot of viral vector studies have 
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Table 1: Transgenic aSyn-based mouse strains






aSyn expression Pathology DAergic system Other
 A30P aSyn
(heterozyg 31 & 18)
WT aSyn 




defi cit up to age 
12 m
A30P: 2x 
accumulation  into 
neurites and cell bodies: 
Purkinje cells, nucleus 
dentatus, SN, STR, Hc, 
neoctx, and brainstem
Both: cytosolic and 
neuritic accumulation, 
no LBs, but swollen 
neurites present,
detergent-insol aSyn




heterozyg 31 & 18) /  













& tail posture to 
paralysis of the 
hind limbs
zona incerta, superior 
colliculus, deep 
mesencephalic
reticular fi eld, central 




PK-resistant & paSyn 
, ubiq+ (fi brils) in 
brainstem, midbrain and 
spinal cord
Hom 9 m, het 24 m
12 m: somal & neuritic 
pathology in amygdala 
some in motor 
& somato-sensory ctx
DA normal at 24 m/het, 
and at 8 m/hom




Neumann et al., 





ND Increased brain aSyn 
expression
12 m: no LB/LN, 
intra-cellular aSyn 
accumulation in ctx, 
Hc, SN
normal TH,
DA storage capacity ↓
Jäkälä et al., 2002, 
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aSyn expression Pathology DAergic system Other















SNc (3.4x), Thalamus 
(6x), DG, Hc CA1-
3, OB & olfactory 
nucleus, orbital/ 
association ctx, motor 
ctx, sensory ctx






STR, ctx, frontal ctx, 
and Hc
6 m: 
STR extracellular DA & 
3-methoxytyramine ↑
14 m: 
STR DA 40% ↓
TH:
WB, 23% ↓ 
IHC 17% ↓
ND Rockenstein et 
al., 2002, Fleming 
et al., 2004 and 
2008, Fleming 
and Chesselet, 
2006, Wang et al., 
2008, Wu et al., 
2010, Lam et al., 
2011, Kudo et al., 












cerebral ctx and 
cerebellum
Cytoplasmic inclusion 






17 m: STR DA 20%↓
ACh ↓
Thalamus DA & 5-HT ↓ 
SN TH+ neurons
12 m: WB TH 30% ↓
STR DA 40%↓
16 m: Cerebellar 
astrocytosis
Ikeda et al., 2009, 
Ono et al., 2009










brainstem, Hc CA1 & 
spinal cord
LB-like pathology 
in spinal cord 
motoneurons, 
ubiq.+  & p-tyrosine +




in spinal cord motor 
neurons








motor response to 
D-amph ↑




12-14 m: pathological 
alterations in SN, neur-
ites, perinuclear aggre-
gates and inclusions
3-12 m: STR 
DA & HVA 30%↓
12 m: STR & SN 
abnormal DAT distri-
bution 
STR DAT 59% ↑
ND Tofaris et al., 
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aSyn expression Pathology DAergic system Other
A53T aSyn(130) trun-
cated (1702)







1.5 x in soma, axons 
and nucleus.
SNc , VTA and NAcc 
and STR terminals
ND 8 w human A53T aSyn 
(130) : SNc TH+ neu-
rons 
45%  ↓, not progressive
rt-PCR: TH, DAT & 
c-ret ↓
STR DA & HVA 50 
% ↓
GAD1 and GFAP nor-
mal








human aSyn expression 
in nerve terminals
2 m: IHC  inclusions 
in neoctx, Hc CA3, 
OB  some in SN TH+ 
neurons





STR: TH+ terminals 
(IHC), total TH  (WB), 
TH activity ↓
STR: TH+ terminals 
45% ↓
DAT+ terminals 43 % ↓
IHC: also in glial cells Masliah, 2000, 
Rockenstein et al., 





ND high expression in 
neoctx & Hc, 
lower level in brain-
stem, thalamus, basal 
ganglia and cerebellum
Large cytoplasmic in-
clusions and granular 
aggregates
Presynaptic synapto-















Memory defi cit 
(impaired contex-




A53T: 2-5x  
OB, ctx, STR, Hc, thal-
amus, VTA, SN 
4 m: abnormal aSyn in 
IHC
20–22 m: ↑ in  neoctx, 
Hc CA1, cingul & en-
torh ctx
ThioS+ inclusions,
aSyn in FA-insol. WB
paSyn ↑ ubiq ↑
ND 14 days:  
NeuN+ cells in DG & 
Hc ↓
caspase-3 activation
21 days: Synaptic loss
Progressive gliosis 
(GFAP)
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aSyn expression Pathology DAergic system Other
aSyn 
Conditional KO /
CaMKIIα or  PrP /
C57BL/6 /
18 w: rotarod ↓
Motor learning ↓
Long-term mem-
ory defi cit; Morris 
water maze ↓
OB, ctx and basal 
gaglia ↑ (WB) 
CaMKIIα driven ex-
pression ↑ than PrP
Colocalization of aSyn 
and TH in OB and SN
CaMKIIα aSyn
25 m: 
DA in OB ↓
normal in STR or mid-
brain
ND Nuber et al., 2008
A53T aSyn
(M83 ja M91) 




 “model of aSynucle-
inopathy”
7 m homozygous 
A53T: disease start 
and proceed in 10-
21 to mice being 
unable to feed 
themselves.
No disease pheno-
type in WT mice
Similar expression 
pattern between mouse 
and human aSyn
A53T: inclusions in, 
spinal cord, brainstem, 
deep cerebellar nuclei 
& white matter, 
neurites in STR, motor 
ctx,
10-11 m: fi lamentous 
inclusions (IEM), in 
deep cerebellar nuclei 
& spinal cord
ND Astrocytic gliosis, 
(GFAP IHC)
Giasson et al., 
2002, Betemps et 
al., 2014
WT aSyn





A53T: Onset of 








sis leading to death 
in 21 days




cumulation in neuronal 
cell bodies and neurites 
in midbrain, brainstem 






insol. HMW aSyn in 
brainstem, dendritic 
aSyn inclusions with 
abnormal mitochondria
A30P: high expressing 
line, accumulation in 
cell bodies, but no ubiq-
uitin accumulation
ND GFAP ↑
A53T (G2-3) 9-15 m: 
motor neurons 75% ↓
Brainstem & spinal 
motor neurons IHC
cleaved caspase-3 ↑ 
spinal motor neurons 
p53 ↑
Symptomatic A53T: 
ER stress & caspase-12 
activation
Lee et al., 2002
used also in 
Martin et al., 










aSyn expression Pathology DAergic system Other
A53T aSyn 
(PrPmtA & B)





length and grip 
strength ↓
human aSyn in neu-
ropil, cell bodies & 
neurites
A53T aSyn:  abnormal 
distribution OB, ce-
rebral ctx, STR, basal 
forebrain, Hc, midbrain, 
pons, medulla oblonga-
ta, cere-bellum, spinal 
cord
A53T aSyn accumu-
lation in the TH+ cell 
bodies in  SN at the 
age of  7 & 16 m, some 
insol. monomeric aSyn 
in SN
no aSyn containing fi la-
mentous LBs at 13 m
Normal TH cell counts 
& TH WB 
Aged A53T:
STR DA ↑




Aged A53T lack of 
LTD in corticostriatal 
neurons
Gispert et al., 










14-16 m: olfactory 
impairment
Not measured in other 
areas
HMW aSyn in adrenal 
gland, 
PK-resistant aSyn in 
myenteric plexus
OB: LB-like aggre-
gates; Thio S+ & 
paSyn+
TH activity & phos-
phorylation ↑
Protein phosphatase 2A 
activity ↓







No motor defi cit 6 w: 5-8x expression 
compared to endoge-
nous aSyn expression




COX1, SOD2 & aSyn 





6 m: 35% ↓
12 m: DA, DOPAC & 
HVA ↓
normal  NE, 5-HT & 
5-HIAA
TH terminals in dorsal 




sions precede DA neu-
ron pathology 
p62 & LC3B +  inclu-
sions ↑











2-4x cytosol, nucleus 
& processes
SN & VTA
cerebral ctx, OB, STR 
cerebellum, brainstem, 
spinal cord, Hc, and 
12 and 18 m: IHC: 
aSyn accumulation 






12 m: SN & VTA:
DA neurons 40 % ↓
SN: GFAP and Iba1 ↑
Golgi fragment.
P62, LC3B & LAMP2 
↑
LC3BII --
Lin et al., 2012
Table 1 cont.
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Table 1 cont.






aSyn expression Pathology DAergic system Other






6-8 w: 0.7x vs. endoge-
nous mouse aSyn (rt-
PCR, WB)
No inclusions at 9-12 
m
No ND Normal synapses, syn-
aptic vesicles, develop-
ment and breeding
Escobar et al., 
2014







ND ND STR DA & DOPAC ↓ ND Plaas et al., 2008
Abbreviations: 5-HIAA, 5-hydroxyindole acetic acid; 5-HT, serotonine; ACh, acetylcholine; aSyn, a-synuclein; COMT, catechol-o-methyl transferase; 
COX1, cyclooxygenase, ctx, cortex; DA, dopamine; DAT, dopamine transporter; DG, dentate gyrus; DOPAC, 3,4-dihydroxyphenylacetic acid; EM, 
electron microscopy; ER, endoplasmic reticulum; GAD, glutamic acid decarboxylase; GFAP, glial fi brillar acid; h, human; Hc, hippocampus; HMW, high-
molecular weight; HVA, homovanillic acid; Iba1, Ionized calcium binding adaptor molecule 1; IHC, immunohistochemistry; KO, knock out; LB, Lewy 
body; LC3B, microtubule associated protein light chain 3B; LAMP2, lysosome-associated membrane protein; LTD, long-term depression; m, month; NAcc, 
nucleus accumbens; ND, not determined; NE, noradrenaline; OB, olfactory bulb; p62, SQSTM1/p62; paSyn, phosphorylated aSyn; PCR, polymerase 
chain reaction; PK, proteinase K; SN, substantia nigra; SOD2, superoxide dismutase; STR, striatum; TH, tyrosine hydroxylase; ThioS, thiofl avin S; Ubiq, 
ubiquitin; VTA, ventral tegmental area w, week; WB, Western blot; WT, wildtype
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been done in rat. Published aSyn viral vector based mouse models are combined in Table 2. The 
fact that the virus will be injected via microinjection which can be made unilaterally, leaving 
the other side of the brain as a control makes it easier to analyse and compare the pathology 
than with TG expression. Moreover, by using viral vectors, the overexpression of the protein 
can be started at any age, whereas TG expression starts when the gene-expression starts, unless 
the model has been designed as a conditional expression system. Usually studies are controlled 
by the use of a green fl uorescent protein (GFP) viral vector, which makes it convenient to also 
analyse the transduction and spreading of the expressed gene.
In the LV-based model, the expression is seen moderately fast, in weeks to months, but the 
aSyn pathology takes some months to occur (Lauwers et al., 2003, Gerard et al., 2010). aSyn-
containing inclusions were formed in the model of Lauwers et al. (Lauwers et al., 2003) in STR 
and SN, where the injections were directed. But they could not fi nd any Thiofl avin S or Congo 
red positive inclusions, which describe the fi bril formation. Although mild neurodegeneration 
was observed in the model by silver staining, the effect on the DAergic system was mild at one 
year post-injection and the mouse motor behaviour was not analysed in the study.
In all the AAV studies the vector was injected into the SN and it produced faster-onset, within 
weeks, aSyn accumulation in the injection area than LV. In these studies, AAV2 serotype was 
the most frequently used and in all vectors, the woodchuck hepatitis virus posttranscriptional 
regulatory element (WPRE) enhancer element was present. The promoters that have been used 
vary from cytomegalovirus (CMV), chicken β-actin (CBA), and Synapsin-1 to PDGFβ. 
In only one of the studies, LB-like inclusion formation, striatonigral DAergic system and motor 
behaviour of the mice were studied, in the model of Olivera-Salva (Oliveras-Salva et al., 2013). 
AAV2/7 human aSyn and human A53T aSyn both induced fast accumulation and localization of 
LB-like, paSyn positive and urea insoluble, inclusions in TH+ SN neurons, which degenerated 
as was shown with the loss of TH+ cells in the SN and STR terminals by 8 weeks post-injection. 
Mice developed later-onset motor defi cit in cylinder, locomotor activity and rotarod tests at 
week 12 post-injection. Furthermore, this was the only model where viral vectors were shown 
to cause motor impairment. Motor behaviour was measured by Decressac et al (Decressac et 
al., 2012b), but AAV human aSyn did not cause toxicity and therefore no turning behaviour 
was observed in the amphetamine-induced rotation test. In most of the models, the viral vector-
delivered aSyn is shown to be expressed in the DAergic neurons in the SN or nigral area within 
two months post-injection, but it does not induce any toxicity, the effect is very mild or the 
effect on the SN neurons was not quantifi ed (Dong et al., 2002, Lauwers et al., 2003, St Martin 
et al., 2007, Theodore et al., 2008, Cao et al., 2010, Decressac et al., 2012b).
Viral vector-mediated gene delivery has a good potential to offer a time- and cost-effi cient 
alternative to conventional TG mice. In most of the studies, the vectors are shown to guide the 
expression of aSyn locally, in the SN. But the data about their effi cacy of producing PD-like 
phenotype, LB-like inclusions, DAergic cell loss and motor impairment is still partially unclear 
and not suffi cient to draw a conclusion about their real usefulness in modeling PD.
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2-10 m: neuronal soma & 
neurites in the injected areas, 
no difference btw WT & 
A30P aSyn
STR inj. 6m: inclusions in 
STR, 60 % ubiq+
12 m: larger inclusions but 




TH 10-25 % ↓
Degeneration of neurons 
detected  by silver-stain-
ing in STR
Lauwers et al., 








3 μl, SNc unilaterally
ND Colocalization of h aSyn in 
TH+ neurons, also other cell 
types affected
4 w: No TH+ cell loss
6 m: TH+ cells 25% ↓










ND Cytoplasmic expression in 
SNc and STR processes 
ND Immune activation by 
aSyn over-expression: 
CD68+ microglial activa-
tion, CD3+ & IgG+ cells 
in SNc/ SNr, peak at 4 w






2 μl SNc unilaterally
ND Expression in SNc, not quan-
tifi ed
SNc TH-neurons 27% ↓ 4 w: activation of nuclear 
factor-κB p65,
microglia activation







2.0 x 107 gc/3μl
6 w: no 




ND SN: TH 91 ± 4% of con-
trol side
Nurr1 cKO mice:
8 w: SN & STR 
TH 56% ↓
SN: VMAT2 65% ↓ 
amph-induced ipsilateral 
turning






“high” ND 7 w: Colocalization of h 
aSyn in TH+ neurons
No TH+ cell loss in SN 
or TH+fi bre loss in STR
aSyn overexpression 
did not enhance MPTP 
toxicity
Dong et al., 
2002
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8 w: No 
motor 
defi cit 






Colocalization of  aSyn in 
TH+ SN neurons
SN: 4 & 8 w: inclusions & 
urea-sol aSyn↑
paSyn in SN ↑, dose & time 
dependently up to 8 w
Progressive AV-dose-
dependent  TH+ cell loss, 
SN:
A53T: 4 w 51% 8 w 9% ↓
WT: 4 w 45%    8 w 
50% ↓
STR: 
A53T: 4w 57% 8w 91% ↓
WT: 4w 56% 8w 86% ↓
ND Oliveras-Salva 
et al., 2013
Abbreviations: AAV, adeno-associated virus; aSyn, a-synuclein; CBA, Chicken β-actin ; CMV, cytomegalovirus; DA, dopamine; GC, genome copy;  h, 
human; KO, knock out ; LV, lentivirus; m, month; MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine;  ND, not determined;   paSyn, phosphorylated 
aSyn; PDGFβ, Platelet-derived growth factor-β; SN, substantia nigra ; STR, striatum ; TH, tyrosine hydroxylase; ThioS, thiofl avin S; Ubiq, ubiquitin; 
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2.6.3  Other mouse models showing α-synuclein accumulation
In this chapter, I will review non-TG mouse models of PD, where aSyn accumulation is induced 
by toxins or by inoculating the brain with exogenous aSyn fi brils. The models are collected to 
Table 3. In the past few years, models using recombinant aSyn Pffs or brain homogenate of TG 
mouse or human PD cases showing aSyn pathology and clinical symptoms have been established. 
These models were set up after evidence of aSyn cell-to-cell transmission in grafted neurons (Li 
et al., 2008, Kordower et al., 2008a and 2008b, Chu and Kordower, 2010). They are based on 
an intracerebral stereotactic injection of Pffs (Luk et al., 2012a and 2012b, Masuda-Suzukake 
et al., 2013, Osterberg et al., 2015) or human (Masuda-Suzukake et al., 2013, Recasens et al., 
2014) or mouse (Luk et al., 2012b) pathological brain tissue homogenates. The common feature 
of all the published models seems to be sonication of the preparation before stereotaxic brain 
injection, suggesting that certain forms of aSyn are pathogenic and able to spread in the brain. 
In all models, injected aSyn seems to be recruiting endogenous mouse aSyn into progressive 
time-dependent LB-like inclusion formation and interestingly, injected human aSyn fi brils were 
visible 24h after the brain injection but had disappeared at the later time points (Recasens et 
al., 2014). This suggests that exogenous pathogenic aSyn species could convert endogenous 
aSyn into a pathogenic conformation. Inclusions typically contain paSyn and colocalize with 
ubiquitin (Luk et al., 2012a and 2012b, Masuda-Suzukake et al., 2013, Recasens et al., 2014, 
Osterberg et al., 2015) and Thiofl avin S (Luk et al., 2012b, Osterberg et al., 2015). Inclusions 
are spreading to the adjacent brain areas and to the contralateral side. Endogenous mouse aSyn 
expression is required for the pathology because the effect is not seen in aSyn KO mice (Luk 
et al., 2012a and 2012b). Furthermore, monomeric aSyn injection did not cause the pathology. 
Although the mice were followed up to 15 months post-injection, the DAergic SNc neuronal 
loss was moderate (Luk et al., 2012a, Recasens et al., 2014), was not seen in the studies 
(Masuda-Suzukake et al., 2013) or was not measured (Luk et al., 2012b, Osterberg et al., 2015). 
Mouse line M83, which was initially characterized by Giasson et al. (2002), has been shown to 
develop symptoms leading to paralysis and death within 21 days after onset. Luk et al (2012b) 
showed that injection of both aSyn fi brils and brain homogenate from symptomatic mice into 
non-symptomatic, young mice advanced the development of these symptoms and earlier death. 
Recasens (2014) and Luk (2012a) observed approximately 35 % cell loss in the SN at 17 and 6 
months after inoculation, respectively. They both showed reduced motor coordination in mice at 
4 and 6 months post-injection, respectively, but in Recasens’ study, the impairment vanished at 
later time points. Considering that this loss of neurons is mild, it is not surprising that mice may 
learn to cope with it over time. 
Taken together, administration of exogenous aSyn species directly into the brain has provided 
new evidence about spreading of aSyn, but most of these models fail to recapitulate the core 
features of PD-related pathology. This supports the idea that multiple mechanisms act together 
in PD, of which the abnormal, toxic form of aSyn is one contributing factor, but aSyn overload 
itself does not necessarily lead to PD.
Three different toxin models have been shown to induce aSyn accumulation in the SN. LC is 
a proteasome inhibitor, which could induce aSyn accumulation by blocking its degradation. It 
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Behaviour aSyn pathology DAergic system Other
aSyn fi brils/ brain homogenates
Sonicated brain-
stem & spinal 
cord homogenate 
from symptomatic 
mice  (>12 m) OR
recombinant h 
aSyn fi brils (trun-
cated h aSyn120 






h A53T aSyn 
PrP mice 
(Line M83), at 
healthy status
30-90 days Reduced survival 
(Age 204 vs. 3016 
days)
Progressive, bilateral spread 
of LB/LN pathology in ctx, 
thalamus, hypothalamus, 
brainstem nuclei, and major 
whitematter tracts
Colocalization of aSyn with 
Ubiq. & ThioS
SDS & FA-sol. aSyn forms
No pathology in aSyn KO 
mice
ND ND Luk et al., 
2012b
Sonicated  SNc 
homogenate from 




C57Bl/6 4 to 17 
months
4 m: pole test, but no 
motor impairment at 
17 m
h aSyn visible 24 hours 
post-injection but not at later 
time points from 4 to 7 m,
4 m: PK-resistant aSyn, 
paSyn in injected SN, co-lo-


















LB/LN pathology in inter-
connected brain areas visible 
at 30 days, progressive
paSyn colocalization with 
Ubiq. & Hsp90
No pathology in aSyn KO 
mice
At 180 days: 
SNc: TH+ cells at 180 
d 35 % ↓
STR: TH & DAT 
OD ↓
ThioS staining in 
AADC+ cells
ND Luk et al., 
2012a)
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Behaviour aSyn pathology DAergic system Other
Sonicated recom-
binant h aSyn 
fi brils OR 
sonicated insol. 









15 months No motor behavioural 
defi cit
Bilateral LN-like pathology 
in SN, Hc, hypothalamus, 
somatosensory area, visual 
ctx, cingulate ctx, corpus 
callosum, amygdala & stria 
terminalis
IHC: pSyn colocalization 
with ubiq. & p62 
WB: endogenous mouse 
aSyn in insol. fraction
No DAergic degen-
eration
No astrogliosis / 
infl ammation







binant m aSyn 
fi brils /
unilateral microin-









ND Progressive LB-like inclu-
sion formation around ctx in-
jection site, bilat. spreading
paSyn, colocali-zation with 
ThioS & Ubiq. 




























2 m: 51 % ↓
STR DA, DOPAC & 
HVA 28 d: 66, 63 & 
47% ↓, 2 m: 52, 46 & 
51 % ↓
Microglia & astroglia 
activation 
Ubiq+ (IHC) aggre-
gates in 5.2% of SN 
neurons & HMW 
Ubiq in insol. mid-
brain fraction 
Zhang et al., 
2005, Zhu et 








28 days Locomotor activity ↓
Rotarod ↓
ND STR DA, DOPAC & 
HVA ↓
Microglia & astroglia 
activation 














50 % increase in aSyn 150% 
increase in paSyn, in SNc & 
SNr (IHC)
SNc TH+ cells ↓
STR DA 40% ↓ 







Age 2.5, 5 & 
12 months
30-45 days Activity ↓ catalepsy ↑
rotarod  ↓ abnormal 
gait
ND Normal SN TH cell 
count, 
STR TH ↑




p.o. gavage 28 
days
C57Bl/6J 28 days Rotarod ↓ ND SN TH cells  & STR 
terminals↓




(100 mg/kg 85% 
†, not included in 
the table)
C57Bl/6N 56 days Rotarod ↓ Time-dependent aSyn in-
crease in SNc TH+ neurons
TH IHC:
SN neurons ↓
No activated astroglia, 
microglia or pTau





45 or 90 days
C57Bl/6J
12 months
(local effect in 
the bovel)




Spinal cord and brainstem 
and SNc accumulation
TH IHC: 
SNc neurons 15.4 % ↓
STR normal
aSyn inclusion-pa-
thology in ENS: 























3 weeks No change Beam walk
Pole test




Normal microglia Fernagut et 
al., 2007
Paraquat 




6 weeks ND STR aSyn ↑
STR & midbrain aSyn colo-
colization with pTau
ND Protesomal (26S) 
activity ↓ 
mTor↓ Beclin 1 ↑
pTau












3 days ND at 3 d, lysosomal accumula-
tion of aSyn in midbrain
ND LAMP-2A ↑ Hsc70/
aSyn interaction
In tg mice w/out 
paraquat, LAMP2A 
↑ together with aSyn 
mRNA ↑  Hsc70 
IHC ↑





i.p. 5 mg/kg 
twice a week
h A30P aSyn 
PrP, Dox KO 
(Nuber, 2011)
6 weeks Locomotor activity  ↓ OB, aSyn  ↑ truncated, 
HMW & insol. aSyn ↑ 
OB, STR & SN TH 
neurons ↓
OB: Astrogliosis 
ATG12, LC3BII & 
LAMP-2A  ↑







h aSyn & 
A53T aSyn-




ND 2 d after inject-tion: aSyn, 
WB↑, 3 w: SN aSyn ↑
Colocalization of aSyn 
&ThioS, not in TH+ cells
ND
controls: SNc TH+ & 
Nissl neurons ↓
ND
In controls Silver 
staining ↑ 
Manning-Bog 
et al., 2002 
and  2003
Abbreviations: AADC, Aromatic amino acid decarboxylase; aSyn, a-synuclein; ctx, cortex; DA, dopamine; DAT, dopamine transporter; DLB, Lewy body 
dementia; DOPAC, 3,4- dihydroxyphenylacetic acid; ENS, enteric nervous system; FA, formic acid; GFAP, glial fi brillar acid; h, human; Hc, hippocampus 
HMW, high-molecular weight; HVA, homovanillic acid; IHC, immunohistochemistry; KO, knock out; LAMP2A, lysosome-associated membrane protein; 
LB, Lewy body; LC3B, microtubule associated protein light chain 3B; LN, Lewy neurite; m, month; ND, not determined;  paSyn, phosphorylated aSyn; PK, 
proteinase K; SDS, sodium dodecyl sulfate; SN, substantia nigra; STR, striatum; TH, tyrosine hydroxylase; ThioS, thiofl avin S; Ubiq, ubiquitin; w, week; 
WB, Western blot; WT, wildtype
Table 3 cont.
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has been administered stereotactically into the medial forebrain bundle (MFB) (Zhang et al., 
2005, Zhu et al., 2007, Pan et al., 2008) or SN (Bentea et al., 2015). Accumulation of aSyn was 
not measured in the studies using MFB lesion, but they show mild accumulation of ubiquitin 
positive aggregates into the SN, microglial activation and moderate (50- 60 %) neuron loss in 
the SN and depletion of DA and its metabolites in the STR. In the studies where LC was injected 
above the SN, it induced marked accumulation of aSyn, together with TH positive cell loss in 
the SN, STR DA loss and motor behavioural defi cits (Bentea et al., 2015). Furthermore, LC 
produces rather quick and robust pathology in the SN in just 7 to 56 days.
Epidemiological studies have linked the use of pesticides and herbicides to an increased risk 
of PD (Uversky, 2004). Therefore, mouse models that are based on an exposure to possible 
neurotoxic agents may offer good means of studying the environmental factors and mechanisms 
affecting PD pathogenesis. Rotenone and paraquat have both been connected to PD, and they 
have also been shown in vitro to accelerate aSyn fi bril formation (Uversky et al., 2001b). The 
pesticide rotenone is an inhibitor of mitochondrial complex 1, which in PD research has mainly 
been administered as daily subcutaneous injection or gavage to mice. In 30-90 days rotenone 
produces motor decline in all studies (Richter et al., 2007, Takeuchi et al., 2009, Pan-Montojo 
et al., 2010, Inden et al., 2011). The administration of rotenone was associated with mild to 
moderate decrease in the SNc cell bodies and STR terminals (Takeuchi et al., 2009, Pan-Montojo 
et al., 2010, Inden et al., 2011) and in one study, it was associated with increased STR TH and 
did not alter SNc TH (Richter et al., 2007).Two of the studies have analysed aSyn in the brain 
and it was shown to be increased after rotenone exposure (Pan-Montojo et al., 2010, Inden et 
al., 2011). Interestingly Pan-Montojo et al. (2010) used rotenone as a form which did not absorb 
from the gut and studied the effects of rotenone toxicity for the enteric and central nervous 
systems. They observed LB-like aSyn pathology in the enteric nervous system and subsequent 
increase of aSyn in the spinal cord, midbrain and SNc, which they suggested to have spread 
from the enteric nervous system.
Paraquat is a herbicide of which the mechanism of toxicity is not fully understood but it is 
connected to oxidative stress, mitochondrial dysfunction (Franco et al., 2010) and reduced 
proteasomal activity and autophagy alterations (Mak et al., 2010, Wills et al., 2012). In mouse 
models, administration of 5-10 mg/kg once or twice a week for 3-6 weeks have been used 
(Manning-Bog et al., 2002, Fernagut et al., 2007, Mak et al., 2010, Wills et al., 2012, Nuber 
et al., 2014). In all studies, paraquat exposure was associated with aSyn accumulation in the 
midbrain (Mak et al., 2010, Wills et al., 2012), SN (Manning-Bog et al., 2002, Fernagut et al., 
2007) or OB (Nuber et al., 2014). If TH-positive neurons were analysed, they were shown to be 
reduced in the SN, STR and OB (Manning-Bog et al., 2002, Fernagut et al., 2007, Nuber et al., 
2014) but DA content was not measured. In most of the studies, the motor phenotype of the mice 
was not assessed, but Nuber (Nuber et al., 2014) showed reduced locomotor activity of the mice 
whereas in the study of Fernagut et al. (2007), no motor decline was seen. Furthermore, Manning-
Bog et al (2002) did not observe pathological alterations in aSyn TG mice whereas paraquat-
induced neurodegeneration was observed in WT littermates, suggesting a neuroprotective effect 
of aSyn overexpression against paraquat toxicity. Paraquat may be useful to study the infl uence 
of environmental stressors on PD pathogenesis. Limitations of studies using paraquat, however, 
seem to be that in most of them all of the PD characteristics have not been quantifi ed, especially 
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DA content in the brain and motor behaviour, therefore it is diffi cult to estimate the usefulness 
of paraquat as a PD model.
2.7  Prolyl oligopeptidase in neurodegeneration and 
α-synuclein pathology
PREP (also known as POP, PEP, PO, EC 3.4.21.26) belongs to a family of serine proteases, 
which cleaves small peptides (less than 30 amino acids) at the C-terminal side of proline residues 
(Gass and Khosla, 2007). It was fi rst discovered in the 70s as a uteral, oxytocin cleaving enzyme, 
and has shown thereafter to cleave angiotensin, substance P, neurotensin and vasopressin 
(Cunningham and O’Connor, 1997). PREP has been identifi ed in bacterial and eukaryotic cells 
at approximately 75 kDA in size and consisting of two domains: catalytic and β-propeller (Gass 
and Khosla, 2007).  The catalytic domain has α/β-hydrolase fold and the catalytic triad of the 
peptidase is formed of three residues: S554, D641 and H680. The β-propeller domain (amino 
acids 73-427) consists of a seven-fold repeat of four-stranded antiparallel β-sheets, which are 
arranged radially around a central pore. The active site is located in the cavity at the interface of 
these two domains (Fülop et al., 1998).
PREP is expressed throughout the body, while the expression is the highest in the brain, liver, 
lung and spleen (Myöhänen et al., 2007, 2008 and 2009). Relatively high PREP activity in the 
brain and the in vitro results of PREP being able to cleave neuropeptides raised the interest 
towards the possible physiological and pathological functions of PREP related to the central 
nervous system. PREP enzyme activity has been correlated to various neurological disorders 
such as AD, depression, schizophrenia and eating disorders (Mantle et al., 1996, Myöhänen et 
al., 2009). PREP inhibitors have been utilized in the study of the role of PREP in the disease, 
and the inhibitors have been shown to have a positive effect on learning and memory, which 
is thought to occur via regulation of neuropeptide levels (Shishido et al., 1998). However, 
there are some studies that have shown controversial data about the correlation between PREP 
inhibition and neuropeptide levels in vivo. (Toide et al., 1997, Miyazaki et al., 1998, Morain 
et al., 2002, Jalkanen et al., 2007 and 2011b). At the subcellular level, PREP localizes mainly 
in the cytosol, but membrane-bound and nuclear localizations have been identifi ed. It has been 
associated with neurotransmitter systems (Peltonen et al., 2011) and inositol-1,4,5-triphosphate 
receptors (Myöhänen et al., 2008) suggesting a potential role in the regulation of their signalling. 
Furthermore, association of PREP with tubulin (Schulz et al., 2005) points to a possible role in 
protein secretion or traffi cking.
To link PREP in brain disorders characterized by protein aggregate deposition, PREP has 
been shown to colocalize in human post-mortem brain samples with marker proteins of 
neurodegenerative diseases: Aβ, tau, aSyn and astroglia (Hannula et al., 2013). PREP inhibitors 
have been shown to inhibit the formation and accumulation of Aβ in mouse in vivo and in 
cell culture studies (Shinoda et al., 1997, Kato et al., 1997). And it had been demonstrated in 
vitro that PREP enhances the aggregation of aSyn, which can be blocked with PREP inhibitors 
(Brandt et al., 2008). PREP is not able to directly cleave Aβ nor aSyn (Petit et al., 2000, Brandt 
et al., 2008) suggesting a possible indirect or non-enzyme activity-related effects of PREP in 
protein aggregation. 
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These interesting fi ndings about PREP and the relevance of aSyn aggregation and deposition in 
the pathophysiology of PD that have been revised in this literature review form the basis for the 
work that is described in this thesis.
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3  AIMS OF THE STUDY
Aggregation and cellular deposition of aSyn are strongly linked to pathogenesis of PD. The 
fi ndings that 1) PREP could accelerate the aggregation process of aSyn in vitro and that 2) 
PREP inhibitors were able to block this effect, generated an interest for further studies of PREP 
inhibitors as a potential new treatment strategy for PD. The aim of this study was to examine the 
role of PREP inhibition in the aSyn aggregation process and the effects of PREP inhibition in 
mouse models, which were also characterized as PD models. 
The role of a PREP inhibitor, KYP-2047, in aSyn aggregation and clearance has now been 
studied using in vitro, cell culture and mouse in vivo models. The specifi c aims of the study 
were:
I. To study if PREP and aSyn form direct protein-protein interaction in cell culture and 
in vitro models. And to fi nd out effects of the protein-protein interaction and KYP-
2047 on aSyn aggregation.
II. To characterize a mouse strain carrying the A30P point mutation in the mouse aSyn 
coding gene (Sncatm(A30P) strain) as a mouse model of PD by assessing mouse be-
haviour, brain aSyn load and DAergic system and 6-hydroxydopamine neurotoxin 
sensitivity
III. To clarify what is the mechanism of increased aSyn clearance after administration 
of KYP-2047 in Sncatm(A30P) mouse strain and in cell culture.
IV. To characterize lactacystin-induced proteasome inhibition as a novel PD mouse 
model and to study the neuroprotective effect of KYP-2047 in this model.
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4 MATERIALS AND MAIN METHODS
4.1 Animals
For study II and III homozygous TG mice carrying the A30P knock-in point mutation in their 
own Snca gene (Sncatm(A30P)) and WT littermates were obtained from the University of Tartu, 
Estonia. Generation of the mouse strain is originally described in (Plaas et al., 2008). The 
difference of this mouse line to others was that it carried only mutated mouse Snca gene and did 
not have aSyn overexpression. Mice were 6–17 months old when used for the experiments in 
study II. Sncatm(A30P) mice were also used for study III at the age of 12-16 months. For the study 
IV, 8-9 weeks old male C57Bl/6RccHsd mice were obtained from Harlan (Horst, Netherlands) 
while aged (12-14 months old) male C57Bl/6RccHsd mice were from University of Helsinki 
laboratory animal facilities. All the animals were maintained at 20-22 °C room temperature 
with 12:12 hours light:dark cycle and had access to food and water ad libitum. The experiments 
were carried out under licences ESLH-2009-02210/Ym-23, ESAVI-553/041003/, ESLH-2007-
06679/Ym-23, 2011ESAVI-2010-07863/Ym-23 and ESAVI/198/04.10.07/2014 according to 
the European Community guidelines for the use of experimental animals and approved by the 
Finnish National board of animal experiments.
4.2 Drugs and treatments
Chemicals were purchased from Sigma-Aldrich (St- Louis, MO, USA) unless otherwise stated. 
6-hydroxydopamine (6-OHDA) was diluted in saline with 0.02% ascorbic acid (Study II). 
Desipramine (25 mg/ kg i.p.) was dissolved in sterile water and administered approximately 
half an hour before 6-OHDA injection to protect noradrenergic neurons. Lactacystin (#L-1147, 
A.G. Scientifi c; San Diego, CA, USA) was diluted in PBS (2mg/ml) (Study IV). PREP inhibitor, 
KYP-2047 (4-phenylbutanoyl-L-prolyl-2(S)-cyanopyrrolidine), was synthetized in Univeristy 
of Eastern Finland, as described in Jarho (Jarho et al., 2004). KYP-2047 is a specifi c inhibitor 
of PREP with no signifi cant inhibition on related peptidases (Jalkanen et al., 2011a). KYP-2047 
was dissolved in 0.5 % DMSO in 0.9 % saline for i.p. injections (10 mg/ kg/ day; Studies III 
and IV) and in 50 % DMSO in 0.9 % saline for i.p. osmotic pump administration (Study III). 0.5 
% or 50 % DMSO in 0.9 % saline was used as a control in the studies. KYP-2047 was injected 
twice a day for 5 days or if an osmotic pump was used, the duration of the treatment was four 
weeks. For cell culture work, 100 mM KYP-2047 stock was dissolved in DMSO (studies III 
and IV). D-amphetamine sulphate (Faculty of Pharmacy, University of Helsinki, Finland) 
was dissolved in 0.9 % saline and injected i.p. (2.5 mg/kg, calculated as free base). Lidocaine 
(Orion Pharma, Espoo, Finland) was used as a local anesthetic during all the surgical operations. 
Subcutaneous injection of buprenorphine (0.1 mg/kg; Temgesic, Reckit Benckiser Healthcare 
Ltd, Slough, UK) was used for post-operative pain relief in studies II, III and IV. Lethal dose 
of sodium pentobarbital (100 mg/kg; Orion Pharma) was used for terminal anaesthesia before 
perfusions.
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4.3 Cell Culture, transfection and treatment
Mouse Neuro-2A (N2A) neuroblastoma cells (Study I) were cultured in full DMEM with 
additional 10% (v/v) FBS (Gibco, Life Technologies, Paisley, UK), 1% (v/v) L-Glutamine-
Penicillin-Streptomycin solution (Lonza, Basel, Switzerland). Cells were maintained at 37°C, 
5% CO2/water saturated air. Transfection of N2A was done using JetPei (Polyplus, New York, 
USA) according to manufacturer’s instructions. Human embryonic kidney (HEK) -293 cells 
(Study III) were cultured in Dulbecco’s modifi ed Eagle’s medium (DMEM; Product #10-013, 
Cellgro/Mediatech, Manassas, VA, USA) containing 10% fetal bovine serum (FBS, Product 
#F2442).
4.3.1  PREP inhibition and macroautophagy in cell culture
24h after plating, autophagy inhibitors, 3-methyladenine (3-MA; 1 or 5 mM; Product #M9281) 
or bafi lomycin A1 (10 nM or 50 nM; Product #B1793) in the presence of KYP-2047 (1 μM) 
or vehicle (0.001% DMSO) were added on the cell culture. The cells were incubated for an 
additional 24 h. Following treatment, cells were homogenized and used for WB analysis.
4.3.2 Beclin 1 mRNA 
HEK-293 cells were homogenized, and the total RNA was extracted with an Aurum Total RNA 
Mini Kit (Bio-Rad, Hercules, CA, USA), including DNase treatment. Reverse transcriptase 
reaction was done on 10 ng of RNA in standard conditions using an iScript™ cDNA Synthesis 
kit (Bio-Rad). PCRwas performed with primers designed to amplify a fragment of beclin 1 
cDNA (Miracco et al., 2007) (forward, 5′ CAA GAT CCT GGA CCG TGT CA 3′; reverse, 5′ 
TGG CAC TTT CTG TGG ACA TCA 3′) or GAPDH cDNA (forward, 5′ TGC ACC ACC AAC 
TGC TTA 3′; reverse, 5′- GAG GGC ATG GAC TGT GGT CAT-3′), using iQ™SYBR® Green 
Supermix (Bio-Rad). Determination was done in triplicate. The fold change of expression of 
beclin 1, with respect to GAPDH, is reported as −2ΔΔC(t).
4.4 Surgical procedures
The mice were deeply anaesthetized (Univentor anaesthesia unit, Zejtun, Malta) with 2-4 % 
isofl uran (Baxter, Deerfi eld, IL, USA) and placed on a stereotactic frame (Stoelting, Wood Dale, 
IL, USA) for stereotactic injections. A unilateral, intrastriatal injection containing 0.33, 1.0 or 
3.0 μg of 6-OHDA (in 2 μl) was delivered with a 10 μl microsyringe (Hamilton, Bonaduz, 
Swizerland) connected to an injector (Quintessential stereotactic injector, Stoelting) at 0.5 μl/
min to the following coordinates in relation to the bregma: A/P +0.7; M/L +1.8; D/V -2.7, and 
the needle was slowly retracted 2 min after the cessation of the injection (Study II). LC (2 μg 
in 1 μl) or PBS as a control were injected above the SNc using 10 μl microsyringe (World 
Precision Instruments, Hertfordshire, UK)  at 0.2 μl/min to the following coordinates: A/P -3.2; 
M/L -1.2 ; D/V -4.3 (Study IV). The needle was left in place for 5 min after injection until it was 
slowly withdrawn.
Alzet osmotic pumps (Durect, Cupertino, CA, USA) for continuous KYP-2047 delivery were 
surgically inserted into mice intraperitoneum under isofl urane anesthesia (Study III).  Mice were 
single-housed after the surgical procedures until they were sacrifi ced.
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4.5  Behavioural tests
4.5.1  Horizontal and Vertical activity
In order to quantify locomotor activity of freely moving mice, the animals were put in a 
transparent plexiglass cages (dimensions: 25 cm x 25 cm x 15 cm) and the activity monitor 
measured infrared beam interruptions (MED Associates, St. Albans, GA, USA). Moving distance 
and vertical activity were measured in 15-min intervals. 24-h locomotor activity tests were done 
to compare phenotypes of genotypes (Study II). Mice were given water and food pellets during 
the 24-h test. 3-h measurement was done to study the responses to D-amphetamine challenge 
between mouse genotypes (Study II) and 2-h measurement to mice after LC and KYP-2047/
vehicle treatment (Study IV).
4.5.2 Cylinder test
Unilateral toxin administration induces a one-sided lesion of the nigrostriatal pathway, which 
may result in a disability of contralateral paw use and increased use of ipsilateral paw. In study 
IV, paw use preference was measured using a cylinder test after lactacystin injection. Mice were 
put in a plexiglass cylinder and camera was attached below the cylinder to record each mouse 
for 5 min. Videos were analysed afterwards in slow motion to count paw touches on the wall or 
fl oor upon mouse rearing and landing, respectively. Paw use percentages were calculated based 
on the numbers of left, right and both paw use.
4.5.3 Rotational behaviour
Drug-induced rotational bias can be observed after one-sided lesion of nigrostriatal pathway. In 
study II, rotational behaviour was measured 2 and 4 weeks after unilateral 6-OHDA lesioning 
of WT and Sncatm(A30P) mice. To induce rotations, 2.5 mg/kg of D-amphetamine was injected i.p. 
Mice were then fastened to the apparatus (MED Associates) with collars made from cable ties. 
Rotational behaviour was automatically detected and measured for 120 min in 5-min intervals. 
Net ipsilateral rotations (ipsilateral-contralateral) were used for data analysis.
4.6  Analysis of brain neurotransmitters and metabolites 
4.6.1  Tissue samples
For brain dissection mice were deeply anesthetized with sodium pentobarbital (150 mg/kg) and 
transcardially perfused with ice-cold phosphate-buffered saline (PBS) to remove blood. The 
brains were quickly removed and placed in a cooled brain matrix to obtain striatal 2 mm slices 
from which the tissue samples were punched (radius 2 mm) (Study II and IV). Alternatively, 
the brain was separated in two hemispheres and the other one was quickly frozen on dry ice. 
Striatal samples from the brain halves were punched later (Study III). All samples were quickly 
frozen on dry ice and stored at -84°C until analysis. The samples were prepared in 0.5 ml of 
homogenization buffer consisting of six parts of 0.2 M HClO4 and one part of antioxidant 
solution (oxalic acid, acetic acid and L-cysteine) and sonicated. The homogenates were 
centrifuged for 35 min at 20,800g at 4°C. Supernatant was removed to 0.5 ml Vivaspin 500 fi lter 
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concentrators (Molecular weight cut-off 10,000; polyethersulfone membrane; Sartorius Stedim 
Biotech GmbH, Goettingen, Germany) and centrifuged for 35 min at 8,600g at 4°C.
4.6.2 High-pressure liquid chromatography analysis
The concentrations of DA and its two main metabolites 3,4-dihydroxyphenylacetic acid 
(DOPAC) and homovanillic acid (HVA), and 5-hydroxytryptamine (5-HT) and its metabolite 
5-hydroxyindoleacetic acid (5-HIAA) were analysed using high-pressure liquid chromatography 
(HPLC) equipped with an electrochemical detector (ESA CoulArray, Chelmsford, MA, USA) as 
earlier described (Airavaara et al., 2006). The chromatograms were analysed and concentrations 
were calculated using CoulArray for windows software.
4.7  Immunohistochemistry
4.7.1  Sample preparation
To prepare the tissue for IHC the remaining caudal parts of the brain (cerebellum removed) 
(Study II) or the left hemisphere of the brain (Study III) were immersed in 4% paraformaldehyde 
(PFA) overnight. In study IV, mice were transcardially perfused with PBS to remove blood and 
then with 4 % paraformaldehyde (in PBS) to fi x the tissue. Brains were removed and immersed 
in 4 % paraformaldehyde overnight to post-fi x the tissue at room temperature. The brains were 
then immersed in 10 % sucrose solution (in PB) at +4°C overnight and thereafter in 30 % 
sucrose solution, kept at +4°C until they sank, after which the samples were quickly frozen 
with isopentane on dry ice and stored at -80 °C until sectioning. Brains were sectioned at 30 μm 
thickness. Floating sections were stored at -20 °C.
4.7.2  Immunohistochemistry
IHC was used for detection of aSyn (Studies II, III and IV), TH (Studies II, III and IV), DAT 
(study II), glutamic acid decarboxylase (GAD), ionized calcium binding adaptor molecule 1 
(Iba1) and glial fi brillary acidic protein (GFAP) (Study IV). Briefl y, sections were quenched 
in 10% methanol and 3% H2O2 in PBS (pH 7.4) for 10 min to block endogenous peroxidase 
activity, and non-specifi c binding was blocked with 10% normal serum in PBS containing 0,5 
% Triton-X-100. The sections were incubated overnight at room temperature with sheep anti-
aSyn (1:500, #ab6162, Abcam, Cambridge, UK), rabbit anti-TH (1:2000, #ab152, Millipore, 
Darmstadt, Germany), rat anti-DAT (1:1000, MAB369, Millipore), rabbit anti-GAD65/67 
(1:2000, #G5163, Sigma), rabbit anti-GFAP (1:2000 ab7260, Abcam) or rabbit anti-Iba1 (1:1000, 
#019-19741, Wako Chemicals, Ltd., Richmond, VA, USA), antibodies. The sections were then 
incubated with appropriate HRP conjugated secondary antibodies for 2 h; donkey anti-sheep 
(aSyn) (1:500, #ab6900, Abcam), goat anti-rabbit (GAD) (1:500, #31460, Thermo Scientifi c, 
Rockford, USA) or  rabbit anti-rat (DAT) (1:750, BA4000, Vector Laboratories, Burlingame, 
CA, USA). For TH, GFAP and Iba1 goat anti-rabbit biotinylated secondary antibody (1:200, 
BA1000, Vector Laboratories) was used and the signal was enhanced with the avidin-biotin 
complex –method (Vectastain® ABC kit standard, Vector Laboratories). The antigen-antibody 
complexes were visualized with 0.05% 3,3’-diaminobenzidine and 0.03% hydrogen peroxide 
solution. Finally, the sections were moved to objective glass, dehydrated in ethanol series (Altia, 
Finland) and mounted with Depex (BDH, Poole, UK).
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4.7.3  Optical density analysis
For optical density (OD) analysis sections were imaged using pictures taken with a Nikon 
stereomicroscope combined with a DS-Fi1 camera head and DS-L2 camera control unit (Nikon, 
Japan) (Study II and III) or with 3DHISTEC slide scanner (3DHISTEC Ltd., Budabest, Hungary) 
(Study IV). Analysis was done in Image Pro Plus program (v. 3.0.1., Media Cybernetics, 
Bethesda, MD, USA) (Study II and III) or using ImageJ (NIH, Bethesda, MD, USA) (Study IV). 
Images were converted into grayscale 8 and inverted before analysis. Brain area to be analysed 
was selected using freehand selection tool. For each brain section background staining values 
were subtracted from raw data values.
4.8 Immunoblotting and native polyacrylamide gel-
electrophoresis
More detailed description of the sample preparation protocols for WB can be found in 
respective original publications. In brief, samples were mechanically homogenized in modifi ed 
RIPA- (50 mM Tris-HCl, 150 mM sodium chloride, 0.25 % sodium deoxycholate, 1 % NP-40, 
protease inhibitors; pH 7.4)  (Studies II, III and IV) or TBS-buffer (Study IV). Supernatants 
were collected after centrifugation (14,000g at 4 °C). For aSyn and Ubiquitin detection, 
pelleted samples were further fractionated in SDS soluble and/or Triton-X soluble samples. 
Protein amounts were measured from soluble fractions using bicinchoninic acid (BCA) assay 
(Thermo Scientifi c). Samples were prepared in denaturing sample buffer, boiled for 5 min and 
centrifuged for 1 min. Lysates (10-50 μg) were loaded onto a polyacrylamide–SDS-gel (4-20 % 
or 8-16 %, Bio-Rad). Standard transfer and blocking techniques were used. Primary antibodies 
were diluted in 5% skim milk containing 0.05% Tween20: anti-mouse aSyn (1:1000; #ab1903, 
AbCam), mouse anti-ubiquitin (1:1000; #3936S, Cell Signaling Technology, Danvers, MA, 
USA) , mouse anti-SQSTM1/p62 (p62, 1:5000; #ab56416, AbCam), rabbit anti-microtubule 
associated protein light chain 3B I-II (LC3BI-II, 1:1000; #L7843), rabbit anti-beclin 1 (1:2000; 
#ab16998, AbCam), rabbit anti-parkin (1:1000; #ab15954), rabbit anti-β-actin (loading control, 
1:2000; #4967S, Cell Signaling Technology) and glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH, loading control, Millipore). After an overnight incubation at +4°C, membranes were 
incubated with  appropriate HRP-conjugated secondary antibodies for 2 h at room temperature: 
for aSyn and SQSTM1/p62, goat anti-mouse HRP (dilution 1:2000 in 5% milk, #31430; Thermo 
Fischer Scientifi c); for ubiquitin, LC3BI-II, beclin 1, parkin and β-actin, goat anti-rabbit 
(dilution 1:2000; Product #31463, Thermo Fisher Scientifi c). β-actin and SQSTM1/p62 (p62) 
goat anti-mouse (tissues; dilution 1:5000; Product #7076, Cell Signaling Technology/ cells; 
dilution 1:2000; Product# AP130P, Millipore), 
The images were captured using GeneGnome (Syngene, Cambridge, UK) or C-Digit imaging 
system (Licor, Lincoln, NE, USA). Three independent WB experiments were performed. ImageJ 
program was used for analyzing bands, and the OD value was calculated by comparing the OD 
value to the corresponding loading control OD value.
For native polyacrylamide-gel- electrophoresis, 6μg of recombinant protein samples were 
diluted in 1:1 native sample buffer (Bio-Rad) and loaded onto a 10 % native gel containing a 
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stacking gel. Gel, sample buffer and Tris-glycine running buffer did not contain SDS. Coomassie 
staining was performed after electrophoresis. Gel was fi xed for 30 min in destaining buffer, 
(45% methanol, 10% acetic acid), stained with 0.1% Coomassie Brilliant Blue R-250 (Thermo 
Scientifi c) for 2 h and destained 3-4 times for 30 min with destaining buffer.
4.9  PREP and proteasomal activity measurement
The brain tissue or cell culture samples were homogenized in PREP assay buffer (0.1 M Na–K-
phosphate buffer, pH 7.0) and centrifuged at 16,000 g at 4 °C for 20 min. Supernatants were 
collected and stored at -80 until PREP or proteasome activity measurement. Protein amount was 
measured using bicinchoninic acid method (BCA Protein Assay Kit, Thermo-Scientifi c)
Both activity assays are based on formation of fl uorescent 7- amino-4-methylcoumarin (AMC) 
upon specifi c substrate cleavage. In PREP activity assay, post-proline-cleavage activity is 
measured. The protocol is described in Myöhänen et al (2008), samples were pre-incubated with 
assay buffer for 30 min at 30°C, then the substrate (4 mM Suc-Gly-Pro-AMC) was added and 
reaction was incubated for 1 h at 30°C. 1 M sodium acetate buffer (pH 4.2) was used to stop the 
reaction. In order to measure the chymotrypsin-like activity of the 20S proteasome, the protocol 
described in Ebrahimi-Fakhari (Ebrahimi-Fakhari et al., 2011) was used. Homogenates were 
incubated with substrate (Suc-Leu-Leu-Val-Tyr-AMC) (Product #I-1395, Bachem, Bubendorf, 
Switzerland) at 37 °C for 60 min. Assay buffer for 20S activity contained 250 mM HEPES, pH 
7.5, 5 mM EDTA and 0.01% SDS. The specifi city of the proteasomal assay was ascertained by 
the ability of additional lactacystin (50 μM) to inhibit the fl uorescence change. The formation 
of AMC was measured using The Wallac 1420 Victor fl uorescence plate reader (PerkinElmer, 
Waltham, MA, USA). The excitation and emission wavelengths were 360 and 460 nm, 
respectively. PREP and proteasomal activities were expressed as the nanomolar amount of free 
AMC/min ∗ mg protein.
4.10  Microscale thermophoresis
Microscale thermophoresis (MST) measures interactions of biomolecules by detecting 
movement of fl uorescently labeled molecules along temperature gradient upon changes in 
their hydration cell, charge or size). MST was used for a protein-protein and a ligand-protein 
interaction study (Study I). Purifi ed recombinant porcine PREP and PREP(S554A) proteins 
were labeled with red fl uorescent dye NT-647 NHS (amine-reactive) using Monolith NT.115 
labeling kit (NanoTemper Technologies, München, Germany) according to the manufacturer’s 
instructions. Labeled proteins were eluted in PBS with 0.05% Tween-20. Interaction studies 
were performed with a Monolith NT.115 MST device using standard capillaries from 
NanoTemper Technologies. During measurements, fl uorescence signal was kept above 200 units 
by diluting labeled protein with assay buffer (0.05% Tween-20, 0.5 mg/ml BSA and 2.5 mM 
DTT in PBS). Constant amount of labeled protein (concentration 1-100 nmol) was titrated by 
purifi ed recombinant human aSyn (#S7820, Sigma) in 1:1 series dilution starting from 35 μM, 
or with KYP-2047 in 10:1 and 1:1 series dilution starting from 10 μM. Curve fi tting was done 
by NTanalysis software (NanoTemper Technologies) in the Thermophoresis + T-jump mode. 
Assimilated curves were analysed and Kd values were calculated in GraphPad Prism using non-
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linear regression and one-site specifi c binding with the Hill slope according to the following 
equation: Kd = Bmax*X / Y - X. Where Bmax = is the maximum binding, X= concentration of aSyn 
and Y= normalized fl uorescence change. Curves were generated from 3 replicate interaction 
assays.
4.11  α-synuclein and PREP plasmid construction
Plasmids were cloned for expression of luciferace-tagged aSyn and PREP in protein-fragment 
complementation assay (PCA). The split Gaussia princeps luciferace (GLuc) expression plasmids 
were previously described in (Nykänen et al., 2012). The human aSyn cDNA to clone aSyn-
GLuc1/HA and asyn-GLuc2/HA was obtained from ORFeome library (version 3.1, Genome 
Biology Unit, Institute of Biotechnology, University of Helsinki, accession number: BC013293), 
and was PCR-cloned in the Gluc-vector with HA-tag using the KpnI-XhoI restriction site. 
The open reading frame for human PREP (hPREP) was amplifi ed from pCMV XL5 plasmid 
(Origene, Rockville, MD, USA) using polymerase chain reaction with oligonucleotide primers 
containing linkers for ligation-independent cloning. These inserts were recombined into the 
BamHI and EcoRV sites of pAAV-EF1a-backbone vector (pOTTC374) using an In-Fusion HD 
cloning kit (Clontech, Mountain View, USA). To create expression plasmid for hPREP (S554A), 
pAAV EF1α hPREP plasmid was used as a source for mutatation. Two separate PCR amplicons 
were constructed to contain the desired S554A mutation and linkers for the ligation-independent 
cloning. Amplicons were inserted into backbone vector using In-Fusion (Clontech) to create 
pAAV EF1α hPREP (S554A). An insert containing clones of newly generated plasmid were 
sequence verifi ed. The PREP and PREP(S554A) plasmids were then used for cloning the PREP-
GLuc2 and PREP(S554A)-GLuc2 constructs. All GLuc constructs used in this study have the 
GLuc-reporter fragment placed at the N-terminus separated by a (GGGGS)2SG linker.
4.12  Protein-fragment complementation assay
PCA is based on a luminescence, which occurs when proteins tagged with a complementary 
GLuc-fragments are close enough proximity to form a functional reporter protein. This was used 
to study aSyn-PREP protein-protein interaction and aSyn dimerization.  PCA was performed 
as described in (Nykänen et al., 2012). N2A cells were plated on 96-well plates (Perkin Elmer, 
white wall) (10,000 cells/ well). 24 h post-plating, reporter plasmids were transfected (125 ng 
of total plasmid DNA/ well). PCA signal was read 24 h post-transfection. GLuc PCA signal was 
detected by injecting 25 μl of native coelenterazine (Nanolight Technology, Pinetop, AZ, USA) 
per well (fi nal concentration of 20 μM), and the emitted luminescence was read by Varioskan 
Flash multiplate reader (Thermo Scientifi c). For each experimental condition, 4 replicate wells 
were used, and 3-4 replicates of independent experiments were performed. A 100 mM stock 
solution of KYP-2047 was prepared in DMSO, further diluted to PBS and added at various 
concentrations (1 μM-10 μM) 4 h before the measurement. The corresponding amount of 
DMSO was used as vehicle control. 4 wells per experiment and 3-4 independent replicates were 
performed.
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4.13  Statistical analysis
Statistical analyses were conducted with SPSS 18 (Study II) or Graph Pad Prism (studies I, 
III and IV) softwares. Student’s t-test, 1-way analysis of variance (ANOVA) with Bonferroni 
or Newman Keuls post hoc test, 2-way ANOVA with Bonferroni post hoc test or repeated 
measeures ANOVA were used as statistical tests for the data analysis.  Data is presented as Mean 
± SEM.
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5  RESULTS
5.1  PREP forms protein-protein interaction with 
α-synuclein and enhances its dimerization (I)
The protein-protein interaction between PREP and aSyn was studied in two models. In MST, a 
method to screen and study protein-protein interactions of purifi ed, recombinant proteins, and 
in PCA, which allows investigation of protein interactions in cell culture. Catalytically inactive 
mutant, PREP(S554A) was used to study the involvement of PREP enzyme activity on the 
interaction. The effects of PREP and inhibition of PREP on aSyn self-association were also 
studied in PCA. 
The fi ndings of the experiments are summarized in Figure 6. In MST, both PREP and inactive 
PREP(S554A) interact with aSyn in μM affi nity, Kd for PREP-aSyn was 2.96 μM and 
PREP(S554A)-aSyn 1.41 μM (Fig. 6 A-B). aSyn and PREP or PREP(S554A) were tagged 
with complement luciferace fragments and expressed in N2A cells. Bioluminescence signal, 
which occurs upon protein-fragment complementation, was signifi cantly increased indicating 
a protein-protein interaction of aSyn with PREP and aSyn with PREP(S554A) (Fig. 6 C). 
The effect of PREP on aSyn dimerization was also studied in the same system by making two 
luciferace-fragment-tagged versions of aSyn. Bioluminescence signal, which is generated upon 
aSyn dimerization, represents the fi rst step in the aSyn aggregation process. Indeed, we saw 
increased aSyn dimerization when PREP or PREP(S554A) were co-expressed with tagged aSyn 
constructs (Fig. 6 D). Once aSyn was expressed with PREP and incubated with KYP-2047, aSyn 
dimerization signal decreased signifi cantly. KYP-2047 did not have an effect on PREP(S554A)-
induced aSyn dimerization (Fig. 6 E). 
To study the conformational forms of purifi ed recombinant PREP and PREP(S554A) proteins, 
the proteins were incubated with KYP-2047 and applied on a native polyacrylamide gel 
electrophoresis (PAGE). Native PAGE revealed that PREP exists in three conformations: 
compact monomer, which is most likely the closed form; open monomer and slowly migrating 
oligomeric form. KYP-2047 incubation shifted open PREP conformation into a closed monomer 
but had no effect on PREP(S554A) (Fig. 6 F). KYP-2047 was shown to bind to both of the 
PREP proteins in our MST experiment  (Kd at 0.1 nM range; data not shown).
5.2  Characterization of A30P α-synuclein transgenic 
mouse strain as a model of Parkinson’s disease (II 
and III)
5.2.1  Horizontal and vertical activity (II)
In order to characterize possible effects of A30P aSyn on mouse locomotor activity, horizontal 
and vertical activities of 6-month (young) and 16-month old (aged) Sncatm(A30P) (Tm) and WT 
mice were compared. A30P aSyn appeared not to cause very prominent effects on locomotion 
because overall total activities did not differ between the genotypes. However, young Tm mice 
were signifi cantly more active than their WT littermates during fi rst hours of measurement; 0–4 




Figure 6: Prolyl oligopeptidase (PREP) and catalytically inactive PREP(S554A) form protein-
protein interaction with α-synuclein (aSyn) in microscale thermophoresis (MST) (A and B). In 
protein complementation assay (PCA) (C), PREP interacts with aSyn as transfection of PREP and 
aSyn tagged with complementary luciferace (GLuc) fragments (1 and 2) signifi cantly enhances PCA 
signal in N2A cells. PREP and PREP(S554A) enhance aSyn dimerization in PCA (D), where aSyn 
tagged with complemetary GLuc fragments (1 and 2) was kept constant and PREP or PREP(S554A) 
were transfected at increasing levels. PREP-induced aSyn dimerization is reduced by PREP-
inhibitor KYP-2047 whereas KYP-2047 does not have an effect on PREP(S554A)-induced aSyn 
dimerization (E). KYP-2047 induces conformational change of purifi ed recombinant PREP into 
compact monomeric form but does not have an effect on PREP(S554A) in native polyacrylamide gel 
electrophoresis and Coomassie blue staining. Purifi ed recombinant PREP or PREP(S554A) were 
incubated with 150 μM KYP-2047 30 minutes before gel electrophoresis (F). n=3-4. * P<0.05; ** 
P<0.01; ***P<0.001, Bonferroni post hoc test, 1-way ANOVA.
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and during 0–2 hours signifi cantly more rearing (F1,20=9.173, P=0.007, repeated measures 
ANOVA) (Fig. 7 A-B) was observed. Similarly, aged Tm mice moved signifi cantly more during 
0-2 hours compared to WT mice (P = 0.012, F1,38=6.994, repeated measures ANOVA) (Fig. 7 
E). Aged mice of each genotype appeared to be signifi cantly more active than young mice when 
total distance travelled and vertical counts were compared but no effect was seen in the post hoc 
test (Total distance: age effect, P = 0.0484, F1,56=4.073, Total vertical activity: age effect, P = 
0.0263, F1,56=5.207, 2-way ANOVA). 
Figure 7: Overall total (inserts) horizontal and vertical activities of young (A,B) and aged (E,F) 
wildtype (WT) and Sncatm(A30P)(Tm) mice did not differ between the genotypes in 24 hours activity 
measurement. On closer inspection, Tm mice were signifi cantly more active at the beginning of the 
measurement. In young mice, increased horizontal activity during fi rst four hours (A) and vertical 
activity during fi rst two hours (B), whereas in aged mice increased horizontal activity during fi rst two 
hours were observed. No signifi cant genotype differences were observed when mice were challenged 
with D-amphetamine 1 mg/kg (C) or 2.5 mg/kg (D) and horizontal activity was measured for 3 hours. 
n=8-20. Lights off at 12-24h. * P<0.05; ** P<0.01 repeated measures ANOVA.
Young mice were also challenged with D-amphetamine and horizontal activity was measured for 
3 hours. No signifi cant alterations in the response for D-amphetamine were observed between 
genotypes (Fig. 7 C-D).
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5.2.2  Sensitivity to 6-OHDA – D-amphetamine-induced 
rotational behaviour and HPLC analysis of striatal 
dopamine, 5-HT and their metabolites (II)
Young Tm and WT mice were randomly divided into groups that received 0.33 μg or 1.0 μg 
unilateral, striatal 6-OHDA microinjection. To assess progression and severity of the lesion of 
the nigrostriatal tract, amphetamine-induced (2.5 mg/kg) rotational behaviour was measured 2 
and 4 weeks post-lesion (Fig. 8 A-B). Interestingly, at both time points lower dose of 6-OHDA 
caused a slight contralateral turning. The dose of 1.0 ug did not cause clear rotational behaviour 
at 2 weeks post-lesion but caused some ipsilateral turning in WT mice at 4 weeks although not 
signifi cantly. Tm mice that received 1.0 ug of 6-OHDA did not show clear turning bias at any 
time point. This data indicates that the 6-OHDA did not cause an extensive enough lesion to the 
nigrostriatal trackt for mice to rotate after D-amphetamine challenge.
Measurement of striatal dopamine content supports our observations in the rotational 
experiment. In HPLC DA measurement, the genotypes had opposite responses on small dose 
of 6-OHDA (Fig. 8 C) (P = 0.0382; F1,54=4.512, 2-way ANOVA); 0.33 ug induced 20 % DA 
loss in WT but 18 % increase in Tm mice. WT mice had more DA loss in the STR at 4 weeks 
post-lesioning (Treatment effect P = 0.0161; F2,54=4.459, P < 0.05, WT intact side vs 1.0 ug 
6-OHDA, Bonferroni post hoc test, 2-way ANOVA), which could explain the observed mild 
ipsilateral turning after D-amphetamine. DOPAC content decreased dose-dependently but the 
effect did not reach signifi cance in post hoc tests (Treatment effect P = 0.0355, F2,54=3.553) 
(Fig. 8 D), and HVA was reduced only mildly (ns, P = 0.0842, F2,54=2.592) (Fig. 8 E). There 
were some alterations in the DA metabolite and DA ratios between the genotypes but it did not 
reach signifi cance in post hoc tests (DOPAC/DA P = 0.0285, F1,54=5.068, HVA/DA P = 0.0329 
F1,54=4.795, 2-way ANOVA) (Fig. 8 F-G). 6-OHDA did not cause alterations in 5-HT and 
5-HIAA concentrations (data not shown). HPLC analysis from the intact hemisphere revealed 
that genotypes had the basal levels of striatal DA, DOPAC, HVA, 5-HT and 5-HIAA.
5.2.3  Effect of age, genotype and PREP inhibition on brain 
α-synuclein amount in Sncatm(A30P) mice (II and III)
aSyn OD was analysed from 6 and 12-16 months old mice to compare amount of WT and A30P 
aSyn and infl uence of ageing on the accumulation. aSyn OD increased age-dependently in the 
STR of both genotypes (P =  0.0001, F3,30=15.57, 2-way ANOVA; P < 0.01 STR: WT and Tm 
young vs aged, Bonferroni post hoc test) and in the M1 motor cortex in Tm mice (P < 0.05 M1 
cortex: Tm young vs aged,  Bonferroni post hoc test). Cortical aSyn OD was also signifi cantly 
higher in aged Tm mice compared to aged WT mice (P < 0.05, Bonferroni post hoc test) (Fig. 9). 
Myöhänen et al. (2012) showed that PREP inhibition signifi cantly reduced aSyn amount in the 
brain of aSyn overexpressing mice. Therefore the effect of PREP inhibition on aSyn amount and 
oligomerization was further studied in Sncatm(A30P) mouse line. Aged mice received 5-day (16 
months old mice) or 28-day (12 months old mice) treatments with PREP inhibitor KYP-2047 
or vehicle. aSyn OD was analysed from the STR, SN and motor cortex after immunostaining. 
KYP-2047 treatments signifi cantly reduced aSyn immunoreactivity in the studied brain areas of 
Tm mice (5-day: P = 0.002, F1,18 = 10.46 and 28-day: P = 0.0028, F1,10 = 6.95, 2-way ANOVA) 
(Fig. 10 G-H). Most reduction of aSyn OD was observed in the SN (5-day: P < 0.01 and 28-day: 
P < 0.05, Bonferroni post hoc test).
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Figure 8: Sensitivity of wildtype (WT) and Sncatm(A30P) (Tm) mice for 6-hydroxydopamine (6-OHDA).  
D-amphetamine-induced rotations were measured 2 and 4 weeks after unilateral, striatal 0.33 (A) or 
1.0 μg (B) 6-OHDA injection, where no signifi cant rotational bias was observed at any time point 
or group. Analysis of striatal dopamine (DA) (C) and its metabolites 3,4- dihydroxyphenylacetic 
acid  (DOPAC) (D) and homovanillic acid (HVA) (E) and ratios of DOPAC/DA (F) and HVA/DA 
(G) 4 weeks after 6-OHDA injection revealed that only 1.0 μg dose of 6-OHDA signifi cantly reduced 
striatal DA in WT mice.  n=6-10. * P<0.05 Intact vs 1.0 μg, Bonferroni post hoc test, 2-way ANOVA.
Figure 9: Optical density (OD) analysis of α-synuclein immunoreactivity in the substantia nigra 
(SN), striatum (STR) and motor cortex (M1 cortex) of young and aged WT and Sncatm(A30P) (Tm) mice. 
n=3-4. * P<0.05; ** P<0.01 vs. young of same genotype, Bonferroni post hoc test, 2-way ANOVA.
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Soluble and insoluble forms of aSyn were separated by fractionation and analysed using WB. 
HMW (over 100 kDa) oligomeric forms of aSyn were increased in Sncatm(A30P) mice compared 
to WT littermates and also A30P aSyn dimers seemed to have increased, although this did not 
reach signifi cance. 28-day KYP-2047 treatment signifi cantly reduced the amount of A30P aSyn 
HMW oligomers (P = 0.019, F1,12= 7.217, 2-way ANOVA, P < 0.05 Snca
tm(A30P), Bonferroni 
post hoc test) and had a tendency to decrease A30P aSyn dimers (Fig. 10 J and M).  Levels of 
soluble and insoluble monomeric aSyn forms remained unchanged after treatments and between 
genotypes (Fig. 10 K-L and N-O).
5.2.4  Effects of PREP inhibition on brain dopaminergic system 
in Sncatm(A30P) mice (III)
In the previous paper from Plaas et al (2008), striatal DA content of Sncatm(A30P) mice was 
decreased in comparison to WT mice. In our HPLC analysis, there was no baseline difference 
in the STR DA content between genotypes at 16 or 12 months of age. Because we observed 
reduced aSyn amount in the brains of Tm mice, which could potentially have an impact on 
the brain dopaminergic system, the DAergic system after the KYP-2047 treatment was 
characterized. Subchronic 5-day treatment with KYP-2047 increased DOPAC and HVA levels 
but DA concentration was unchanged in both groups (Treatment effect: DOPAC: P = 0.0444, 
F1,34=4.356, HVA: P = 0.027, F1,34=5,329, 2-way ANOVA; Fig. 11 A-B). Chronic 28-day KYP-
treatment had opposite effects between the genotypes on DA and metabolite levels. 
The STR DA content signifi cantly increased in the Tm mice (Interaction: P = 0.01, F1,17 = 15.72; 
genotype effect: P = 0.02, F1,17 = 6.647; Bonferroni post hoc test: Tm vehicle vs. KYP-2047 
P < 0.01, 2-way ANOVA; Fig. 11 C). DOPAC and HVA amounts seemed to increase in Tm 
and slightly reduce in WT mice after KYP-2047 (HVA: interaction: F1,17= 5.428; P = 0.032, 
2-way ANOVA;  P < 0.01, Tm veh vs Tm KYP-2047, Bonferroni post hoc test) and DOPAC 
(Interaction: P = 0.008, F1,17= 8.909 2-way ANOVA) (Fig. 11 D).  To analyse the DAergic 
markers in the STR, IHC staining and OD analysis of DAT and TH were performed. 5-day 
KYP-2047 did not have an effect on DAT immunostaining but 28-day treatment signifi cantly 
decreased DAT OD in both genotypes (Treatment effect: P = 0.02, F1,12 = 7.37; 2-way ANOVA) 
(Fig. 11 E). TH was not changed due to aSyn genotype or KYP-2047 treatment (data not shown).
28-day KYP-2047 treatment was delivered using i.p. micro-osmotic pumps. Their functionality 
was confi rmed by measuring PREP activity from the brain, which was reduced by 50 % 
compared to vehicle treated controls (Fig. 11 F).
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Figure 10: Brain α-synuclein (aSyn) analysis of KYP-2047(a prolyl oligopeptidase inhibitor, KYP) 
or vehicle (veh) treated wildtype (WT) and Sncatm(A30P) (Tm) mice. Representing images of aSyn 
immunohistochemistry of WT (A,D), Tm vehicle (B,E) and Tm KYP-2047 (C,F) samples. Substantia 
nigra (SN) top row and striatum (Stri) bottom row. 5-day (G) and 28-day (H) KYP-2047 treatment 
reduced aSyn optical density (OD). Representing image of aSyn Western blot (I). High-molecular 
weight (HMW) (J,K), dimers (K,N) and monomers (L,K) of aSyn after 5 and 28-day KYP-2047 
treatments. n=3-4. * P<0.05 Bonferroni post hoc test, 2-way ANOVA.
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Figure 11: Analysis of striatal dopamine (DA) (A, C) and its metabolites 3,4- dihydroxyphenylacetic 
acid  (DOPAC) and homovanillic acid (HVA) (B, D) of wildtype (WT) and and Sncatm(A30P) 
(Tm) mice after 5 and 28-day KYP-2047, a prolyl oligopeptidase (PREP) inhibitor, treatment. 
Immunohistochemical staining and optical density (OD) analysis of striatal dopamine transporter 
(DAT) after 28-day KYP-207 treatment (E). PREP activity measurement from the brain after 28-day 
KYP-2047 administraion with intraperitoneal micro-osmotic pumps (F). n=3-10. * P<0.05; ** 
P<0.001; Bonferroni post hoc test, 2-way ANOVA.
5.3  PREP inhibition induces macroautophagy in 
Sncatm(A30P) mice and in HEK-293 cell culture (III)
To clarify the mechanism of KYP-2047-induced aSyn clearance, we decided to investigate the 
markers of UPS and autophagy pathways, which both take part in aSyn degradation and are 
interesting candidates for aSyn-modulating drug therapy. 20S proteasome activity seemed to 
be reduced in Tm animals, whereas 28-day but not 5-day KYP-2047 treatment increased the 
activity in Tm mice (Interaction: P = 0.066, F1,32 = 3.598, 2-way ANOVA; Fig. 12 A-B). 
In addition, macroautophagy could be altered due to A30P-mutated aSyn or KYP-2047 
treatment. Therefore, we used WB to investigate autophagosome marker, LC3BII, levels, 
which is known to accumulate in the cells when more autophagosomes are formed or if their 
lysosomal degradation is compromised. In Tm mice, increased LC3BII levels were observed 
indicating higher basal activity of macroautophagy (Genotype effect: P = 0.02, F1,8 = 8.427, 
2-way ANOVA). A 5-day KYP-2047 treatment signifi cantly increased LC3BII levels in both 
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genotypes, especially in the Tm mice (Treatment effect: P = 0.017, F1,8 = 8.980; 2-way ANOVA, 
P < 0.05 KYP-2047 vs. vehicle in Sncatm(A30P), Bonferroni post hoc test; Fig. 12 C). Yet, the same 
effect was not seen after 28-day treatment (Fig. 12 D). 
Figure 12: In vivo brain 20S proteasome activity of KYP-2047 (a prolyl oligopeptidase inhibitor) or 
vehicle treated wildtype (WT) and Sncatm(A30P) (Tm) mice; 5-day (A) and 28-day (B) treatments. Brain 
autophagosome marker, LC3BII, levels after 5-day (C) and 28-day (D) treatments. n=3-10. * P<0.05 
KYP-2047 vs. vehicle, Bonferroni post hoc test, 2-way ANOVA.
We utilized pharmacological inhibition of autophagy with 3-MA, an inhibitor of autophagosome 
formation, and Baf, an inhibitor of lysosomal autophagosome degradation, together with 
PREP inhibition. WB analysis showed that inhibition of autophagosome formation by 3-MA 
signifi cantly increased accumulation marker, p62, levels (F2,12 = 4.042; P = 0.045; 3-MA vs. 
control, 2-way ANOVA), and KYP-2047 returned p62 levels to the normal in the 5 mM 3-MA 
group (P < 0.05, KYP-2047 vs. vehicle, Bonferroni post hoc test; Fig. 13 A). Baf caused minor 
increase in the accumulation of p62. 
3-MA decreased the amount of the autophagosome marker, LC3BII, pointing to impaired 
autophagy, and KYP-2047 (1 μM), signifi cantly increased LC3BII levels in all groups (Fig. 13 
B; F1,12 = 19.28; P = 0.0009 KYP-2047 effect;: P < 0.01 KYP-2047 vs. vehicle in 5 mM 3-MA, 
Bonferroni post hoc test, 2-way ANOVA). To study that the observed increase in autophagosome 
amount was due to autophagy induction via KYP-2047 and not blocked lysosomal degradation, 
the degradation of autophagosomes was inhibited by 10 or 50 nM Baf. The levels of LC3BII 
were increased by 2–3-fold compared to control (Fig 13 B; F2,22 = 15.73; P = 0.0001 Baf effect, 
2-way ANOVA), and KYP-2047 further increased the LC3BII levels, pointing to autophagosome 
formation enhancing effect (F1,22 = 5.762; P = 0.025 KYP-2047 effect; P < 0.05 KYP-2047 vs. 
vehicle in Baf 50 nM group, Bonferroni post hoc test, 2-way ANOVA). 
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Beclin 1 is a positive regulator of autophagy and both concentrations of 3-MA decreased the 
levels of beclin 1 (F2,15 = 4.242; P = 0.035 3-MA effect, 2-way ANOVA; Fig. 13 C). Similar to 3- 
MA, both Baf concentrations insignifi cantly decreased the levels of beclin 1 dose-dependently. 
However, KYP-2047 signifi cantly increased beclin 1 levels in all study groups (3-MA: F1,5 = 
6.42; P= 0.023 KYP-2047 effect; Baf: F1,12 =11.00; P = 0.006 KYP-2047 effect, 2-way ANOVA) 
indicating a positive regulation of autophagy. To confi rm the observations with beclin 1 levels 
in WB analysis, beclin 1 mRNA levels after KYP-2047 exposure were measured. 24h KYP-
2047 exposure for HEK-293 cells signifi cantly increased the beclin 1 mRNA levels (P = 0.025, 
Student’s t-test; Fig. 13 D), indicating an activation of autophagy.
Figure 13: The effects of autophagy inhibitors 3-methyladenine (3-MA) and bafi lomycin A1 (Baf) 
combined with 1 μM KYP-2047 (a prolyl oligopeptidase inhibitor) or vehicle on autophagy in HEK-
293 cell culture. 3-MA signifi cantly increased accumulation marker, p62, levels and incubation with 
KYP-2047 signifi cantly decreased the 5mM 3-MA-dependent increase in p62, whereas 24h incubation 
with Baf had no effect on p62 (A). 3-MA reduced the formation of autophagosomes but KYP-2047 
overcame this by increasing the autophagosome marker, LC3BII, levels, Baf signifi cantly increased 
autophagosomes and KYP-2047 further increased the LC3BII (B). Beclin 1 levels decreased by 3-MA 
and insignifi cantly by Baf, while KYP-2047 signifi cantly increased beclin 1 in both cases (C). Beclin 
1 mRNA level signifi cantly increased after KYP-2047 treatment in qPCR analysis (D). n=3-6. * 




5.4  Lactacystin-induced ubiquitin-proteasome system 
defi ciency as a mouse model of Parkinson’s Disease 
and the effects of PREP inhibition in the model (IV)
UPS dysfunction is linked to aSyn pathology in PD. To characterize UPS inhibition as a PD 
mouse model, LC was administered above SNc using stereotactic microinjection. 10 days after 
the LC injection, young and aged mice were sacrifi ced, and IHC analysis of aSyn and markers 
Figure 14: Proteasome inhibitor lactacystin (LC) -induced α-synuclein (aSyn) accumulation 
and neurodegeneration in young and aged mice. Representative images of aSyn, glutamic acid 
decarboxylase (GAD) and tyrosine hydroxylase (TH) stained brain sections (A). Microinjection of LC 
above the substantia nigra (SN) pars compacta induces aSyn (B, G) and GAD (C, H) accumulation, 
TH+ neuron loss in SN (E-F, J-K) and loss of striatal (STR) TH+ terminals (D, I) of young and aged 
mice.  LC-injected mice received a 5-day treatment of KYP-2047 (a prolyl oligopeptidase inhibitor) 
or vehicle immediately after LC microinjection. KYP-2047 reduced LC-induced TH OD loss. PBS 
microinjection was used as a sham control for LC.  young n=4-9, aged n=3-4 (data for aged mice are 
supplemental results). * P<0.05; ** P<0.01; P<0.001 Newman-Keuls post hoc test, 1-way ANOVA.
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of DAergic, GABAergic and neuroinfl ammation were performed. IHC data for aged animals are 
supplemental to the manuscript. In IHC, signifi cant accumulation of aSyn was observed in the 
lesioned side of the brain, particularly in the SN pars reticulata (SNr) (Fig. 14 B, G). Number of 
TH+ neurons in the SNc as well as density of TH+ fi bres in the SNr were reduced (Fig. 14 E-F 
and J-K), while GABAergic marker GAD was signifi cantly increased in the SNr (Fig. 14 C and 
H). In the STR, aSyn accumulation was not observed in IHC (data not shown), but small lesion 
was visible when TH OD was analysed in the STR (Fig. 14 D and I). In young mice, STR DA, 
DOPAC, HVA, 5-HT and 5-HIAA content were analysed, and LC induced signifi cant depletion 
of DA and DOPAC (DA: P < 0.0001, F1,23= 30.82, LC vs intact P < 0.01 in vehicle, Bonferroni 
post hoc test; DOPAC: P =0.0006, F1,22=16, LC vs intact P < 0.01, Bonferroni post hoc test, 
2-way ANOVA) whereas it did not have an effect of HVA (Fig. 15) or 5-HT and 5-HIAA (data 
not shown). In young mice, IHC staining for astroglial marker GFAP and microglial marker 
Iba1, revealed remarkable activation of glial cells throughout the lesioned hemisphere at the 
nigral level, and mild astroglial activation was also observed in the ipsilateral STR (Fig. 16). 
Figure 15: Microinjection 
of lactacystin (LC) above 
substantia nigra pars 
compacta induced depletion 
of striatal dopamine DA (A) 
and 3,4 dihydroxyphenylacetic 
acid (DOPAC) (B) whereas 
homovanillic acid (HVA) (C) 
content was not signifi cantly 
altered. Mice received a prolyl 
oligopeptidase inhibitor, KYP-
2047 (10mg/kg/day i.p.), or 
vehicle for 5 days after LC-injection. Tissue samples were collected 10 days after LC. n=6-7. * 
P<0.05; ** P<0.01 LC vs. intact, Bonferroni post hoc test, 2-way ANOVA
In motor behavioural tests, LC induced motor defi cits, which were partially different between 
young and aged mice. Behavioral results for aged mice are supplemental data. LC reduced both 
horizontal and vertical activity of young mice, (P = 0.0391; F2,27 = 3.664; 1-way ANOVA; Fig. 
17 A-B). Whereas, no signifi cant differences were observed in aged mice (Fig. 17 C-D). In 
cylinder test, there was a statistically signifi cant LC-effect (P = 0.0380; F2,27 = 3.680, 1-way 
ANOVA) when the landing paw preference was counted. LC mice used more contralateral paw 
compared to PBS (Fig. 17 E-F). In the group of aged mice, LC treated mice preferred to use 
ipsilateral paw for rearing signifi cantly more than control group (P = 0.0107; F2,7 = 9.294, 1-way 
ANOVA; P < 0.05, PBS vs. LC, Newman-Keuls post hoc test).  For the landing, aged LC mice 
used more ipsilateral paw but it did not signifi cantly differ from PBS controls in post hoc test. 
In order to study PREP inhibition in LC-based model, mice were treated with KYP-2047 for 
fi ve days starting immediately after the LC microinjection. In young, KYP-2047 treated mice 
we did not see differences in IHC of aSyn in the SN or STR but smaller TH loss in the STR was 
observed after KYP-2047 treatment. Moreover, KYP-2047 treated mice had signifi cantly higher 
amount of TH+ fi bres left in the lesion side compared to vehicle treated mice. GAD remained 
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unchanged between the treatment groups, and KYP-2047 did not have an effect on DA content 
in the STR or activation of astroglia and microglia. In aged mice, neuroprotective effects with 
KYP-2047 were not observed (supplemental results).
 
Figure 16: Neuroinfl ammation around injected brain hemisphere after lactacystin (LC)-
induced proteasome inhibition in the subsantia nigra pars compacta of mice (9 weeks old). 
Immunohistochemical staining and optical density (OD) analysis of astroglial (GFAP, glial fi brillary 
acidic protein, A-F, M) and microglial (Iba1, Ionized calcium binding adaptor molecule 1, G-L, N) 
cells. n=3. * P<0.05; ** P<0.01; *** P<0.001 vs. PBS control, Newman-Keuls post hoc test, 1-way 
ANOVA.
In motor behavioural tests, LC-induced reduction of horizontal and vertical activity of young 
mice was not seen in the KYP-2047 treated group (vertical counts: P = 0.0391; F2,27 = 3.664; 
P < 0.05, vehicle vs. KYP-2047, Newman-Keuls post hoc test, 1-way ANOVA; Fig. 17 A-B). 
KYP-2047 did not have an effect on the activity of aged mice (Fig. 17 C-D). In cylinder test, no 
KYP-2047 or LC induced differences were observe in young mice upon rearing but the paw use 
for landing was at the same level between PBS and LC + KYP-2047 group, and LC + vehicle 
mice used more contralateral paw (P = 0.0380; F2,27 = 3.680, 1-way ANOVA) although this did 
not reach signifi cance in post hoc tests (Fig. 17 E-F). 
In the aged mice, LC-induced ipsilateral paw use was upended for the use of contralateral paw 
by KYP-2047; statistically signifi cant difference between LC + vehicle and LC + KYP-2047 
groups upon rearing (P < 0.01, Newman-Keuls post hoc test), and for the landing, (P = 0.0053; 
F2,8 = 10.83, 1-way ANOVA, P < 0.05 PBS vs. LC + KYP-2047, P < 0.01 LC + vehicle vs. LC + 
KYP-2047, Newman-Keuls post hoc test).
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Figure 17: The effect of KYP-2047 (a prolyl oligopeptidase inhibitor) on lactacystin (LC)-
induced motor decline in mice. Characterization of motor behaviour of young and aged mice after 
microinjection of LC above substantia nigra pars compacta, PBS microinjection was used as a 
control. Mice were treated with KYP-2047 for 5 days after LC injection. Horizontal and vertical 
activities were measured for 2 hours and cylinder test was recorded for 5 min. Young n=4-9, aged 





6.1  Enhanced dimerization of α-synuclein via direct 
protein-protein interaction with PREP is modulated by 
KYP-2047(I)
Earlier cell-free in vitro studies have shown that purifi ed recombinant PREP enhances aSyn 
aggregation in vitro, whereas inactive mutant, PREP(S554A), did not have the same effect 
(Brandt et al., 2008). Furthermore, inhibition of enzyme activity of PREP by small-molecule 
inhibitors abolished the aggregation-promoting effect of PREP. PREP inhibitors were also 
shown to reduce oxidative-stress-induced aSyn aggregation in cell culture models (Myöhänen 
et al., 2012, Van der Veken et al., 2012) and accumulation of aSyn in aSyn overexpressing TG 
mice (Myöhänen et al., 2012). Furthermore, PREP had been shown to colocalize with aSyn in 
cell culture (Myöhänen et al., 2012) and in brain of PD patients (Hannula et al., 2013). These 
data suggests PREP inhibition as an interesting candidate for further investigation as an aSyn 
aggregation-modulating drug. 
Dimerization is the fi rst step of aSyn aggregation process (Wood, 1999, Uversky et al., 2001a 
and 2007), and we showed that PREP and PREP(S554A) interact with aSyn in both MST and 
PCA, and that they promote dimerization of aSyn in PCA in living cells. This, together with the 
fi ndings that PREP enhances aSyn aggregation in in vitro aggregation assay (Brandt et al., 2008) 
suggest that PREP  acts as a seeding point for aSyn nucleation as does the interaction of aSyn 
with some other proteins, such as Aβ (Masliah et al., 2001), Tau (Giasson et al., 2003), tubulin 
(Kim et al., 2008) and FK506 binding proteins (Gerard et al., 2010). Interestingly, we also 
observed that the interaction happened between catalytically inactive PREP and aSyn. PREP 
and PREP(S554A) could therefore both act as a seeding point for the aggregation. 
PREP is an enzyme and its main physiological function is connected to degradation and 
maturation of small, less than 30 amino acids long, peptides (Toide et al., 1995, Garcia-
Horsman et al., 2007). It does not cleave aSyn (Brandt et al., 2008) and therefore it had been a 
question if PREP could have relevance in aSyn aggregation and what would be the mechanism 
of it. Interestingly, several studies provide evidence that PREP has other, in some cases 
enzyme activity-independent, neuronal functions in addition to its neuropeptide cleaving role, 
such as a role in cell-death via GAPDH regulated genotoxic stress (Matsuda et al., 2013), a 
regulatory role in growth cone function via interaction with GAP-43 (Di Daniel et al., 2009), 
a role in axonal transport and protein secretion (Schulz et al., 2005), or regulation of insulin 
and glucagon secretion via hypothalamic regulatory pathway (Kim et al., 2014). It was also 
shown in previously mentioned and other studies that PREP interacts with GAPDH and GAP-43 
proteins (Di Daniel et al., 2009, Szeltner et al., 2010, Matsuda et al., 2013), and now our studies 
show that PREP can interact with aSyn, thus regulating its dimerization and aggregation.
It was an intriguing fi nding that KYP-2047 only reduced PREP-induced aSyn dimerization 
and had no effect on PREP(S554A)-induced aSyn dimerization in the cell culture model. Other 
studies have shown that PREP adopts different conformational states, which can be modifi ed by 
KYP-2047 or other inhibitors (Tarrago et al., 2009, Szeltner et al., 2010, Kichik et al., 2011). 
This is supported by fi ndings of this study indicating that KYP-2047 modifi es the conformational 
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state of PREP but not PREP(S554A). Furthermore, when gating properties of PREP have been 
studied and modelled, it has been suggested to undergo conformational alterations upon inhibitor 
binding (Kaszuba et al., 2012, Szeltner et al., 2013, Kaushik et al., 2014). These observations 
propose that the closed conformation of PREP, which can be induced by KYP-2047, binds to 
aSyn and reduces its dimerization, whereas other conformations promote aggregation. To study 
this further, the infl uence of different conformational states on aSyn interaction and aggregation 
could be examined. These methods could also be used to screen and characterize protein-protein 
interactions of PREP with other aggregate-prone proteins.
6.2  Characterization of brain α-synuclein pathology, 
dopaminergic system and neurotoxin sensitivity of 
Sncatm(A30P) mouse strain (II & III)
A30P mutated aSyn is associated with early-onset PD in humans (Krüger et al., 1998). It is 
more prone to form fi brils than WT aSyn (Conway et al., 2000b) and therefore appears to be 
more neurotoxic. The majority of TG mouse strains carry additional human aSyn transgene 
on top of endogenous Snca gene. The reason to use a mouse strain that had point mutation 
insertion in endogenous Snca gene and no aSyn TG addition, was to more closely mimic human 
genetic background in the disease model. In the earlier study, where Sncatm(A30P) mouse line was 
characterized, the main fi ndings of Plaas et al. (2008) were age-dependent motor decline in 
beam walk and stride length tests, and reduced DA and DOPAC content in the STR. In the 
study II, horizontal and vertical activities, brain aSyn immunostaining, DA neurochemistry and 
6-OHDA sensitivity were compared between Tm mice and WT littermates. We showed that Tm 
mice were more active during the fi rst hours of activity measurement, they had accumulation of 
aSyn in the brain compared to WT mice, but there were no differences in the basal DA levels as 
the mice aged to 6, 13 or 16 months. Moreover, A30P mutation in Snca gene did not sensitize 
the 6 months old mice to toxicity of 6-OHDA. The main observations in this study were partially 
different than the results of Plaas et al. (2008)
Unexpectedly, we did not observe either age-dependent motor decline or DA depletion in the 
STR of Tm mice. Instead, we detected increased horizontal activity of aged and young mice in 
the beginning of the activity measurement and normal DA in the STR. The distinct observations 
between us and Plaas et al. might be explained by difference in the generation of the mice in 
the studies. aSyn regulates synaptic vesicular pool (Murphy et al., 2000) and A30P mutation 
has been shown to reduce its vesicle binding activity (Jensen et al., 1998). Therefore, altered 
presynaptic vesicle pool regulation affecting Tm mice could explain our observation of minor 
changes in motor behaviour. Moreover, A30P aSyn reduces DAT activity (Wersinger et al., 
2003) and inhibition of DAT is shown to cause hyperactive behaviour in monkeys (Andersen et 
al., 2012). Increased motor activity has also been described in aSyn overexpressing mouse lines 
(Neumann et al., 2002, Lam et al., 2011, Farrell et al., 2014). Furthermore, it is possible that TG 
mice develop compensatory mechanisms against pathological aSyn (Kreiner, 2015). 
At 4 weeks post-lesion, 1.0 μg 6-OHDA reduced STR DA content in both genotypes by 
approximately 30 %, but it reached signifi cance only in WT mice. The data is consistent with 
our behavioural observations where 6-OHDA did not induce signifi cant rotational bias after 
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D-amphetamine challenge, although at 4 weeks post-lesion WT mice rotate to ipsilateral 
direction. A30P aSyn-induced alterations in DAT or VMAT2 activities could make Tm mice more 
vulnerable or resistant to 6-OHDA toxicity, because 6-OHDA is taken up into neurons via DAT 
and sequestration of it into vesicles via VMAT2 could reduce its toxicity (Cleren et al., 2003, 
Schober, 2004). A30P aSyn is shown to be a negative regulator of DAT activity as compared to 
WT aSyn and they both protect cells from DA-mediated cellular stress and toxicity (Wersinger 
et al., 2003). A30P aSyn could therefore reduce the 6-OHDA induced neurodegeneration. When 
toxin sensitivity was tested, no robust toxicity of 6-OHDA in general could be observed in either 
of the genotypes. Therefore it seems that A30P mutation in mouse Snca gene does not induce 
remarkable alterations in DAT or VMAT functions. 
It is shown in mice that reduction of over 70 % of the SN TH+ neurons is required for motor 
defi cit to occur (Grealish et al., 2010), which supports the results of the current study where no 
great alterations in STR DA and in motor behaviour were detected. In literature, 6-OHDA is 
commonly used at higher doses than in our study: doses range from 4 ug (Akerud et al., 2001, 
Alvarez-Fischer et al., 2008), 8 ug (Morroni et al., 2014), 10 ug (Hernandes et al., 2013) and up 
to 20 ug (Silva et al., 2005). It was therefore likely that the doses of 0.33 and 1.0 μg, as used in 
study II, were too small to induce striatal lesion.
In the earlier report by Plaas et al. (2008) of Sncatm(A30P) strain, brain aSyn was not characterized. 
We thus wanted to measure if mouse A30P aSyn accumulates in the brain more than WT aSyn. 
The mice of both genotypes had only one copy of Snca gene but the brain aSyn levels were 
increased in aged Tm mice in IHC and WB observations. aSyn accumulated in the brain also 
by age in both of the genotypes. In WB analysis, A30P aSyn appeared to form more oligomers 
than WT aSyn in aged mice. Oligomeric forms of aSyn tend to accumulate in neurons, which 
may explain the stronger IHC staining. These results are supported by earlier fi ndings that 
human A30P aSyn causes early-onset PD in human, is more prone for aggregation than WT 
aSyn and disturbs its own cellular clearance (Krüger et al., 1998, Conway et al., 1998, Li et al., 
2001, Cuervo et al., 2004). Mouse A30P aSyn may have differences in its aggregation and toxic 
properties, since it is normal to mouse to carry A53T mutation in aSyn whereas in human it is 
abnormal and associated with PD (Lavedan, 1998). Most of the studies that have examined aSyn 
toxicity and accumulation have been done using human aSyn, which is clearly justifi ed. But 
the fundamental difference of the Sncatm(A30P) mouse not to have human aSyn expression makes 
it interesting for providing insight about differences between species. Indeed, A30P mutation 
appeared to cause aSyn accumulation and mild behavioural alterations, suggesting that it is 
more pathogenic than mouse WT aSyn.
For a good PD model and to study aSyn-modifying drugs, many features are expected from 
the model: LB-like aSyn accumulation and dopaminergic cell loss in the SNc, loss of DA in 
the STR and motor behaviour defi cits are the most important (Beal, 2010). Even though, some 
degree of accumulation of A30P aSyn was observed we did not detect motor decline or loss 
of DA and from this point of view the Sncatm(A30P) mouse model did not meet the requirements 
for a PD model, at least until the age of 16 months, which was used as an endpoint. We 
observed accumulation of A30P aSyn and also some disturbances in the DAergic system and 
motor behaviour. This implicates that the model recapitulates some pathological alterations 
of PD or other synucleinopathies and more likely refl ects the early changes occuring upon 
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aSyn accumulation. In this sense, it would be rational to use this model for studies of aSyn 
accumulation and its effects on brain function. In order to fi nd a better mouse PD model with 
aSyn pathology, it would be interesting to combine Sncatm(A30P)  mouse strain or some other 
mild aSyn pathology exhibiting TG mouse strain and pharmacological tools that induce aSyn 
aggregation or accumulation.
6.3  Benefi cial effects of KYP-2047 treatment in Sncatm(A30P) 
mice  and α-synuclein clearance associated with 
activation of macroautophagy (III)
Earlier studies had shown that PREP inhibition reduces the aggregation of aSyn in in vitro 
(Brandt et al., 2008), cell culture (Myöhänen et al., 2012, Van der Veken et al., 2012) and in 
the brain of aSyn TG mice (Myöhänen et al., 2012). Therefore, the purpose of the study III 
was to further assess the effects of KYP-2047 on aSyn conformations in Sncatm(A30P) mouse 
line. The main observations in study III were that KYP-2047 treatment reduced brain aSyn 
immunoreactivity in IHC, and in long-term treatment it also reduced HMW aSyn species in WB. 
Additionally, KYP-2047 modulated DA and metabolite levels in the STR, partly differentially. 
A30P aSyn oligomer accumulation was associated with reduced 20S proteasome activity, 
which returned to the control level after 28-day KYP-2047 treatment. Furthermore, short-term 
KYP-2047 treatment increased the brain LC3BII level, which is a marker of autophagosomes, 
suggesting enhanced autophagy. When PREP inhibition and autophagy were studied more 
closely in cell culture, KYP-2047 was shown to enhance beclin 1-mediated autophagy.
It is shown that oligomeric forms are the neurotoxic species of aSyn (Feng et al., 2010, Winner 
et al., 2011, Colla et al., 2012b) and their reduction is suggested as a feasible PD-modifying 
therapy option (Outeiro and Kazantsev, 2008, Lashuel et al., 2013). Because we did not observe 
robust PD-like pathology in Sncatm(A30P) mice, we did not expect a lot of changes, for example in 
behavioural assays, in association with drug treatments. The lack of strong aSyn pathology is also 
a drawback of this model because it limits the possibilities to fully evaluate the effects of drug 
treatment. Nonetheless, reduced load of HMW aSyn oligomers was observed in Tm mice after 
28-day KYP-2047 administration. Interestingly, we also measured altered DA and metabolite 
levels in the STR following the KYP-2047 treatment. Short-term KYP-2047 administration 
appeared to increase DA metabolite levels in both mouse strains but 28-day treatment robustly 
increased DA and HVA levels only in Tm mice. We therefore suggest that the elevated DA and 
HVA levels after longer treatment are associated with reduced HMW aSyn amount and follow the 
changes in aSyn-mediated modulation of DA turnover. These alterations could occur via altered 
aSyn effects on DA production or degradation, since aSyn overexpression and accumulation 
have been associated with Nurr1 downregulation in cell culture (Baptista et al., 2003) and in 
PD patients (Jankovic et al., 2005), Nurr1 reduction can lead to reduction of expression of DAT, 
TH, VMAT2 and AADC (Baptista et al., 2003, Jankovic et al., 2005). aSyn has been shown to 
inhibit TH activity (Perez et al., 2002, Peng et al., 2005) and aSyn aggregation into LB-like 
inclusions has also been linked to reduced inhibitory capacity over TH activity (Alerte et al., 
2008, Wu et al., 2012). Because no changes were observed in TH immunorectivity between 
genotypes or treatments it is likely that reduced aSyn amount in KYP-2047 treated Tm mice 
could contribute to increased activity of TH and subsequently increased DA content in the brain. 
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Interestingly, we also noticed reduced DAT immunoreactivity in the STR after 28-day KYP-
2047 treatment in both of the genotypes. aSyn overexpression is associated with augmented 
DAT expression in mice (Bellucci et al., 2011), KYP-2047-mediated aSyn reduction could have 
thus induced DAT down regulation. 
 
The observations of KYP-2047-induced reduction of HMW aSyn were done in the aged Tm 
mice, which had A30P aSyn accumulation in the brain. Since KYP-2047 had an effect on already 
accumulated aSyn load, it raised the question if PREP could have an effect on aSyn cellular 
clearance. Therefore, the relevant pathways for aSyn clearance were studied more closely. 
UPS is important for aSyn degradation, but it can be compromised by A30P aSyn or HMW 
aSyn (Tanaka et al., 2001, Snyder et al., 2003, Alvarez-Castelao et al., 2014). As expected, we 
observed mild reduction of 20S proteasome activity in aged Tm mice. Proteasome dysfunction 
has been associated with aSyn overexpression also in other studies (Chen et al., 2006). KYP-
2047 itself does not have an effect on proteasome activity in cell culture (unpublished data, 
Myöhänen TT) and because PREP inhibition did not have the same effect on both genotypes it is 
likely that the recovery of proteasomal activity after KYP-2047 treatment in Tm mice is a result 
of reduced aSyn oligomer burden. Thus, we ruled out the possibility of PREP inhibition as a 
proteasomal function modifying agent.
Macroautophagy is an interesting target for drug research due to its inducible nature. It is also 
thought to participate in the degradation of HMW protein complexes, including aSyn. Elevated 
levels of LC3BII in Tm mice after KYP-2047 treatment could refl ect either enhanced autophagy 
or accumulation of autophagosomes as a result of their blocked lysosomal degradation (Klionsky 
et al., 2008). We therefore tested the effect of KYP-2047 together with autophagy inhibitors in 
cell culture. KYP-2047 reversed the 3-MA-inhibited formation of autophagosomes and reduced 
the level of accumulation marker, p62. Moreover, when the fusion of the autophagosome and 
the lysosome was blocked with Baf, KYP-2047 treatment further elevated the LC3BII levels. 
This data points to a KYP-2047-mediated increase in the formation of autophagosomes, 
which was further supported by the fi ndings that KYP-2047 elevated the levels of beclin 1 
in autophagy inhibitor assay in WB and increased amount of beclin 1 mRNA. Beclin 1 is a 
positive regulator of autophagy, which is controlled by a complex network of many positive and 
negative regulators (Spencer et al., 2009, Kang et al., 2011, Fu et al., 2013). Beclin 1 is also 
an anti-apoptotic protein (Kang et al., 2011, Decuypere et al., 2012). Our results suggest that 
PREP could be one of the direct modulators which interact with beclin 1, or it could have an 
effect on some downstream factor along the cascade. Some studies have suggested that PREP 
is an indirect negative regulator of inositol 1,4,5- triphosphate, because PREP inhibitors and 
loss of PREP coding gene have been shown to transiently elevate  inositol 1,4,5- triphosphate 
levels (Williams et al., 1999, Harwood, 2011). Inositol 1,4,5 –triphosphate receptor-mediated 
signaling may positively or negatively regulate autophagy depending on the cellular conditions 
(Parys et al., 2012). Based on the fi ndings of this and other studies showing a positive role of 
PREP inhibition on aSyn clearance and cell survival (Lambeir, 2011, Myöhänen et al., 2012, 
Dokleja et al., 2014), the inositol 1,4,5-triphosphatecould be a target for the observed actions of 
PREP inhibitors. However, as multiple pathways play a role in autophagy the mechanism for the 
observed beclin 1-mediated autophagy enhancement and resulting aSyn clearance remains to be 
further clarifi ed in the future.
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Autophagy enhancement has proved to facilitate protection against aSyn toxicity; in cell culture, 
curcumin-directed autophagy enhancement protects cells from A53T aSyn toxicity (Jiang et al., 
2013) and lentivirus-mediated beclin 1 overexpression effectively reduced aSyn accumulation 
(Spencer et al., 2009). It is intriguing that PREP inhibition has been shown to modulate Aβ 
formation and secretion in cell culture and to prevent the formation of amyloid-like inclusions in 
a mouse model (Shinoda et al., 1997, Kato et al., 1997), but it was also shown that PREP is not 
directly involved in Aβ formation and degradation (Petit et al., 2000). In light of the fi ndings of 
Study III, it is an interesting question whether the benefi cial effects of PREP inhibition seen in 
the mouse study that were not related to direct effect of PREP on Aβ, could have been associated 
with autophagy inductory function of PREP inhibition. At least in cell culture, autophagy-
induction has been proven to be neuroprotective against Aβ (Hung et al., 2009).
6.4  Lactacystin-induced proteasome inhibition as a 
mouse model of Parkinson’s disease and effects of 
KYP-2047 (IV)
Impaired UPS function in the SN is connected to PD pathophysiology (McNaught and Jenner, 
2001, McNaught et al., 2003). It is not only aSyn, which accumulate in LB-like inclusions, but 
over 70 components have been indentifi ed in the LBs, for example aSyn- or synphilin-binding 
proteins, proteins associated with proteasome or autophagy, lipids and many more (Wakabayashi 
et al., 2007). UPS pathway is in part responsible for cellular clearance of aSyn (Bennett et al., 
1999, Webb et al., 2003, Ebrahimi-Fakhari et al., 2011). However, aSyn inhibits the function of 
proteasomes (Bence et al., 2001, Tanaka et al., 2001, Snyder et al., 2003, Lindersson et al., 2004), 
other factors such as genetic mutations and oxidative stress may also impair UPS (Betarbet et 
al., 2005). UPS dysfunction may be responsible for increased aSyn accumulation, making the 
proteasome a cofactor in PD pathophysiology. Moreover, aSyn genetic overexpression is only 
a minor cause for PD and in many TG mouse models, very robust PD-like phenotype is not 
seen in spite of high expression of aSyn. To that end it was reasonable to study the features of 
proteasome-inhibition as a PD mouse model, which was the fi rst aim of study IV. Autophagy 
inductors have already been studied in some LC models: in cell culture, natural substances 
with an autophagy enhancing effect have been shown to improve cell viability (Bae et al., 2011 
and 2014), and autophagy enhancement by rapamycin has been benefi cial in a mouse study, 
where LC was injected into MFB (Pan et al., 2008). We hypothesized that autophagy induction 
by KYP-2047 might have benefi cial neuroprotective effects against toxicity of proteasome 
inhibition. Therefore, the second aim of study IV was to evaluate the ability of KYP-2047 to 
protect neurons against toxicity of LC.
The main fi ndings after unilateral LC administration above the SN were increased amount of 
aSyn and GAD-immunoreactivity in the lesioned side of the SN, associated with TH+ neuron 
and fi bre loss in the SNc and TH+ terminal loss and reduction of DA content in the STR. Similar 
to PD, astroglial and microglial activation was observed throughout the injected hemisphere. 




In earlier studies, LC injection has been introduced in the MFB or STR (Fornai et al., 2003, 
Vernon et al., 2011, Shen et al., 2013, Konieczny et al., 2014), and a recent paper described a 
mouse model based on intranigral LC injection, where Bentea et al. (2015) showed similar results 
to us: reduced amount of TH+ neurons, increased amount of aSyn and behavioural defi cits. In 
study IV, the end-point for the experiment was 10 days, which seems to be suffi cient for the 
manifestation of a PD-like phenotype. In Bentea et al. (2015) LC-induced lesion was shown 
to be non-progressive when lesion severity was compared at 1 and 3 weeks post-injection. LC 
induced rapid-onset neurodegeneration, which has been observed also in other studies (Vernon 
et al., 2011, Bentea et al., 2015). LC is an irreversible inhibitor of the proteasome (Fenteany and 
Schreiber, 1998), but it is possible that some spontaneous recovery occurs at later time points 
if the effect of LC is lost as new proteasomes are synthetized in the cells. Therefore, the LC 
model can be useful for an assessment of neuroprotective drugs but whether it is suitable for an 
evaluation of long-term treatments, remains to be elucidated.
LC reduced both the number of TH+ neurons and fi bres in the SN, which was consistent with 
the observed striatal DA depletion. Interestingly, we did not see as great a loss of DAergic TH+ 
terminals in the STR as would have been expected from the DA content. In young mice, KYP-
2047 appeared to partially protect TH+ fi bres in the SN and dopaminergic terminals in the STR, 
but could neither rescue cell bodies in the SNc nor restore DA in the STR. Additionally, in the 
behavioural assays KYP-2047 treatment opposed some of the LC-induced changes. This data 
suggests a neuroprotective effect of PREP inhibition over dopaminercig system.
LC did not have an effect on 5-HT and 5-HIAA levels in the STR. In Bentea et al (2015), 
parvalbumin IHC, a marker of GABAergic neurons was assessed in the SN and no changes in 
the number of neurons were observed. Therefore, the UPS inhibition seems to be specifi cally 
toxic to DAergic neurons in the SNc. In our hands the expression of GABAergic marker GAD 
was signifi cantly increased in the SNr. These results suggest that the observed GAD increase 
occurs due to reduced DAergic inhibition. Earlier studies with PD toxin models support this 
fi nding as increased GABAergic activity (Wang et al., 2010) and GAD mRNA expression (Salin 
et al., 2002, Wang et al., 2010) in the 6-OHDA lesion side of PD rat model were reported. 
Increased aSyn amount and pS129 aSyn after UPS inhibition have been shown (Bentea et 
al., 2015). Also in our study, increased aSyn accumulation in the SN was measured in the 
LC-lesioned side. In standard aSyn IHC, we did not detect differences in aSyn amount in the 
brain after KYP-2047. We tried to use PK-treatment, described in (Angot et al., 2012) and aSyn 
IHC to study the insoluble aSyn in the brain sections, but the assay did not work in our hands. 
Therefore, it remains a challenge to set up a functional assay for aSyn conformational analysis.
Previous studies have reported microglial and astroglial activation in the SN after LC injection 
into MFB (Zhu et al., 2007, Li et al., 2010). aSyn has been shown to activate infl ammatory 
responses of astroglial cells, (Lee et al., 2010a, Fellner et al., 2013). In this study, aSyn 
immunoreactivity was mainly increased in the SN, whereas marked astrogliosis and microgliosis 
were evident throughout the whole hemisphere at the nigral level. The widespread activation 
cannot be explained solely by direct infl uence of LC, because it has a local effect in the SN. This 
points to a more widespread activation of an infl ammation cascade due to UPS inhibition and 
imbalance in protein homeostasis. Glial activation is linked to PD pathogenesis; microglia and 
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astroglia normally have neuronal and brain tissue homeostasis supporting functions and they are 
activated upon stress, infl ammation and neurodegeneration. It has been proposed that they may 
promote neurodegeneration by pro-neuroinfl ammatory signals or they might be neuroprotective 
by participating in the degradation of pathological aSyn and release neuroprotective factors 
(Brück et al., 2015). Regulation of glial responses has been suggested as an option to target 
neurodegenerative diseases (Hirsch and Hunot, 2009). Based on the fi ndings of study IV, 
LC-based model could be utilized in the study of neuroinfl ammation in PD.
Neurodegeneration is a complex process and if it has proceeded enough, neuroprotective 
treatments might not be effective. Now KYP-2047 was administered for 5 days, immediately 
after LC injection. In other neuroprotection studies, the treatments have been generally started 7 
days before (Zhu et al., 2007, Li et al., 2010) or after (Zhu et al., 2007, Pan et al., 2008) the LC 
injection and continued 4 weeks post-injection, at which time point signifi cant neuroprotective 
effects were observed. In study IV, the endpoint was 10 days, and it is likely that the observed 
changes in the markers of DAergic system after KYP-2047 administration refl ect early recovery 
after LC microinjection. 
Taken together, UPS inhibition induces fast-onset PD-like phenotype in mice recapitulating the 
cardinal features of PD pathology: aSyn accumulation, DAergic neuron and DA loss, motor 
impairment and neuroinfl ammation. Moreover, KYP-2047-mediated partial neuroprotection 
was seen in young mice. This suggests that PREP inhibition can, at least in part, overcome the 




The aim of this work has been to study the effects of PREP inhibition in relation to aSyn 
aggregation in vitro and in vivo. In the study, multiple approaches were used in order to induce 
and examine aSyn aggregation and accumulation in vivo. Our fi ndings support the earlier 
studies that PREP inhibitors reduce aSyn aggregation, and provide evidence about mechanisms 
underlying this phenomena. Furthermore, PREP inhibition could be a benefi cial aSyn-modifying 
treatment strategy in PD and other synucleinopathies. The main fi ndings of the cell culture and 
in vitro models in addition to studies with TG mice and toxin administrations to mice, are:
I PREP and aSyn interact via direct protein-protein interaction. The interaction enhances 
aSyn dimerization independently of PREP enzyme activity, and aSyn dimerization is 
reduced when PREP is inhibited. This might be explained by PREP conformation shift 
into a compact form by the inhibitor.
II A30P point mutation in mouse Snca gene (Sncatm(A30P) strain) slightly induces aSyn 
aggregation but does not produce PD-like phenotype since it lacks motor defi cit and 
TH-positive cell loss. 
III In Sncatm(A30P) mice, PREP-inhibition reduces the amount of HMW forms of aSyn, which 
are considered to be the neurotoxic aSyn species. In the mouse model and in cell culture, 
KYP-2047 induces macroautophagic protein clearance, which may explain the reduced 
aSyn burden. 
IV Nigral administration of a proteasome inhibitor, lactacystin, produces fast-onset PD-like 
phenotype in mice, which is characterized by aSyn accumulation, neuroinfl ammation, 
loss of TH-positive neurons in the sustantia nigra and striatum together with motor 
behavioural defi cits. KYP-2047 partially protected substantia nigra TH-positive fi bres 




This work was carried out at the Division of Pharmacology and Pharmacotherapy, Faculty of 
Pharmacy, University of Helsinki during the years 2011 and 2015.
The fi nancial support from the following funders is gratefully acknowledged: FinPharma 
Doctoral Program Pharmacy section, The Emil Aaltonen Foundation, The Finnish Parkinson 
Foundation and The Finnish Pharmaceutical Society.
I wish to express my deepest gratitude to my supervisors Docent Timo Myöhänen and Professor 
(emeritus) Pekka Männistö. Timo is warmly thanked for giving me the opportunity to work in 
his group, for guidance and support on my way of becoming a scientist, and for introducing 
me to the world of α-synuclein and prolyl oligopeptidase. Thank you for reminding me during 
the times of despair that “it will go well / hyvin se menee”. Pekka, thank you for sharing your 
expertise in pharmacology and neuroscience. I appreciate guidance with scientifi c writing and 
encouragement that you have given.
Professor Raimo Tuominen is thanked for agreeing to act as a custos in the public defense of this 
thesis and for giving advice during the years.
Reviewers of this thesis, Professors Anne-Marie Lambeir and Markus Forsberg, are thanked for 
the constructive comments and suggestions, which substantially improved the thesis manuscript.
I would like to thank Professor Heikki Tanila for agreeing to act as my opponent in the public 
defense of this thesis.
I wish to express my gratitude to all my co-authors for their contribution, which has made this 
work possible. Especially I would like to thank Dr. Marjo Piltonen for sharing her knowledge 
in the beginning of my PhD project, Dr. Brandon Harvey and Dr. Christopher Richie, for 
sharing their expertise and giving me the great opportunity to learn molecular biology methods 
in NIDA, Baltimore, and M.Sc. Xu Yan and M.Sc.Katrina Albert for great collaboration. Dr. 
Mikko Airavaara, for generous assistance and advice with my experiments and Docent Henri 
Huttunen for sharing his expertise.
The current and former colleagues of Division of Pharmacology and Pharmacotherapy are 
warmly thanked for their help during all these years. Particularly, Johanna, Iida, Susanne, Virpi 
and Jaakko, I appreciate our scientifi c discussions over the years. I would like to express my 
gratitude to laboratory technicians Marjo Vaha and Liisa Lappalainen for outstanding technical 
assistance with my experiments. I would especially like to thank Kati Rautio, without her, I 
would most likely still be doing sectioning and stainings.
I am deeply thankful to my dear colleagues in Myöhänen research group. Mirva for friendship 
since the fi rst day of our master’s studies, for sharing so many great moments and for the support 
in the diffi cult times. Reinis, Ulrika and Susanna, I greatly appreciate your friendship and the 
positive environment in the offi ce that you have created.
Acknowledgements
74
I would also like to thank all my friends outside the world of science for continuous 
encouragement and most importantly all the discussions and free time activities from dinners 
and late-nights, to travels and networking activities. Especially Laura, Eve M., Liisa, Eve R., 
Merja and Piia, I am so lucky to have such a great friends around me.
Finally, I express my deepest gratitude to my dearly loved family. I want to thank my mother 
Tuula, my brother Sakari, and my sister Johanna and her family, my father Kalle and his family, 








Abeliovich, A. (2000). Mice lacking alpha-synuclein display functional defi cits in the nigrostriatal 
dopamine system. Neuron 25: 239-52.
Abeywardana, T., Pratt, M. R. (2015). Extent of inhibition of alpha-synuclein aggregation in vitro by 
SUMOylation is conjugation site- and SUMO isoform-selective. Biochemistry 54: 959-61.
Abou-Sleiman, P.M., Muqit, M. M. & Wood, N. W. (2006). Expanding insights of mitochondrial 
dysfunction in Parkinson’s disease. Nat.Rev.Neurosci. 7: 207-19.
Ahn, K.J., Paik, S. R., Chung, K. C. & Kim, J. (2006). Amino acid sequence motifs and mechanistic 
features of the membrane translocation of alpha-synuclein. J.Neurochem. 97: 265-79.
Airavaara, M., Mijatovic, J., Vihavainen, T., Piepponen, T. P., Saarma, M. & Ahtee, L. (2006). In het-
erozygous GDNF knockout mice the response of striatal dopaminergic system to acute morphine is 
altered. Synapse 59: 321-9.
Akerud, P., Canals, J. M., Snyder, E. Y. & Arenas, E. (2001). Neuroprotection through delivery of 
glial cell line-derived neurotrophic factor by neural stem cells in a mouse model of Parkinson’s 
disease. J.Neurosci. 21: 8108-18.
Alerte, T.N., Akinfolarin, A. A., Friedrich, E. E., Mader, S. A., Hong, C. S. & Perez, R. G. (2008). 
Alpha-synuclein aggregation alters tyrosine hydroxylase phosphorylation and immunoreactivity: 
lessons from viral transduction of knockout mice. Neurosci.Lett. 435: 24-9.
Alvarez-Castelao, B., Goethals, M., Vandekerckhove, J. & Castano, J. G. (2014). Mechanism of 
cleavage of alpha-synuclein by the 20S proteasome and modulation of its degradation by the RedOx 
state of the N-terminal methionines. Biochim.Biophys.Acta 1843: 352-65.
Alvarez-Erviti, L., Seow, Y., Schapira, A. H., Gardiner, C., Sargent, I. L., Wood, M. J., et al. (2011). 
Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission. 
Neurobiol.Dis. 42: 360-7.
Alvarez-Fischer, D., Henze, C., Strenzke, C., Westrich, J., Ferger, B., Hoglinger, G. U., et al. (2008). 
Characterization of the striatal 6-OHDA model of Parkinson’s disease in wild type and alpha-synu-
clein-deleted mice. Exp.Neurol. 210: 182-93.
Ancolio, K., Alves da Costa, C., Ueda, K. & Checler, F. (2000). Alpha-synuclein and the Parkin-
son’s disease-related mutant Ala53Thr-alpha-synuclein do not undergo proteasomal degradation in 
HEK293 and neuronal cells. Neurosci.Lett. 285: 79-82.
Andersen, M.L., Sawyer, E. K., Carroll, F. I. & Howell, L. L. (2012). Infl uence of chronic dopamine 
transporter inhibition by RTI-336 on motor behavior, sleep, and hormone levels in rhesus monkeys. 
Exp.Clin.Psychopharmacol. 20: 77-83.
Anderson, J.P., Walker, D. E., Goldstein, J. M., de Laat, R., Banducci, K., Caccavello, R. J., et al. 
(2006). Phosphorylation of Ser-129 is the dominant pathological modifi cation of alpha-synuclein in 
familial and sporadic Lewy body disease. J.Biol.Chem. 281: 29739-52.
Angot, E., Steiner, J. A., Lema Tome, C. M., Ekstrom, P., Mattsson, B., Björklund, A., et al. (2012). 
Alpha-synuclein cell-to-cell transfer and seeding in grafted dopaminergic neurons in vivo. PLoS 
One 7: e39465.
Arima, K. (1998). Immunoelectronmicroscopic demonstration of NACP/alpha-synuclein-epitopes on 
the fi lamentous component of Lewy bodies in Parkinson’s disease and in dementia with Lewy bod-
ies. Brain Res. 808: 93-100.
Auluck, P.K., Chan, H. Y., Trojanowski, J. Q., Lee, V. M. & Bonini, N. M. (2002). Chaperone suppres-
sion of alpha-synuclein toxicity in a Drosophila model for Parkinson’s disease. Science 295: 865-8.
References
76
Baba, M., Nakajo, S., Tu, P. H., Tomita, T., Nakaya, K., Lee, V. M., et al. (1998). Aggregation of 
alpha-synuclein in Lewy bodies of sporadic Parkinson’s disease and dementia with Lewy bodies. 
Am.J.Pathol. 152: 879-84.
Bae, E.J., Lee, H. J., Rockenstein, E., Ho, D. H., Park, E. B., Yang, N. Y., et al. (2012). Antibody-aid-
ed clearance of extracellular alpha-synuclein prevents cell-to-cell aggregate transmission. J.Neuro-
sci. 32: 13454-69.
Bae, N., Ahn, T., Chung, S., Oh, M. S., Ko, H., Oh, H., et al. (2011). The neuroprotective effect of 
modifi ed Yeoldahanso-tang via autophagy enhancement in models of Parkinson’s disease. J.Ethno-
pharmacol. 134: 313-22.
Bae, N., Chung, S., Kim, H. J., Cha, J. W., Oh, H., Gu, M. Y., et al. (2014). Neuroprotective effect of 
modifi ed Chungsimyeolda-tang, a traditional Korean herbal formula, via autophagy induction in 
models of Parkinsons disease. J.Ethnopharmacol. 159C: 93-101.
Baptista, M.J., O’Farrell, C., Daya, S., Ahmad, R., Miller, D. W., Hardy, J., et al. (2003). Co-ordinate 
transcriptional regulation of dopamine synthesis genes by alpha-synuclein in human neuroblastoma 
cell lines. J.Neurochem. 85: 957-68.
Bayer, T.A. (1999). Alpha-synuclein accumulates in Lewy bodies in Parkinson’s disease and demen-
tia with Lewy bodies but not in Alzheimer’s disease beta]-amyloid plaque cores. Neurosci.Lett. 
266: 213-6.
Beal, M.F. (2010). Parkinson’s disease: a model dilemma. Nature 466: S8-10.
Bellucci, A., Navarria, L., Falarti, E., Zaltieri, M., Bono, F., Collo, G., et al. (2011). Redistribution of 
DAT/alpha-synuclein complexes visualized by “in situ” proximity ligation assay in transgenic mice 
modelling early Parkinson’s disease. PLoS One 6: e27959.
Bence, N.F., Sampat, R. M. & Kopito, R. R. (2001). Impairment of the ubiquitin-proteasome system 
by protein aggregation. Science 292: 1552-5.
Bennett, M.C., Bishop, J. F., Leng, Y., Chock, P. B., Chase, T. N. & Mouradian, M. M. (1999). Deg-
radation of alpha-synuclein by proteasome. J.Biol.Chem. 274: 33855-8.
Bentea, E., Van der Perren, A., Van Liefferinge, J., El Arfani, A., Albertini, G., Demuyser, T., et al. 
(2015). Nigral proteasome inhibition in mice leads to motor and non-motor defi cits and increased 
expression of Ser129 phosphorylated alpha-synuclein. Front.Behav.Neurosci. 9: 68.
Betarbet, R., Sherer, T. B. & Greenamyre, J. T. (2005). Ubiquitin-proteasome system and Parkinson’s 
diseases. Exp.Neurol. 191 Suppl 1: S17-27.
Betemps, D., Verchere, J., Brot, S., Morignat, E., Bousset, L., Gaillard, D., et al. (2014). Alpha-sy-
nuclein spreading in M83 mice brain revealed by detection of pathological alpha-synuclein by 
enhanced ELISA. Acta Neuropathol.Commun. 2: 29,5960-2-29.
Biasini, E., Fioriti, L., Ceglia, I., Invernizzi, R., Bertoli, A., Chiesa, R., et al. (2004). Proteasome inhi-
bition and aggregation in Parkinson’s disease: a comparative study in untransfected and transfected 
cells. J.Neurochem. 88: 545-53.
Bisaglia, M., Mammi, S. & Bubacco, L. (2009). Structural insights on physiological functions and 
pathological effects of alpha-synuclein. FASEB J. 23: 329-40.
Braak, H., Del Tredici, K., Rub, U., de Vos, R. A., Jansen Steur, E. N. & Braak, E. (2003). Staging of 
brain pathology related to sporadic Parkinson’s disease. Neurobiol.Aging 24: 197-211.
Braak, H., Ghebremedhin, E., Rub, U., Bratzke, H. & Del Tredici, K. (2004). Stages in the develop-
ment of Parkinson’s disease-related pathology. Cell Tissue Res. 318: 121-34.
Brandt, I., Gerard, M., Sergeant, K., Devreese, B., Baekelandt, V., Augustyns, K., et al. (2008). Prolyl 
oligopeptidase stimulates the aggregation of alpha-synuclein. Peptides 29: 1472-8.
References
77
Brück, D., Wenning, G. K., Stefanova, N. & Fellner, L. (2015). Glia and alpha-synuclein in neurode-
generation: A complex interaction. Neurobiol.Dis. (in press).
Burré, J., Sharma, M., Tsetsenis, T., Buchman, V., Etherton, M. R. & Südhof, T. C. (2010). Alpha-sy-
nuclein promotes SNARE-complex assembly in vivo and in vitro. Science 329: 1663-7.
Büttner, S., Delay, C., Franssens, V., Bammens, T., Ruli, D., Zaunschirm, S., et al. (2010). Synphilin-1 
enhances alpha-synuclein aggregation in yeast and contributes to cellular stress and cell death in a 
Sir2-dependent manner. PLoS One 5: e13700.
Cao, S., Theodore, S. & Standaert, D. G. (2010). Fcgamma receptors are required for NF-kappaB 
signaling, microglial activation and dopaminergic neurodegeneration in an AAV-synuclein mouse 
model of Parkinson’s disease. Mol.Neurodegener 5: 42,1326-5-42.
Chadchankar, H., Ihalainen, J., Tanila, H. & Yavich, L. (2011). Decreased reuptake of dopamine in the 
dorsal striatum in the absence of alpha-synuclein. Brain Res. 1382: 37-44.
Chan, T., Chow, A. M., Cheng, X. R., Tang, D. W., Brown, I. R. & Kerman, K. (2012). Oxidative 
Stress Effect of Dopamine on alpha-Synuclein: Electroanalysis of Solvent Interactions. ACS Chem.
Neurosci. 3: 569-74.
Chandra, S., Gallardo, G., Fernandez-Chacon, R., Schluter, O. M. & Südhof, T. C. (2005). Alpha-sy-
nuclein cooperates with CSPalpha in preventing neurodegeneration. Cell 123: 383-96.
Chartier-Harlin, M.C., Kachergus, J., Roumier, C., Mouroux, V., Douay, X., Lincoln, S., et al. (2004). 
Alpha-synuclein locus duplication as a cause of familial Parkinson’s disease. Lancet 364: 1167-9.
Chen, L., Jin, J., Davis, J., Zhou, Y., Wang, Y., Liu, J., et al. (2007). Oligomeric alpha-synuclein in-
hibits tubulin polymerization. Biochem.Biophys.Res.Commun. 356: 548-53.
Chen, L., Thiruchelvam, M. J., Madura, K. & Richfi eld, E. K. (2006). Proteasome dysfunction in aged 
human alpha-synuclein transgenic mice. Neurobiol.Dis. 23: 120-6.
Chen, L., Xie, Z., Turkson, S. & Zhuang, X. (2015). A53T human alpha-synuclein overexpression 
in transgenic mice induces pervasive mitochondria macroautophagy defects preceding dopamine 
neuron degeneration. J.Neurosci. 35: 890-905.
Chesselet, M.F., Richter, F. (2011). Modelling of Parkinson’s disease in mice. Lancet Neurol. 10: 
1108-18.
Chesselet, M.F., Richter, F., Zhu, C., Magen, I., Watson, M. B. & Subramaniam, S. R. (2012). A pro-
gressive mouse model of Parkinson’s disease: the Thy1-aSyn (“Line 61”) mice. Neurotherapeutics 
9: 297-314.
Choi, W., Zibaee, S., Jakes, R., Serpell, L. C., Davletov, B., Crowther, R. A., et al. (2004). Mutation 
E46K increases phospholipid binding and assembly into fi laments of human alpha-synuclein. FEBS 
Lett. 576: 363-8.
Chu, Y., Kordower, J. H. (2010). Lewy body pathology in fetal grafts. Ann.N.Y.Acad.Sci. 1184: 55-
67.
Clark, J., Clore, E. L., Zheng, K., Adame, A., Masliah, E. & Simon, D. K. (2010). Oral N-acetyl-cys-
teine attenuates loss of dopaminergic terminals in alpha-synuclein overexpressing mice. PLoS One 
5: e12333.
Cleren, C., Naudin, B. & Costentin, J. (2003). Apparent opposite effects of tetrabenazine and reser-
pine on the toxic effects of 1-methyl-4-phenylpyridinium or 6-hydroxydopamine on nigro-striatal 
dopaminergic neurons. Brain Res. 989: 187-95.
Colla, E., Coune, P., Liu, Y., Pletnikova, O., Troncoso, J. C., Iwatsubo, T., et al. (2012a). Endoplasmic 




Colla, E., Jensen, P. H., Pletnikova, O., Troncoso, J. C., Glabe, C. & Lee, M. K. (2012b). Accumula-
tion of toxic alpha-synuclein oligomer within endoplasmic reticulum occurs in alpha-synucleinop-
athy in vivo. J.Neurosci. 32: 3301-5.
Colley, W.C., Sung, T. C., Roll, R., Jenco, J., Hammond, S. M., Altshuller, Y., et al. (1997). Phos-
pholipase D2, a distinct phospholipase D isoform with novel regulatory properties that provokes 
cytoskeletal reorganization. Curr.Biol. 7: 191-201.
Conway, K.A., Harper, J. D. & Lansbury, P. T. (2000a). Fibrils formed in vitro from alpha-synuclein 
and two mutant forms linked to Parkinson’s disease are typical amyloid. Biochemistry 39: 2552-63.
Conway, K.A., Harper, J. D. & Lansbury, P. T. (1998). Accelerated in vitro fi bril formation by a mu-
tant alpha-synuclein linked to early-onset Parkinson disease. Nat.Med. 4: 1318-20.
Conway, K.A., Lee, S. J., Rochet, J. C., Ding, T. T., Williamson, R. E. & Lansbury, P. T.,Jr (2000b). 
Acceleration of oligomerization, not fi brillization, is a shared property of both alpha-synuclein mu-
tations linked to early-onset Parkinson’s disease: implications for pathogenesis and therapy. Proc.
Natl.Acad.Sci.U.S.A. 97: 571-6.
Conway, K.A., Rochet, J. C., Bieganski, R. M. & Lansbury, P. T.,Jr (2001). Kinetic stabilization of the 
alpha-synuclein protofi bril by a dopamine-alpha-synuclein adduct. Science 294: 1346-9.
Crews, L., Spencer, B., Desplats, P., Patrick, C., Paulino, A., Rockenstein, E., et al. (2010). Selective 
molecular alterations in the autophagy pathway in patients with Lewy body disease and in models 
of alpha-synucleinopathy. PLoS One 5: e9313.
Crowther, R.A., Jakes, R., Spillantini, M. G. & Goedert, M. (1998). Synthetic fi laments assembled 
from C-terminally truncated alpha-synuclein. FEBS Lett. 436: 309-12.
Cuervo, A.M., Stefanis, L., Fredenburg, R., Lansbury, P. T. & Sulzer, D. (2004). Impaired degradation 
of mutant alpha-synuclein by chaperone-mediated autophagy. Science 305: 1292-5.
Cuervo, A.M., Wong, E. (2014). Chaperone-mediated autophagy: roles in disease and aging. Cell Res. 
24: 92-104.
Culvenor, J.G., McLean, C. A., Cutt, S., Campbell, B. C., Maher, F., Jäkälä, P., et al. (1999). Non-Abe-
ta component of Alzheimer’s disease amyloid (NAC) revisited. NAC and alpha-synuclein are not 
associated with Abeta amyloid. Am.J.Pathol. 155: 1173-81.
Cunningham, D.F., O’Connor, B. (1997). Proline specifi c peptidases. Biochim.Biophys.Acta 1343: 
160-86.
Danzer, K.M., Kranich, L. R., Ruf, W. P., Cagsal-Getkin, O., Winslow, A. R., Zhu, L., et al. (2012). 
Exosomal cell-to-cell transmission of alpha synuclein oligomers. Mol.Neurodegener 7: 42,1326-
7-42.
Davidson, W.S., Jonas, A., Clayton, D. F. & George, J. M. (1998). Stabilization of alpha-synuclein 
secondary structure upon binding to synthetic membranes. J.Biol.Chem. 273: 9443-9.
Decressac, M., Mattsson, B. & Björklund, A. (2012a). Comparison of the behavioural and histological 
characteristics of the 6-OHDA and alpha-synuclein rat models of Parkinson’s disease. Exp.Neurol.
Decressac, M., Mattsson, B., Lundblad, M., Weikop, P. & Björklund, A. (2012b). Progressive neuro-
degenerative and behavioural changes induced by AAV-mediated overexpression of alpha-synucle-
in in midbrain dopamine neurons. Neurobiol.Dis. 45: 939-53.
Decuypere, J.P., Parys, J. B. & Bultynck, G. (2012). Regulation of the autophagic bcl-2/beclin 1 in-
teraction. Cells 1: 284-312.
Del Tredici, K., Rub, U., De Vos, R. A., Bohl, J. R. & Braak, H. (2002). Where does parkinson disease 
pathology begin in the brain? J.Neuropathol.Exp.Neurol. 61: 413-26.
References
79
Desplats, P., Lee, H. J., Bae, E. J., Patrick, C., Rockenstein, E., Crews, L., et al. (2009). Inclusion 
formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc.
Natl.Acad.Sci.U.S.A. 106: 13010-5.
Di Daniel, E., Glover, C. P., Grot, E., Chan, M. K., Sanderson, T. H., White, J. H., et al. (2009). Prolyl 
oligopeptidase binds to GAP-43 and functions without its peptidase activity. Mol.Cell.Neurosci. 
41: 373-82.
Dice, J.F. (2007). Chaperone-mediated autophagy. Autophagy 3: 295-9.
Dijkstra, A.A., Voorn, P., Berendse, H. W., Groenewegen, H. J., Netherlands Brain Bank, Rozemuller, 
A. J., et al. (2014). Stage-dependent nigral neuronal loss in incidental Lewy body and Parkinson’s 
disease. Mov.Disord. 29: 1244-51.
Ding, T.T., Lee, S. J., Rochet, J. C. & Lansbury, P. T.,Jr (2002). Annular alpha-synuclein protofi brils 
are produced when spherical protofi brils are incubated in solution or bound to brain-derived mem-
branes. Biochemistry 41: 10209-17.
Dokleja, L., Hannula, M. J. & Myöhänen, T. T. (2014). Inhibition of prolyl oligopeptidase increases 
the survival of alpha-synuclein overexpressing cells after rotenone exposure by reducing alpha-sy-
nuclein oligomers. Neurosci.Lett. 583: 37-42.
Dong, Z., Ferger, B., Feldon, J. & Bueler, H. (2002). Overexpression of Parkinson’s disease-associ-
ated alpha-synucleinA53T by recombinant adeno-associated virus in mice does not increase the 
vulnerability of dopaminergic neurons to MPTP. J.Neurobiol. 53: 1-10.
Doty, R.L. (2012). Olfactory dysfunction in Parkinson disease. Nat.Rev.Neurol. 8: 329-39.
Doyle, K.M., Kennedy, D., Gorman, A. M., Gupta, S., Healy, S. J. & Samali, A. (2011). Unfold-
ed proteins and endoplasmic reticulum stress in neurodegenerative disorders. J.Cell.Mol.Med. 15: 
2025-39.
Duda, J.E., Giasson, B. I., Chen, Q., Gur, T. L., Hurtig, H. I., Stern, M. B., et al. (2000). Widespread 
nitration of pathological inclusions in neurodegenerative synucleinopathies. Am.J.Pathol. 157: 
1439-45.
Ebrahimi-Fakhari, D., Cantuti-Castelvetri, I., Fan, Z., Rockenstein, E., Masliah, E., Hyman, B. T., et 
al. (2011). Distinct roles in vivo for the ubiquitin-proteasome system and the autophagy-lysosomal 
pathway in the degradation of alpha-synuclein. J.Neurosci. 31: 14508-20.
El-Agnaf, O., Jakes, R., Curran, M. D. & Wallace, A. (1998a). Effects of the mutations Ala30 to Pro 
and Ala53 to Thr on the physical and morphological properties of alpha-synuclein protein implicat-
ed in Parkinson’s disease. FEBS Lett. 440: 67-70.
El-Agnaf, O.M., Bodles, A. M., Guthrie, D. J., Harriott, P. & Irvine, G. B. (1998b). The N-terminal 
region of non-A beta component of Alzheimer’s disease amyloid is responsible for its tendency to 
assume beta-sheet and aggregate to form fi brils. Eur.J.Biochem. 258: 157-63.
Engelender, S. (1999). Synphilin-1 associates with alpha-synuclein and promotes the formation of 
cytosolic inclusions. Nature Genet. 22: 110-4.
Escobar, V.D., Kuo, Y. M., Orrison, B. M., Giasson, B. I. & Nussbaum, R. L. (2014). Transgenic mice 
expressing S129 phosphorylation mutations in alpha-synuclein. Neurosci.Lett. 563: 96-100.
Fahn, S. (2003). Description of Parkinson’s disease as a clinical syndrome. Ann.N.Y.Acad.Sci. 991: 
1-14.
Farrell, K.F., Krishnamachari, S., Villanueva, E., Lou, H., Alerte, T. N., Peet, E., et al. (2014). 
Non-motor parkinsonian pathology in aging A53T alpha-synuclein mice is associated with progres-
sive synucleinopathy and altered enzymatic function. J.Neurochem. 128: 536-46.
Fearnley, J.M., Lees, A. J. (1991). Ageing and Parkinson’s disease: substantia nigra regional selectiv-
ity. Brain 114 ( Pt 5): 2283-301.
References
80
Feder, M.E., Hofmann, G. E. (1999). Heat-shock proteins, molecular chaperones, and the stress re-
sponse: evolutionary and ecological physiology. Annu.Rev.Physiol. 61: 243-82.
Fellner, L., Irschick, R., Schanda, K., Reindl, M., Klimaschewski, L., Poewe, W., et al. (2013). Toll-
like receptor 4 is required for alpha-synuclein dependent activation of microglia and astroglia. Glia 
61: 349-60.
Feng, L.R., Federoff, H. J., Vicini, S. & Maguire-Zeiss, K. A. (2010). Alpha-synuclein mediates al-
terations in membrane conductance: a potential role for alpha-synuclein oligomers in cell vulnera-
bility. Eur.J.Neurosci. 32: 10-7.
Fenteany, G., Schreiber, S. L. (1998). Lactacystin, proteasome function, and cell fate. J.Biol.Chem. 
273: 8545-8.
Fernagut, P.O., Hutson, C. B., Fleming, S. M., Tetreaut, N. A., Salcedo, J., Masliah, E., et al. (2007). 
Behavioral and histopathological consequences of paraquat intoxication in mice: Effects of al-
pha-synuclein over-expression. Synapse 61: 991-1001.
Fleming, S.M., Chesselet, M. F. (2006). Behavioral phenotypes and pharmacology in genetic mouse 
models of Parkinsonism. Behav.Pharmacol. 17: 383-91.
Fleming, S.M., Salcedo, J., Fernagut, P. O., Rockenstein, E., Masliah, E., Levine, M. S., et al. (2004). 
Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-sy-
nuclein. J.Neurosci. 24: 9434-40.
Fleming, S.M., Tetreault, N. A., Mulligan, C. K., Hutson, C. B., Masliah, E. & Chesselet, M. (2008). 
Olfactory defi cits in mice overexpressing human wildtype alpha-synuclein. Eur.J.Neurosci. 28: 
247-56.
Fornai, F., Lenzi, P., Gesi, M., Ferrucci, M., Lazzeri, G., Busceti, C. L., et al. (2003). Fine structure 
and biochemical mechanisms underlying nigrostriatal inclusions and cell death after proteasome 
inhibition. J.Neurosci. 23: 8955-66.
Franco, R., Li, S., Rodriguez-Rocha, H., Burns, M. & Panayiotidis, M. I. (2010). Molecular mech-
anisms of pesticide-induced neurotoxicity: Relevance to Parkinson’s disease. Chem.Biol.Interact. 
188: 289-300.
Freichel, C., Neumann, M., Ballard, T., Muller, V., Woolley, M., Ozmen, L., et al. (2007). Age-de-
pendent cognitive decline and amygdala pathology in alpha-synuclein transgenic mice. Neurobiol.
Aging 28: 1421-35.
Fu, L.L., Cheng, Y. & Liu, B. (2013). Beclin-1: autophagic regulator and therapeutic target in cancer. 
Int.J.Biochem.Cell Biol. 45: 921-4.
Fujiwara, H., Hasegawa, M., Dohmae, N., Kawashima, A., Masliah, E., Goldberg, M. S., et al. (2002). 
Alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat.Cell Biol. 4: 160-4.
Fülop, V., Bocskei, Z. & Polgar, L. (1998). Prolyl oligopeptidase: an unusual beta-propeller domain 
regulates proteolysis. Cell 94: 161-70.
Gallegos, S., Pacheco, C., Peters, C., Opazo, C. M. & Aguayo, L. G. (2015). Features of alpha-synu-
clein that could explain the progression and irreversibility of Parkinson’s disease. Front.Neurosci. 
9: 59.
Galvin, J.E., Lee, V. M. & Trojanowski, J. Q. (2001). Synucleinopathies: clinical and pathological 
implications. Arch.Neurol. 58: 186-90.
Garcia-Horsman, J.A., Männistö, P. T. & Venäläinen, J. I. (2007). On the role of prolyl oligopeptidase 
in health and disease. Neuropeptides 41: 1-24.
Gass, J., Khosla, C. (2007). Prolyl endopeptidases. Cell Mol.Life Sci. 64: 345-55.
References
81
George, J.M., Jin, H., Woods, W. S. & Clayton, D. F. (1995). Characterization of a novel protein reg-
ulated during the critical period for song learning in the zebra fi nch. Neuron 15: 361-72.
Gerard, M., Deleersnijder, A., Daniels, V., Schreurs, S., Munck, S., Reumers, V., et al. (2010). Inhi-
bition of FK506 binding proteins reduces alpha-synuclein aggregation and Parkinson’s disease-like 
pathology. J.Neurosci. 30: 2454-63.
Giasson, B.I. (2000). Oxidative damage linked to neurodegeneration by selective alpha-synuclein 
nitration in synucleinopathy lesions. Science 290: 985-9.
Giasson, B.I., Duda, J. E., Quinn, S. M., Zhang, B., Trojanowski, J. Q. & Lee, V. M. (2002). Neuronal 
alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-sy-
nuclein. Neuron 34: 521-33.
Giasson, B.I., Lee, V. M. & Trojanowski, J. Q. (2003). Interactions of amyloidogenic proteins. Neu-
romolecular Med. 4: 49-58.
Giasson, B.I., Murray, I. V., Trojanowski, J. Q. & Lee, V. M. (2001). A hydrophobic stretch of 12 ami-
no acid residues in the middle of alpha-synuclein is essential for fi lament assembly. J.Biol.Chem. 
276: 2380-6.
Giasson, B.I., Uryu, K., Trojanowski, J. Q. & Lee, V. M. -. (1999). Mutant and wild-type human al-
pha-synuclein assemble into elongated fi laments with distinct morphologies in vitro. J.Biol.Chem. 
274: 7619-22.
Gispert, S., Del Turco, D., Garrett, L., Chen, A., Bernard, D. J., Hamm-Clement, J., et al. (2003). 
Transgenic mice expressing mutant A53T human alpha-synuclein show neuronal dysfunction in the 
absence of aggregate formation. Mol.Cell.Neurosci. 24: 419-29.
Goldman, J.E., Yen, S. H., Chiu, F. C. & Peress, N. S. (1983). Lewy bodies of Parkinson’s disease 
contain neurofi lament antigens. Science 221: 1082-4.
Gosavi, N., Lee, H. J., Lee, J. S., Patel, S. & Lee, S. J. (2002). Golgi fragmentation occurs in the cells 
with prefi brillar alpha-synuclein aggregates and precedes the formation of fi brillar inclusion. J.Biol.
Chem. 277: 48984-92.
Grealish, S., Mattsson, B., Draxler, P. & Björklund, A. (2010). Characterisation of behavioural and 
neurodegenerative changes induced by intranigral 6-hydroxydopamine lesions in a mouse model of 
Parkinson’s disease. Eur.J.Neurosci. 31: 2266-78.
Guo, J.T., Chen, A. Q., Kong, Q., Zhu, H., Ma, C. M. & Qin, C. (2008). Inhibition of vesicular 
monoamine transporter-2 activity in alpha-synuclein stably transfected SH-SY5Y cells. Cell.Mol.
Neurobiol. 28: 35-47.
Haas, A.L., Siepmann, T. J. (1997). Pathways of ubiquitin conjugation. FASEB J. 11: 1257-68.
Hannula, M.J., Myöhänen, T. T., Tenorio-Laranga, J., Männistö, P. T. & Garcia-Horsman, J. A. (2013). 
Prolyl oligopeptidase colocalizes with alpha-synuclein, beta-amyloid, tau protein and astroglia in 
the post-mortem brain samples with Parkinson’s and Alzheimer’s diseases. Neuroscience 242: 140-
50.
Hansen, C., Angot, E., Bergstrom, A. L., Steiner, J. A., Pieri, L., Paul, G., et al. (2011). Alpha-Sy-
nuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in 
cultured human cells. J.Clin.Invest. 121: 715-25.
Harwood, A.J. (2011). Prolyl oligopeptidase, inositol phosphate signalling and lithium sensitivity. 
CNS Neurol.Disord.Drug Targets 10: 333-9.
Hasegawa, M., Fujiwara, H., Nonaka, T., Wakabayashi, K., Takahashi, H., Lee, V. M., et al. (2002). 




Hashimoto, M., Hsu, L. J., Sisk, A., Xia, Y., Takeda, A., Sundsmo, M., et al. (1998). Human recombi-
nant NACP/alpha-synuclein is aggregated and fi brillated in vitro: relevance for Lewy body disease. 
Brain Res. 799: 301-6.
Hashimoto, M., Hsu, L. J., Xia, Y., Takeda, A., Sisk, A., Sundsmo, M., et al. (1999a). Oxidative stress 
induces amyloid-like aggregate formation of NACP/alpha-synuclein in vitro. Neuroreport 10: 717-
21.
Hashimoto, M., Rockenstein, E., Mante, M., Mallory, M. & Masliah, E. (2001). beta-Synuclein inhib-
its alpha-synuclein aggregation: a possible role as an anti-parkinsonian factor. Neuron 32: 213-23.
Hashimoto, M., Takeda, A., Hsu, L. J., Takenouchi, T. & Masliah, E. (1999b). Role of cytochrome c 
as a stimulator of alpha-synuclein aggregation in Lewy body disease. J.Biol.Chem. 274: 28849-52.
Hauser, R.A., Freeman, T. B., Snow, B. J., Nauert, M., Gauger, L., Kordower, J. H., et al. (1999). 
Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease. Arch.Neurol. 
56: 179-87.
Hernandes, M.S., Santos, G. D., Cafe-Mendes, C. C., Lima, L. S., Scavone, C., Munhoz, C. D., et 
al. (2013). Microglial cells are involved in the susceptibility of NADPH oxidase knockout mice to 
6-hydroxy-dopamine-induced neurodegeneration. PLoS One 8: e75532.
Hirsch, E.C., Hunot, S. (2009). Neuroinfl ammation in Parkinson’s disease: a target for neuroprotec-
tion? Lancet Neurol. 8: 382-97.
Hokenson, M.J., Uversky, V. N., Goers, J., Yamin, G., Munishkina, L. A. & Fink, A. L. (2004). Role 
of individual methionines in the fi brillation of methionine-oxidized alpha-synuclein. Biochemistry 
43: 4621-33.
Hung, S.Y., Huang, W. P., Liou, H. C. & Fu, W. M. (2009). Autophagy protects neuron from Abeta-in-
duced cytotoxicity. Autophagy 5: 502-10.
Ikeda, M., Kawarabayashi, T., Harigaya, Y., Sasaki, A., Yamada, S., Matsubara, E., et al. (2009). Mo-
tor impairment and aberrant production of neurochemicals in human alpha-synuclein A30P+A53T 
transgenic mice with alpha-synuclein pathology. Brain Res. 1250: 232-41.
Inden, M., Kitamura, Y., Abe, M., Tamaki, A., Takata, K. & Taniguchi, T. (2011). Parkinsonian rote-
none mouse model: reevaluation of long-term administration of rotenone in C57BL/6 mice. Biol.
Pharm.Bull. 34: 92-6.
Ischiropoulos, H. (2009). Protein tyrosine nitration--an update. Arch.Biochem.Biophys. 484: 117-21.
Iwai, A., Masliah, E., Yoshimoto, M., Ge, N., Flanagan, L., de Silva, H. A., et al. (1995). The precur-
sor protein of non-A beta component of Alzheimer’s disease amyloid is a presynaptic protein of the 
central nervous system. Neuron 14: 467-75.
Iwata, A., Maruyama, M., Akagi, T., Hashikawa, T., Kanazawa, I., Tsuji, S., et al. (2003). Alpha-sy-
nuclein degradation by serine protease neurosin: implication for pathogenesis of synucleinopathies. 
Hum.Mol.Genet. 12: 2625-35.
Jäkälä, P., Puoliväli, J., Kerokoski, P. & van Groen, T. (2002). Intracellular alpha-synuclein accumula-
tion in transgenic mice expressing A30P alpha-synuclein mutation. Neurobiology of aging23, S252.
Jakes, R., Spillantini, M. G. & Goedert, M. (1994). Identifi cation of two distinct synucleins from 
human brain. FEBS Lett. 345: 27-32.
Jalkanen, A.J., Hakkarainen, J. J., Lehtonen, M., Venäläinen, T., Kaariainen, T. M., Jarho, E., et al. 
(2011a). Brain Pharmacokinetics of Two Prolyl Oligopeptidase Inhibitors, JTP-4819 and KYP-
2047, in the Rat. Basic Clin.Pharmacol.Toxicol.
Jalkanen, A.J., Puttonen, K. A., Venäläinen, J. I., Sinerva, V., Mannila, A., Ruotsalainen, S., et al. 
(2007). Benefi cial effect of prolyl oligopeptidase inhibition on spatial memory in young but not in 
References
83
old scopolamine-treated rats. Basic Clin.Pharmacol.Toxicol. 100: 132-8.
Jalkanen, A.J., Savolainen, K. & Forsberg, M. M. (2011b). Inhibition of prolyl oligopeptidase by 
KYP-2047 fails to increase the extracellular neurotensin and substance P levels in rat striatum. 
Neurosci.Lett. 502: 107-11.
Jankovic, J., Chen, S. & Le, W. D. (2005). The role of Nurr1 in the development of dopaminergic 
neurons and Parkinson’s disease. Prog.Neurobiol. 77: 128-38.
Jarho, E.M., Venäläinen, J. I., Huuskonen, J., Christiaans, J. A., Garcia-Horsman, J. A., Forsberg, 
M. M., et al. (2004). A cyclopent-2-enecarbonyl group mimics proline at the P2 position of prolyl 
oligopeptidase inhibitors. J.Med.Chem. 47: 5605-7.
Jariel-Encontre, I., Bossis, G. & Piechaczyk, M. (2008). Ubiquitin-independent degradation of pro-
teins by the proteasome. Biochim.Biophys.Acta 1786: 153-77.
Jellinger, K.A. (2004). Lewy body-related alpha-synucleinopathy in the aged human brain. J.Neural 
Transm. 111: 1219-35.
Jenco, J.M., Rawlingson, A., Daniels, B. & Morris, A. J. (1998). Regulation of phospholipase D2: 
selective inhibition of mammalian phospholipase D isoenzymes by alpha- and beta-synucleins. 
Biochemistry 37: 4901-9.
Jenner, P. (2003). Oxidative stress in Parkinson’s disease. Ann.Neurol. 53 Suppl 3: S26,36; discussion 
S36-8.
Jensen, P.H., Hojrup, P., Hager, H., Nielsen, M. S., Jacobsen, L., Olesen, O. F., et al. (1997). Binding 
of Abeta to alpha- and beta-synucleins: identifi cation of segments in alpha-synuclein/NAC precur-
sor that bind Abeta and NAC. Biochem.J. 323 ( Pt 2): 539-46.
Jensen, P.H., Nielsen, M. H., Jakes, R., Dotti, C. G. & Goedert, M. (1998). Binding of alpha-synu-
clein to rat brain vesicles is abolished by familial Parkinson’s disease mutation. J.Biol.Chem. 273: 
26292-4.
Jiang, T.F., Zhang, Y. J., Zhou, H. Y., Wang, H. M., Tian, L. P., Liu, J., et al. (2013). Curcumin ame-
liorates the neurodegenerative pathology in A53T alpha-synuclein cell model of Parkinson’s dis-
ease through the downregulation of mTOR/p70S6K signaling and the recovery of macroautophagy. 
J.Neuroimmune Pharmacol. 8: 356-69.
Jin, H., Clayton, D. F. (1997). Synelfi n regulation during the critical period for song learning in nor-
mal and isolated juvenile zebra fi nches. Neurobiol.Learn.Mem. 68: 271-84.
Jo, E., McLaurin, J., Yip, C. M., St George-Hyslop, P. & Fraser, P. E. (2000). Alpha-Synuclein mem-
brane interactions and lipid specifi city. J.Biol.Chem. 275: 34328-34.
Junn, E., Ronchetti, R. D., Quezado, M. M., Kim, S. Y. & Mouradian, M. M. (2003). Tissue transglu-
taminase-induced aggregation of alpha-synuclein: Implications for Lewy body formation in Parkin-
son’s disease and dementia with Lewy bodies. Proc.Natl.Acad.Sci.U.S.A. 100: 2047-52.
Kahle, P.J. (2000). Subcellular localization of wild-type and Parkinson’s disease-associated mutant 
alpha-synuclein in human and transgenic mouse brain. J.Neurosci. 20: 6365-73.
Kahle, P.J., Neumann, M., Ozmen, L., Muller, V., Odoy, S., Okamoto, N., et al. (2001). Selective 
insolubility of alpha-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse 
model. Am.J.Pathol. 159: 2215-25.
Kang, R., Zeh, H. J., Lotze, M. T. & Tang, D. (2011). The Beclin 1 network regulates autophagy and 
apoptosis. Cell Death Differ. 18: 571-80.
Kaszuba, K., Rog, T., Danne, R., Canning, P., Fülop, V., Juhasz, T., et al. (2012). Molecular dynamics, 
crystallography and mutagenesis studies on the substrate gating mechanism of prolyl oligopepti-
dase. Biochimie 94: 1398-411.
References
84
Kato, A., Fukunari, A., Sakai, Y. & Nakajima, T. (1997). Prevention of amyloid-like deposition by a 
selective prolyl endopeptidase inhibitor, Y-29794, in senescence-accelerated mouse. J.Pharmacol.
Exp.Ther. 283: 328-35.
Kaushik, S., Etchebest, C. & Sowdhamini, R. (2014). Decoding the structural events in substrate-gat-
ing mechanism of eukaryotic prolyl oligopeptidase using normal mode analysis and molecular dy-
namics simulations. Proteins 82: 1428-43.
Khodr, C.E., Becerra, A., Han, Y. & Bohn, M. C. (2014). Targeting alpha-synuclein with a microR-
NA-embedded silencing vector in the rat substantia nigra: positive and negative effects. Brain Res. 
1550: 47-60.
Khodr, C.E., Sapru, M. K., Pedapati, J., Han, Y., West, N. C., Kells, A. P., et al. (2011). An alpha-sy-
nuclein AAV gene silencing vector ameliorates a behavioral defi cit in a rat model of Parkinson’s 
disease, but displays toxicity in dopamine neurons. Brain Res. 1395: 94-107.
Kichik, N., Tarrago, T., Claasen, B., Gairi, M., Millet, O. & Giralt, E. (2011). 15N relaxation NMR 
studies of prolyl oligopeptidase, an 80 kDa enzyme, reveal a pre-existing equilibrium between dif-
ferent conformational states. Chembiochem 12: 2737-9.
Kim, H.Y., Cho, M. K., Kumar, A., Maier, E., Siebenhaar, C., Becker, S., et al. (2009). Structural 
properties of pore-forming oligomers of alpha-synuclein. J.Am.Chem.Soc. 131: 17482-9.
Kim, J.D., Toda, C., D’Agostino, G., Zeiss, C. J., DiLeone, R. J., Elsworth, J. D., et al. (2014). Hypo-
thalamic prolyl endopeptidase (PREP) regulates pancreatic insulin and glucagon secretion in mice. 
Proc.Natl.Acad.Sci.U.S.A.
Kim, M., Jung, W., Lee, I. H., Bhak, G., Paik, S. R. & Hahn, J. S. (2008). Impairment of microtubule 
system increases alpha-synuclein aggregation and toxicity. Biochem.Biophys.Res.Commun. 365: 
628-35.
Kisos, H., Pukass, K., Ben-Hur, T., Richter-Landsberg, C. & Sharon, R. (2012). Increased neuronal 
alpha-synuclein pathology associates with its accumulation in oligodendrocytes in mice modeling 
alpha-synucleinopathies. PLoS One 7: e46817.
Klionsky, D.J., Abeliovich, H., Agostinis, P., Agrawal, D. K., Aliev, G., Askew, D. S., et al. (2008). 
Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. 
Autophagy 4: 151-75.
Klucken, J., Shin, Y., Masliah, E., Hyman, B. T. & McLean, P. J. (2004). Hsp70 Reduces alpha-Synu-
clein Aggregation and Toxicity. J.Biol.Chem. 279: 25497-502.
Komatsu, M., Waguri, S., Ueno, T., Iwata, J., Murata, S., Tanida, I., et al. (2005). Impairment of star-
vation-induced and constitutive autophagy in Atg7-defi cient mice. J.Cell Biol. 169: 425-34.
Konieczny, J., Jantas, D., Lenda, T., Domin, H., Czarnecka, A., Kuter, K., et al. (2014). Lack of neu-
roprotective effect of celastrol under conditions of proteasome inhibition by lactacystin in in vitro 
and in vivo studies: implications for Parkinson’s disease. Neurotox Res. 26: 255-73.
Kordower, J.H., Chu, Y., Hauser, R. A., Freeman, T. B. & Olanow, C. W. (2008a). Lewy body-like 
pathology in long-term embryonic nigral transplants in Parkinson’s disease. Nat.Med. 14: 504-6.
Kordower, J.H., Chu, Y., Hauser, R. A., Olanow, C. W. & Freeman, T. B. (2008b). Transplanted do-
paminergic neurons develop PD pathologic changes: a second case report. Mov.Disord. 23: 2303-6.
Kordower, J.H., Freeman, T. B., Snow, B. J., Vingerhoets, F. J., Mufson, E. J., Sanberg, P. R., et 
al. (1995). Neuropathological evidence of graft survival and striatal reinnervation after the trans-
plantation of fetal mesencephalic tissue in a patient with Parkinson’s disease. N.Engl.J.Med. 332: 
1118-24.
Kreiner, G. (2015). Compensatory mechanisms in genetic models of neurodegeneration: are the mice 
better than humans? Front.Cell.Neurosci. 9: 56.
References
85
Kroemer, G., Reed, J. C. (2000). Mitochondrial control of cell death. Nat.Med. 6: 513-9.
Krüger, R., Kuhn, W., Muller, T., Woitalla, D., Graeber, M., Kosel, S., et al. (1998). Ala30Pro muta-
tion in the gene encoding alpha-synuclein in Parkinson’s disease. Nat.Genet. 18: 106-8.
Krumova, P., Meulmeester, E., Garrido, M., Tirard, M., Hsiao, H. H., Bossis, G., et al. (2011). Sumoy-
lation inhibits alpha-synuclein aggregation and toxicity. J.Cell Biol. 194: 49-60.
Kudo, T., Loh, D. H., Truong, D., Wu, Y. & Colwell, C. S. (2011). Circadian dysfunction in a mouse 
model of Parkinson’s disease. Exp.Neurol. 232: 66-75.
Kurz, A., Double, K. L., Lastres-Becker, I., Tozzi, A., Tantucci, M., Bockhart, V., et al. (2010). 
A53T-alpha-synuclein overexpression impairs dopamine signaling and striatal synaptic plasticity 
in old mice. PLoS One 5: e11464.
Kuzuhara, S., Mori, H., Izumiyama, N., Yoshimura, M. & Ihara, Y. (1988). Lewy bodies are ubiquiti-
nated. A light and electron microscopic immunocytochemical study. Acta Neuropathol. 75: 345-53.
Lam, H.A., Wu, N., Cely, I., Kelly, R. L., Hean, S., Richter, F., et al. (2011). Elevated tonic ex-
tracellular dopamine concentration and altered dopamine modulation of synaptic activity precede 
dopamine loss in the striatum of mice overexpressing human alpha-synuclein. J.Neurosci.Res. 89: 
1091-102.
Lambeir, A.M. (2011). Interaction of prolyl oligopeptidase with alpha-synuclein. CNS Neurol.Disord.
Drug Targets 10: 349-54.
Laplante, M., Sabatini, D. M. (2009). mTOR signaling at a glance. J.Cell.Sci. 122: 3589-94.
Lashuel, H.A., Petre, B. M., Wall, J., Simon, M., Nowak, R. J., Walz, T., et al. (2002). Alpha-synu-
clein, especially the Parkinson’s disease-associated mutants, forms pore-like annular and tubular 
protofi brils. J.Mol.Biol. 322: 1089-102.
Lashuel, H.A., Overk, C. R., Oueslati, A. & Masliah, E. (2013). The many faces of alpha-synuclein: 
from structure and toxicity to therapeutic target. Nature reviews.Neuroscience 14: 38-48.
Lauwers, E., Debyser, Z., Van Dorpe, J., De Strooper, B., Nuttin, B. & Baekelandt, V. (2003). Neuro-
pathology and neurodegeneration in rodent brain induced by lentiviral vector-mediated overexpres-
sion of alpha-synuclein. Brain Pathol. 13: 364-72.
Lavedan, C. (1998). The synuclein family. Genome Res. 2: 871-80.
Lee, E.N., Lee, S. Y., Lee, D., Kim, J. & Paik, S. R. (2003). Lipid interaction of alpha-synuclein during 
the metal-catalyzed oxidation in the presence of Cu2+ and H2O2. J.Neurochem. 84: 1128-42.
Lee, H.J., Khoshaghideh, F., Patel, S. & Lee, S. J. (2004). Clearance of alpha-synuclein oligomeric 
intermediates via the lysosomal degradation pathway. J.Neurosci. 24: 1888-96.
Lee, H.J., Suk, J. E., Bae, E. J. & Lee, S. J. (2008). Clearance and deposition of extracellular alpha-sy-
nuclein aggregates in microglia. Biochem.Biophys.Res.Commun. 372: 423-8.
Lee, H.J., Suk, J. E., Patrick, C., Bae, E. J., Cho, J. H., Rho, S., et al. (2010a). Direct transfer of al-
pha-synuclein from neuron to astroglia causes infl ammatory responses in synucleinopathies. J.Biol.
Chem. 285: 9262-72.
Lee, M.K., Stirling, W., Xu, Y., Xu, X., Qui, D., Mandir, A. S., et al. (2002). Human alpha-synucle-
in-harboring familial Parkinson’s disease-linked Ala-53 --> Thr mutation causes neurodegenerative 
disease with alpha-synuclein aggregation in transgenic mice. Proc.Natl.Acad.Sci.U.S.A. 99: 8968-
73.
Lee, S.J., Desplats, P., Lee, H. J., Spencer, B. & Masliah, E. (2012). Cell-to-cell transmission of al-
pha-synuclein aggregates. Methods Mol.Biol. 849: 347-59.
Lee, S.J., Desplats, P., Sigurdson, C., Tsigelny, I. & Masliah, E. (2010b). Cell-to-cell transmission of 
non-prion protein aggregates. Nat.Rev.Neurol. 6: 702-6.
References
86
Lesage, S., Anheim, M., Letournel, F., Bousset, L., Honore, A., Rozas, N., et al. (2013). G51D al-
pha-synuclein mutation causes a novel parkinsonian-pyramidal syndrome. Ann.Neurol. 73: 459-71.
Li, C., Guo, Y., Xie, W., Li, X., Janokovic, J. & Le, W. (2010). Neuroprotection of pramipexole in 
UPS impairment induced animal model of Parkinson’s disease. Neurochem.Res. 35: 1546-56.
Li, J., Uversky, V. N. & Fink, A. L. (2001). Effect of familial Parkinson’s disease point mutations 
A30P and A53T on the structural properties, aggregation, and fi brillation of human alpha-synuclein. 
Biochemistry 40: 11604-13.
Li, J.Y., Englund, E., Holton, J. L., Soulet, D., Hagell, P., Lees, A. J., et al. (2008). Lewy bodies in 
grafted neurons in subjects with Parkinson’s disease suggest host-to-graft disease propagation. Nat.
Med. 14: 501-3.
Li, W., West, N., Colla, E., Pletnikova, O., Troncoso, J. C., Marsh, L., et al. (2005). Aggregation pro-
moting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the 
familial Parkinson’s disease-linked mutations. Proc.Natl.Acad.Sci.U.S.A. 102: 2162-7.
Lim, Y., Kehm, V. M., Lee, E. B., Soper, J. H., Li, C., Trojanowski, J. Q., et al. (2011). Alpha-Syn 
suppression reverses synaptic and memory defects in a mouse model of dementia with Lewy bod-
ies. J.Neurosci. 31: 10076-87.
Lim, Y., Kehm, V. M., Li, C., Trojanowski, J. Q. & Lee, V. M. (2010). Forebrain overexpression of 
alpha-synuclein leads to early postnatal hippocampal neuron loss and synaptic disruption. Exp.
Neurol. 221: 86-97.
Lin, X., Parisiadou, L., Sgobio, C., Liu, G., Yu, J., Sun, L., et al. (2012). Conditional expression of 
Parkinson’s disease-related mutant alpha-synuclein in the midbrain dopaminergic neurons causes 
progressive neurodegeneration and degradation of transcription factor nuclear receptor related 1. 
J.Neurosci. 32: 9248-64.
Lindersson, E., Beedholm, R., Højrup, P., Moos, T., Gai, W., Hendil, K. B., et al. (2004). Proteasomal 
Inhibition by α-Synuclein Filaments and Oligomers. Journal of Biological Chemistry 279: 12924-
34.
Lo Bianco, C., Shorter, J., Regulier, E., Lashuel, H., Iwatsubo, T., Lindquist, S., et al. (2008). Hsp104 
antagonizes alpha-synuclein aggregation and reduces dopaminergic degeneration in a rat model of 
Parkinson disease. J.Clin.Invest. 118: 3087-97.
Lu, Y., Prudent, M., Fauvet, B., Lashuel, H. A. & Girault, H. H. (2011). Phosphorylation of alpha-Sy-
nuclein at Y125 and S129 alters its metal binding properties: implications for understanding the role 
of alpha-Synuclein in the pathogenesis of Parkinson’s Disease and related disorders. ACS Chem.
Neurosci. 2: 667-75.
Luk, K.C., Kehm, V., Carroll, J., Zhang, B., O’Brien, P., Trojanowski, J. Q., et al. (2012a). Pathologi-
cal alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. 
Science 338: 949-53.
Luk, K.C., Kehm, V. M., Zhang, B., O’Brien, P., Trojanowski, J. Q. & Lee, V. M. (2012b). Intracere-
bral inoculation of pathological alpha-synuclein initiates a rapidly progressive neurodegenerative 
alpha-synucleinopathy in mice. J.Exp.Med. 209: 975-86.
Luk, K.C., Song, C., O’Brien, P., Stieber, A., Branch, J. R., Brunden, K. R., et al. (2009). Exogenous 
alpha-synuclein fi brils seed the formation of Lewy body-like intracellular inclusions in cultured 
cells. Proc.Natl.Acad.Sci.U.S.A. 106: 20051-6.
Lynch-Day, M.A., Mao, K., Wang, K., Zhao, M. & Klionsky, D. J. (2012). The role of autophagy in 
Parkinson’s disease. Cold Spring Harb Perspect.Med. 2: a009357.
References
87
Machiya, Y., Hara, S., Arawaka, S., Fukushima, S., Sato, H., Sakamoto, M., et al. (2010). Phosphor-
ylated alpha-synuclein at Ser-129 is targeted to the proteasome pathway in a ubiquitin-independent 
manner. J.Biol.Chem. 285: 40732-44.
Mak, S.K., McCormack, A. L., Manning-Bog, A. B., Cuervo, A. M. & Di Monte, D. A. (2010). Lyso-
somal degradation of alpha-synuclein in vivo. J.Biol.Chem. 285: 13621-9.
Mandler, M., Valera, E., Rockenstein, E., Mante, M., Weninger, H., Patrick, C., et al. (2015). Active 
immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demy-
elination in a model of multiple system atrophy. Mol.Neurodegener 10: 10.
Mandler, M., Valera, E., Rockenstein, E., Weninger, H., Patrick, C., Adame, A., et al. (2014). 
Next-generation active immunization approach for synucleinopathies: implications for Parkinson’s 
disease clinical trials. Acta Neuropathol. 127: 861-79.
Manning-Bog, A.B., McCormack, A. L., Li, J., Uversky, V. N., Fink, A. L. & Di Monte, D. A. (2002). 
The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat 
and alpha-synuclein. J.Biol.Chem. 277: 1641-4.
Manning-Bog, A.B., McCormack, A. L., Purisai, M. G., Bolin, L. M. & Di Monte, D. A. (2003). 
Alpha-synuclein overexpression protects against paraquat-induced neurodegeneration. J.Neurosci. 
23: 3095-9.
Mantle, D., Falkous, G., Ishiura, S., Blanchard, P. J. & Perry, E. K. (1996). Comparison of proline 
endopeptidase activity in brain tissue from normal cases and cases with Alzheimer’s disease, Lewy 
body dementia, Parkinson’s disease and Huntington’s disease. Clin.Chim.Acta 249: 129-39.
Maroteaux, L., Campanelli, J. T. & Scheller, R. H. (1988). Synuclein: a neuron-specifi c protein local-
ized to the nucleus and presynaptic nerve terminal. J.Neurosci. 8: 2804-15.
Martin, L.J., Pan, Y., Price, A. C., Sterling, W., Copeland, N. G., Jenkins, N. A., et al. (2006). Parkin-
son’s disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and 
cell death. J.Neurosci. 26: 41-50.
Martinez-Vicente, M., Talloczy, Z., Kaushik, S., Massey, A. C., Mazzulli, J., Mosharov, E. V., et al. 
(2008). Dopamine-modifi ed alpha-synuclein blocks chaperone-mediated autophagy. J.Clin.Invest. 
118: 777-88.
Masliah, E. (2000). Dopaminergic loss and inclusion body formation in alpha-synuclein mice: impli-
cations for neurodegenerative disorders. Science 287: 1265-9.
Masliah, E., Rockenstein, E., Adame, A., Alford, M., Crews, L., Hashimoto, M., et al. (2005). Effects 
of alpha-synuclein immunization in a mouse model of Parkinson’s disease. Neuron 46: 857-68.
Masliah, E., Rockenstein, E., Mante, M., Crews, L., Spencer, B., Adame, A., et al. (2011). Passive 
immunization reduces behavioral and neuropathological defi cits in an alpha-synuclein transgenic 
model of Lewy body disease. PLoS One 6: e19338.
Masliah, E., Rockenstein, E., Veinbergs, I., Sagara, Y., Mallory, M., Hashimoto, M., et al. (2001). 
beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal defi cits in a transgenic 
mouse model linking Alzheimer’s disease and Parkinson’s disease. Proc.Natl.Acad.Sci.U.S.A. 98: 
12245-50.
Masuda-Suzukake, M., Nonaka, T., Hosokawa, M., Oikawa, T., Arai, T., Akiyama, H., et al. (2013). 
Prion-like spreading of pathological alpha-synuclein in brain. Brain 136: 1128-38.
Matsuda, T., Sakaguchi, M., Tanaka, S., Yoshimoto, T. & Takaoka, M. (2013). Prolyl oligopeptidase 
is a glyceraldehyde-3-phosphate dehydrogenase-binding protein that regulates genotoxic stress-in-
duced cell death. Int.J.Biochem.Cell Biol. 45: 850-7.
McCormack, A.L., Mak, S. K., Henderson, J. M., Bumcrot, D., Farrer, M. J. & Di Monte, D. A. 
(2010). Alpha-synuclein suppression by targeted small interfering RNA in the primate substantia 
nigra. PLoS One 5: e12122.
References
88
McFarland, N.R., Dimant, H., Kibuuka, L., Ebrahimi-Fakhari, D., Desjardins, C. A., Danzer, K. M., et 
al. (2014). Chronic treatment with novel small molecule Hsp90 inhibitors rescues striatal dopamine 
levels but not alpha-synuclein-induced neuronal cell loss. PLoS One 9: e86048.
McNaught, K.S., Belizaire, R., Isacson, O., Jenner, P. & Olanow, C. W. (2003). Altered proteasomal 
function in sporadic Parkinson’s disease. Exp.Neurol. 179: 38-46.
McNaught, K.S., Björklund, L. M., Belizaire, R., Isacson, O., Jenner, P. & Olanow, C. W. (2002). 
Proteasome inhibition causes nigral degeneration with inclusion bodies in rats. Neuroreport 13: 
1437-41.
McNaught, K.S., Jenner, P. (2001). Proteasomal function is impaired in substantia nigra in Parkin-
son’s disease. Neurosci.Lett. 297: 191-4.
Metcalf, D.J., Garcia-Arencibia, M., Hochfeld, W. E. & Rubinsztein, D. C. (2012). Autophagy and 
misfolded proteins in neurodegeneration. Exp.Neurol. 238: 22-8.
Miracco, C., Cosci, E., Oliveri, G., Luzi, P., Pacenti, L., Monciatti, I., et al. (2007). Protein and mRNA 
expression of autophagy gene Beclin 1 in human brain tumours. Int.J.Oncol. 30: 429-36.
Miyazaki, A., Toide, K., Sasaki, Y., Ichitani, Y. & Iwasaki, T. (1998). Effect of a prolyl endopeptidase 
inhibitor, JTP-4819, on radial maze performance in hippocampal-lesioned rats. Pharmacol.Bio-
chem.Behav. 59: 361-8.
Morain, P., Lestage, P., De Nanteuil, G., Jochemsen, R., Robin, J. L., Guez, D., et al. (2002). S 17092: 
a prolyl endopeptidase inhibitor as a potential therapeutic drug for memory impairment. Preclinical 
and clinical studies. CNS Drug Rev. 8: 31-52.
Morroni, F., Sita, G., Tarozzi, A., Cantelli-Forti, G. & Hrelia, P. (2014). Neuroprotection by 6-(meth-
ylsulfi nyl)hexyl isothiocyanate in a 6-hydroxydopamine mouse model of Parkinsons disease. Brain 
Res. 1589: 93-104.
Murphy, D.D., Rueter, S. M., Trojanowski, J. Q. & Lee, V. M. (2000). Synucleins are developmen-
tally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary 
hippocampal neurons. J.Neurosci. 20: 3214-20.
Myöhänen, T.T., Garcia-Horsman, J. A., Tenorio-Laranga, J. & Männistö, P. T. (2009). Issues about 
the physiological functions of prolyl oligopeptidase based on its discordant spatial association with 
substrates and inconsistencies among mRNA, protein levels, and enzymatic activity. J.Histochem.
Cytochem. 57: 831-48.
Myöhänen, T.T., Hannula, M. J., Van Elzen, R., Gerard, M., Van Der Veken, P., Garcia-Horsman, J. 
A., et al. (2012). A prolyl oligopeptidase inhibitor, KYP-2047, reduces alpha-synuclein protein lev-
els and aggregates in cellular and animal models of Parkinson’s disease. Br.J.Pharmacol.
Myöhänen, T.T., Venäläinen, J. I., Garcia-Horsman, J. A. & Männistö, P. T. (2008). Spatial association 
of prolyl oligopeptidase, inositol 1,4,5-triphosphate type 1 receptor, substance P and its neuroki-
nin-1 receptor in the rat brain: an immunohistochemical colocalization study. Neuroscience 153: 
1177-89.
Myöhänen, T.T., Venäläinen, J. I., Tupala, E., Garcia-Horsman, J. A., Miettinen, R. & Männistö, P. T. 
(2007). Distribution of immunoreactive prolyl oligopeptidase in human and rat brain. Neurochem.
Res. 32: 1365-74.
Nemani, V.M., Lu, W., Berge, V., Nakamura, K., Onoa, B., Lee, M. K., et al. (2010). Increased expres-
sion of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering 
after endocytosis. Neuron 65: 66-79.
Nestler, EJ, Hyman, S & Malenka, R (2009). Molecular neuropharmacology: a foundation for clini-
cal neuroscience. New York: McGraw-Hill Medical.
References
89
Neumann, M., Kahle, P. J., Giasson, B. I., Ozmen, L., Borroni, E., Spooren, W., et al. (2002). Mis-
folded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with 
locomotor deterioration and in human alpha-synucleinopathies. J.Clin.Invest. 110: 1429-39.
Nuber, S., Petrasch-Parwez, E., Winner, B., Winkler, J., von Horsten, S., Schmidt, T., et al. (2008). 
Neurodegeneration and motor dysfunction in a conditional model of Parkinson’s disease. J.Neuro-
sci. 28: 2471-84.
Nuber, S., Tadros, D., Fields, J., Overk, C. R., Ettle, B., Kosberg, K., et al. (2014). Environmental 
neurotoxic challenge of conditional alpha-synuclein transgenic mice predicts a dopaminergic olfac-
tory-striatal interplay in early PD. Acta Neuropathol. 127: 477-94.
Nykänen, N.P., Kysenius, K., Sakha, P., Tammela, P. & Huttunen, H. J. (2012). gamma-Aminobutyric 
acid type A (GABAA) receptor activation modulates tau phosphorylation. J.Biol.Chem. 287: 6743-
52.
Okochi, M. (2000). Constitutive phosphorylation of the Parkinson’s disease-associated alpha-synu-
clein. J.Biol.Chem. 275: 390-7.
Oliveras-Salva, M., Van der Perren, A., Casadei, N., Stroobants, S., Nuber, S., D’Hooge, R., et al. 
(2013). rAAV2/7 vector-mediated overexpression of alpha-synuclein in mouse substantia nigra in-
duces protein aggregation and progressive dose-dependent neurodegeneration. Mol.Neurodegener 
8: 44,1326-8-44.
Ono, K., Ikemoto, M., Kawarabayashi, T., Ikeda, M., Nishinakagawa, T., Hosokawa, M., et al. (2009). 
A chemical chaperone, sodium 4-phenylbutyric acid, attenuates the pathogenic potency in human 
alpha-synuclein A30P + A53T transgenic mice. Parkinsonism Relat.Disord. 15: 649-54.
Osterberg, V.R., Spinelli, K. J., Weston, L. J., Luk, K. C., Woltjer, R. L. & Unni, V. K. (2015). Progres-
sive aggregation of alpha-synuclein and selective degeneration of lewy inclusion-bearing neurons 
in a mouse model of parkinsonism. Cell.Rep. 10: 1252-60.
Ott, M., Robertson, J. D., Gogvadze, V., Zhivotovsky, B. & Orrenius, S. (2002). Cytochrome c release 
from mitochondria proceeds by a two-step process. Proc.Natl.Acad.Sci.U.S.A. 99: 1259-63.
Outeiro, T.F., Kazantsev, A. (2008). Drug Targeting of alpha-Synuclein Oligomerization in Synucle-
inopathies. Perspect.Medicin Chem. 2: 41-9.
Outeiro, T.F., Klucken, J., Bercury, K., Tetzlaff, J., Putcha, P., Oliveira, L. M., et al. (2009). Dopa-
mine-induced conformational changes in alpha-synuclein. PLoS One 4: e6906.
Paik, S.R., Lee, J. H., Kim, D. H., Chang, C. S. & Kim, Y. S. (1998). Self-oligomerization of NACP, 
the precursor protein of the non-amyloid beta/A4 protein (A beta) component of Alzheimer’s dis-
ease amyloid, observed in the presence of a C-terminal A beta fragment (residues 25-35). FEBS 
Lett. 421: 73-6.
Paik, S.R., Shin, H. J., Lee, J. H., Chang, C. S. & Kim, J. (1999). Copper(II)-induced self-oligomeri-
zation of alpha-synuclein. Biochem.J. 340 ( Pt 3): 821-8.
Pan, T., Kondo, S., Zhu, W., Xie, W., Jankovic, J. & Le, W. (2008). Neuroprotection of rapamycin 
in lactacystin-induced neurodegeneration via autophagy enhancement. Neurobiol.Dis. 32: 16-25.
Pan-Montojo, F., Anichtchik, O., Dening, Y., Knels, L., Pursche, S., Jung, R., et al. (2010). Progres-
sion of Parkinson’s disease pathology is reproduced by intragastric administration of rotenone in 
mice. PLoS One 5: e8762.
Parihar, M.S., Parihar, A., Fujita, M., Hashimoto, M. & Ghafourifar, P. (2009). Alpha-synuclein over-
expression and aggregation exacerbates impairment of mitochondrial functions by augmenting ox-
idative stress in human neuroblastoma cells. Int.J.Biochem.Cell Biol. 41: 2015-24.
Parihar, M.S., Parihar, A., Fujita, M., Hashimoto, M. & Ghafourifar, P. (2008). Mitochondrial associ-
ation of alpha-synuclein causes oxidative stress. Cell Mol.Life Sci. 65: 1272-84.
References
90
Parkinson, J. (1817). An essay on the shaking palsy. Sherwood, Neely and Jones, London
Parys, J.B., Decuypere, J. P. & Bultynck, G. (2012). Role of the inositol 1,4,5-trisphosphate receptor/
Ca2+-release channel in autophagy. Cell.Commun.Signal. 10: 17,811X-10-17.
Paxinou, E., Chen, Q., Weisse, M., Giasson, B. I., Norris, E. H., Rueter, S. M., et al. (2001). Induction 
of alpha-synuclein aggregation by intracellular nitrative insult. J.Neurosci. 21: 8053-61.
Peltonen, I., Myöhänen, T. T. & Männistö, P. T. (2011). Association of prolyl oligopeptidase with 
conventional neurotransmitters in the brain. CNS Neurol.Disord.Drug Targets 10: 311-8.
Peng, X., Tehranian, R., Dietrich, P., Stefanis, L. & Perez, R. G. (2005). Alpha-synuclein activation 
of protein phosphatase 2A reduces tyrosine hydroxylase phosphorylation in dopaminergic cells. 
J.Cell.Sci. 118: 3523-30.
Perez, R.G., Waymire, J. C., Lin, E., Liu, J. J., Guo, F. & Zigmond, M. J. (2002). A role for alpha-sy-
nuclein in the regulation of dopamine biosynthesis. J.Neurosci. 22: 3090-9.
Perrin, R.J., Woods, W. S., Clayton, D. F. & George, J. M. (2000). Interaction of human alpha-synu-
clein and Parkinson’s disease variants with phospholipids. J.Biol.Chem. 275: 34393-8.
Petit, A., Barelli, H., Morain, P. & Checler, F. (2000). Novel proline endopeptidase inhibitors do not 
modify Abeta40/42 formation and degradation by human cells expressing wild-type and swedish 
mutated beta-amyloid precursor protein. Br.J.Pharmacol. 130: 1613-7.
Pham, C.L., Leong, S. L., Ali, F. E., Kenche, V. B., Hill, A. F., Gras, S. L., et al. (2009). Dopamine and 
the dopamine oxidation product 5,6-dihydroxylindole promote distinct on-pathway and off-path-
way aggregation of alpha-synuclein in a pH-dependent manner. J.Mol.Biol. 387: 771-85.
Pickart, C.M. (2000). Ubiquitin in chains. Trends Biochem.Sci. 25: 544-8.
Plaas, M., Karis, A., Innos, J., Rebane, E., Baekelandt, V., Vaarmann, A., et al. (2008). Alpha-sy-
nuclein A30P point-mutation generates age-dependent nigrostriatal defi ciency in mice. J.Physiol.
Pharmacol. 59: 205-16.
Polymeropoulos, M.H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., et al. (1997). Mu-
tation in the alpha-synuclein gene identifi ed in families with Parkinson’s disease. Science 276: 
2045-7.
Proukakis, C., Dudzik, C. G., Brier, T., MacKay, D. S., Cooper, J. M., Millhauser, G. L., et al. (2013). 
A novel alpha-synuclein missense mutation in Parkinson disease. Neurology 80: 1062-4.
Rapti, K., Louis-Jeune, V., Kohlbrenner, E., Ishikawa, K., Ladage, D., Zolotukhin, S., et al. (2012). 
Neutralizing antibodies against AAV serotypes 1, 2, 6, and 9 in sera of commonly used animal 
models. Mol.Ther. 20: 73-83.
Rasia, R.M., Bertoncini, C. W., Marsh, D., Hoyer, W., Cherny, D., Zweckstetter, M., et al. (2005). 
Structural characterization of copper(II) binding to alpha-synuclein: Insights into the bioinorganic 
chemistry of Parkinson’s disease. Proc.Natl.Acad.Sci.U.S.A. 102: 4294-9.
Recasens, A., Dehay, B., Bove, J., Carballo-Carbajal, I., Dovero, S., Perez-Villalba, A., et al. (2014). 
Lewy body extracts from Parkinson disease brains trigger alpha-synuclein pathology and neurode-
generation in mice and monkeys. Ann.Neurol. 75: 351-62.
Reith, M.E., Xu, C. & Chen, N. H. (1997). Pharmacology and regulation of the neuronal dopamine 
transporter. Eur.J.Pharmacol. 324: 1-10.
Reyes, J.F., Rey, N. L., Bousset, L., Melki, R., Brundin, P. & Angot, E. (2014). Alpha-synuclein trans-
fers from neurons to oligodendrocytes. Glia 62: 387-98.
Richter, F., Hamann, M. & Richter, A. (2007). Chronic rotenone treatment induces behavioral effects 
but no pathological signs of parkinsonism in mice. J.Neurosci.Res. 85: 681-91.
References
91
Rideout, H.J., Larsen, K. E., Sulzer, D. & Stefanis, L. (2001). Proteasomal inhibition leads to for-
mation of ubiquitin/alpha-synuclein-immunoreactive inclusions in PC12 cells. J.Neurochem. 78: 
899-908.
Rockenstein, E., Mallory, M., Hashimoto, M., Song, D., Shults, C. W., Lang, I., et al. (2002). Differ-
ential neuropathological alterations in transgenic mice expressing alpha-synuclein from the plate-
let-derived growth factor and Thy-1 promoters. J.Neurosci.Res. 68: 568-78.
Rockenstein, E., Nuber, S., Overk, C. R., Ubhi, K., Mante, M., Patrick, C., et al. (2014). Accumu-
lation of oligomer-prone alpha-synuclein exacerbates synaptic and neuronal degeneration in vivo. 
Brain 137: 1496-513.
Rockenstein, E., Schwach, G., Ingolic, E., Adame, A., Crews, L., Mante, M., et al. (2005). Lysosomal 
pathology associated with alpha-synuclein accumulation in transgenic models using an eGFP fu-
sion protein. J.Neurosci.Res. 80: 247-59.
Rutherford, N.J., Moore, B. D., Golde, T. E. & Giasson, B. I. (2014). Divergent effects of the H50Q 
and G51D SNCA mutations on the aggregation of alpha-synuclein. J.Neurochem. 131: 859-67.
Salin, P., Manrique, C., Forni, C. & Kerkerian-Le Goff, L. (2002). High-frequency stimulation of 
the subthalamic nucleus selectively reverses dopamine denervation-induced cellular defects in the 
output structures of the basal ganglia in the rat. J.Neurosci. 22: 5137-48.
Sampathu, D.M., Giasson, B. I., Pawlyk, A. C., Trojanowski, J. Q. & Lee, V. M. (2003). Ubiquitina-
tion of alpha-synuclein is not required for formation of pathological inclusions in alpha-synucle-
inopathies. Am.J.Pathol. 163: 91-100.
Savolainen, M.H., Richie, C. T., Harvey, B. K., Männistö, P. T., Maguire-Zeiss, K. A. & Myöhänen, T. 
T. (2014). The benefi cial effect of a prolyl oligopeptidase inhibitor, KYP-2047, on alpha-synuclein 
clearance and autophagy in A30P transgenic mouse. Neurobiol.Dis. 68: 1-15.
Schapira, A.H. (2015). Glucocerebrosidase and Parkinson disease: Recent advances. Mol.Cell.Neu-
rosci. 66: 37-42.
Schmidt, F., Levin, J., Kamp, F., Kretzschmar, H., Giese, A. & Botzel, K. (2012). Single-channel elec-
trophysiology reveals a distinct and uniform pore complex formed by alpha-synuclein oligomers in 
lipid membranes. PLoS One 7: e42545.
Schneeberger, A., Mandler, M., Mattner, F. & Schmidt, W. (2012). Vaccination for Parkinson’s dis-
ease. Parkinsonism Relat.Disord. 18 Suppl 1: S11-3.
Schober, A. (2004). Classic toxin-induced animal models of Parkinson’s disease: 6-OHDA and MPTP. 
Cell Tissue Res. 318: 215-24.
Schulz, I., Zeitschel, U., Rudolph, T., Ruiz-Carrillo, D., Rahfeld, J. U., Gerhartz, B., et al. (2005). 
Subcellular localization suggests novel functions for prolyl endopeptidase in protein secretion. 
J.Neurochem. 94: 970-9.
Serpell, L.C., Berriman, J., Jakes, R., Goedert, M. & Crowther, R. A. (2000). Fiber diffraction of 
synthetic alpha-synuclein fi laments shows amyloid-like cross-beta] conformation. Proc.Natl.Acad.
Sci.USA 97: 4897-902.
Shen, Y.F., Tang, Y., Zhang, X. J., Huang, K. X. & Le, W. D. (2013). Adaptive changes in autophagy 
after UPS impairment in Parkinson’s disease. Acta Pharmacol.Sin. 34: 667-73.
Shimshek, D.R., Mueller, M., Wiessner, C., Schweizer, T. & van der Putten, P. H. (2010). The HSP70 
molecular chaperone is not benefi cial in a mouse model of alpha-synucleinopathy. PLoS One 5: 
e10014.
Shimura, H., Schlossmacher, M. G., Hattori, N., Frosch, M. P., Trockenbacher, A., Schneider, R., et al. 
(2001). Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications 
for Parkinson’s disease. Science 293: 263-9.
References
92
Shinoda, M., Toide, K., Ohsawa, I. & Kohsaka, S. (1997). Specifi c inhibitor for prolyl endopeptidase 
suppresses the generation of amyloid beta protein in NG108-15 cells. Biochem.Biophys.Res.Com-
mun. 235: 641-5.
Shishido, Y., Furushiro, M., Tanabe, S., Taniguchi, A., Hashimoto, S., Yokokura, T., et al. (1998). Ef-
fect of ZTTA, a prolyl endopeptidase inhibitor, on memory impairment in a passive avoidance test 
of rats with basal forebrain lesions. Pharm.Res. 15: 1907-10.
Silva, R.M., Ries, V., Oo, T. F., Yarygina, O., Jackson-Lewis, V., Ryu, E. J., et al. (2005). CHOP/
GADD153 is a mediator of apoptotic death in substantia nigra dopamine neurons in an in vivo 
neurotoxin model of parkinsonism. J.Neurochem. 95: 974-86.
Simuni, T., Sethi, K. (2008). Nonmotor manifestations of Parkinson’s disease. Ann.Neurol. 64 Suppl 
2: S65-80.
Singleton, A.B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., et al. (2003). Al-
pha-Synuclein locus triplication causes Parkinson’s disease. Science 302: 841.
Smith, W.W., Jiang, H., Pei, Z., Tanaka, Y., Morita, H., Sawa, A., et al. (2005). Endoplasmic reticu-
lum stress and mitochondrial cell death pathways mediate A53T mutant alpha-synuclein-induced 
toxicity. Hum.Mol.Genet. 14: 3801-11.
Snyder, H., Mensah, K., Theisler, C., Lee, J., Matouschek, A. & Wolozin, B. (2003). Aggregated and 
monomeric alpha-synuclein bind to the S6’ proteasomal protein and inhibit proteasomal function. 
J.Biol.Chem. 278: 11753-9.
Spencer, B., Potkar, R., Trejo, M., Rockenstein, E., Patrick, C., Gindi, R., et al. (2009). Beclin 1 gene 
transfer activates autophagy and ameliorates the neurodegenerative pathology in alpha-synuclein 
models of Parkinson’s and Lewy body diseases. J.Neurosci. 29: 13578-88.
Spillantini, M.G. (1997). Alpha-synuclein in Lewy bodies. Nature 388: 839-40.
Spillantini, M.G., Crowther, R. A., Jakes, R., Hasegawa, M. & Goedert, M. (1998). Alpha-Synuclein 
in fi lamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with lewy bodies. 
Proc.Natl.Acad.Sci.U.S.A. 95: 6469-73.
Spillantini, M.G., Goedert, M. (2000). The alpha-synucleinopathies: Parkinson’s disease, dementia 
with Lewy bodies, and multiple system atrophy. Ann.N.Y.Acad.Sci. 920: 16-27.
St Martin, J.L., Klucken, J., Outeiro, T. F., Nguyen, P., Keller-McGandy, C., Cantuti-Castelvetri, I., 
et al. (2007). Dopaminergic neuron loss and up-regulation of chaperone protein mRNA induced by 
targeted over-expression of alpha-synuclein in mouse substantia nigra. J.Neurochem. 100: 1449-57.
Südhof, T.C. (1995). The synaptic vesicle cycle: a cascade of protein-protein interactions. Nature 375: 
645-53.
Sung, J.Y., Park, S. M., Lee, C. H., Um, J. W., Lee, H. J., Kim, J., et al. (2005). Proteolytic cleavage of 
extracellular secreted alpha-synuclein via matrix metalloproteinases. J.Biol.Chem. 280: 25216-24.
Surguchov, A. (2008). Molecular and cellular biology of synucleins. Int.Rev.Cell.Mol.Biol. 270: 225-
317.
Swant, J., Goodwin, J. S., North, A., Ali, A. A., Gamble-George, J., Chirwa, S., et al. (2011). Al-
pha-Synuclein stimulates a dopamine transporter-dependent chloride current and modulates the 
activity of the transporter. J.Biol.Chem. 286: 43933-43.
Szeltner, Z., Juhasz, T., Szamosi, I., Rea, D., Fülop, V., Modos, K., et al. (2013). The loops facing 
the active site of prolyl oligopeptidase are crucial components in substrate gating and specifi city. 
Biochim.Biophys.Acta 1834: 98-111.
Szeltner, Z., Morawski, M., Juhasz, T., Szamosi, I., Liliom, K., Csizmok, V., et al. (2010). GAP43 




Takeda, A., Mallory, M., Sundsmo, M., Honer, W., Hansen, L. & Masliah, E. (1998). Abnormal ac-
cumulation of NACP/alpha-synuclein in neurodegenerative disorders. Am.J.Pathol. 152: 367-72.
Takeuchi, H., Yanagida, T., Inden, M., Takata, K., Kitamura, Y., Yamakawa, K., et al. (2009). Nic-
otinic receptor stimulation protects nigral dopaminergic neurons in rotenone-induced Parkinson’s 
disease models. J.Neurosci.Res. 87: 576-85.
Tanaka, Y., Engelender, S., Igarashi, S., Rao, R. K., Wanner, T., Tanzi, R. E., et al. (2001). Inducible 
expression of mutant α-synuclein decreases proteasome activity and increases sensitivity to mito-
chondria-dependent apoptosis. Human Molecular Genetics 10: 919-26.
Tanik, S.A., Schultheiss, C. E., Volpicelli-Daley, L. A., Brunden, K. R. & Lee, V. M. (2013). Lewy 
body-like alpha-synuclein aggregates resist degradation and impair macroautophagy. J.Biol.Chem. 
288: 15194-210.
Tarrago, T., Martin-Benito, J., Sabido, E., Claasen, B., Madurga, S., Gairi, M., et al. (2009). A new 
side opening on prolyl oligopeptidase revealed by electron microscopy. FEBS Lett. 583: 3344-8.
Tehranian, R., Montoya, S. E., Van Laar, A. D., Hastings, T. G. & Perez, R. G. (2006). Alpha-synu-
clein inhibits aromatic amino acid decarboxylase activity in dopaminergic cells. J.Neurochem. 99: 
1188-96.
Tenreiro, S., Reimao-Pinto, M. M., Antas, P., Rino, J., Wawrzycka, D., Macedo, D., et al. (2014). 
Phosphorylation modulates clearance of alpha-synuclein inclusions in a yeast model of Parkinson’s 
disease. PLoS Genet. 10: e1004302.
Theodore, S., Cao, S., McLean, P. J. & Standaert, D. G. (2008). Targeted overexpression of human 
alpha-synuclein triggers microglial activation and an adaptive immune response in a mouse model 
of Parkinson disease. J.Neuropathol.Exp.Neurol. 67: 1149-58.
Tofaris, G.K., Garcia Reitbock, P., Humby, T., Lambourne, S. L., O’Connell, M., Ghetti, B., et al. 
(2006). Pathological changes in dopaminergic nerve cells of the substantia nigra and olfactory bulb 
in mice transgenic for truncated human alpha-synuclein(1-120): implications for Lewy body disor-
ders. J.Neurosci. 26: 3942-50.
Tofaris, G.K., Layfi eld, R. & Spillantini, M. G. (2001). Alpha-Synuclein Metabolism and Aggrega-
tion is Linked to Ubiquitin-Independent Degradation by the Proteasome. FEBS Lett. 509: 22-6.
Tofaris, G.K., Razzaq, A., Ghetti, B., Lilley, K. S. & Spillantini, M. G. (2003). Ubiquitination of al-
pha-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome 
function. J.Biol.Chem. 278: 44405-11.
Toide, K., Iwamoto, Y., Fujiwara, T. & Abe, H. (1995). JTP-4819: a novel prolyl endopeptidase inhib-
itor with potential as a cognitive enhancer. J.Pharmacol.Exp.Ther. 274: 1370-8.
Toide, K., Shinoda, M., Fujiwara, T. & Iwamoto, Y. (1997). Effect of a novel prolyl endopeptidase 
inhibitor, JTP-4819, on spatial memory and central cholinergic neurons in aged rats. Pharmacol.
Biochem.Behav. 56: 427-34.
Tsigelny, I.F., Bar-On, P., Sharikov, Y., Crews, L., Hashimoto, M., Miller, M. A., et al. (2007). Dy-
namics of alpha-synuclein aggregation and inhibition of pore-like oligomer development by be-
ta-synuclein. FEBS J. 274: 1862-77.
Tsigelny, I.F., Sharikov, Y., Wrasidlo, W., Gonzalez, T., Desplats, P. A., Crews, L., et al. (2012). Role 
of alpha-synuclein penetration into the membrane in the mechanisms of oligomer pore formation. 
FEBS J. 279: 1000-13.
Tu, P.-. (1998). Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system 
atrophy brains contain insoluble alpha-synuclein. Ann.Neurol. 44: 415-22.
Ueda, K. (1993). Molecular cloning of cDNA encoding an unrecognized component of amyloid in 
Alzheimer disease. Proc.Natl.Acad.Sci.USA 90: 11282-6.
References
94
Uversky, V.N. (2007). Neuropathology, biochemistry, and biophysics of alpha-synuclein aggregation. 
J.Neurochem. 103: 17-37.
Uversky, V.N. (2004). Neurotoxicant-induced animal models of Parkinson’s disease: understanding 
the role of rotenone, maneb and paraquat in neurodegeneration. Cell Tissue Res. 318: 225-41.
Uversky, V.N., Li, J. & Fink, A. K. (2001a). Evidence for a partially folded intermediate in alpha-sy-
nuclein fi bril formation. J.Biol.Chem. 276: 10737-44.
Uversky, V.N., Li, J. & Fink, A. L. (2001b). Pesticides directly accelerate the rate of alpha-synuclein 
fi bril formation: a possible factor in Parkinson’s disease. FEBS Lett. 500: 105-8.
Uversky, V.N., Yamin, G., Munishkina, L. A., Karymov, M. A., Millett, I. S., Doniach, S., et al. 
(2005). Effects of nitration on the structure and aggregation of alpha-synuclein. Brain Res.Mol.
Brain Res. 134: 84-102.
Uversky, V.N., Yamin, G., Souillac, P. O., Goers, J., Glaser, C. B. & Fink, A. L. (2002). Methionine 
oxidation inhibits fi brillation of human alpha-synuclein in vitro. FEBS Lett. 517: 239-44.
Valera, E., Masliah, E. (2013). Immunotherapy for neurodegenerative diseases: focus on alpha-synu-
cleinopathies. Pharmacol.Ther. 138: 311-22.
van de Berg, W.D., Hepp, D. H., Dijkstra, A. A., Rozemuller, J. A., Berendse, H. W. & Foncke, E. 
(2012). Patterns of alpha-synuclein pathology in incidental cases and clinical subtypes of Parkin-
son’s disease. Parkinsonism Relat.Disord. 18 Suppl 1: S28-30.
van der Putten, H., Wiederhold, K. H., Probst, A., Barbieri, S., Mistl, C., Danner, S., et al. (2000). 
Neuropathology in mice expressing human alpha-synuclein. J.Neurosci. 20: 6021-9.
Van der Veken, P., Fülop, V., Rea, D., Gerard, M., Van Elzen, R., Joossens, J., et al. (2012). P2-sub-
stituted N-acylprolylpyrrolidine inhibitors of prolyl oligopeptidase: biochemical evaluation, bind-
ing mode determination, and assessment in a cellular model of synucleinopathy. J.Med.Chem. 55: 
9856-67.
Vernon, A.C., Crum, W. R., Johansson, S. M. & Modo, M. (2011). Evolution of extra-nigral damage 
predicts behavioural defi cits in a rat proteasome inhibitor model of Parkinson’s disease. PLoS One 
6: e17269.
Vilchez, D., Saez, I. & Dillin, A. (2014). The role of protein clearance mechanisms in organismal 
ageing and age-related diseases. Nat.Commun. 5: 5659.
Vogiatzi, T., Xilouri, M., Vekrellis, K. & Stefanis, L. (2008). Wild type alpha-synuclein is degraded by 
chaperone-mediated autophagy and macroautophagy in neuronal cells. J.Biol.Chem. 283: 23542-
56.
Volpicelli-Daley, L.A., Luk, K. C., Patel, T. P., Tanik, S. A., Riddle, D. M., Stieber, A., et al. (2011). 
Exogenous alpha-synuclein fi brils induce Lewy body pathology leading to synaptic dysfunction 
and neuron death. Neuron 72: 57-71.
Wakabayashi, K., Tanji, K., Mori, F. & Takahashi, H. (2007). The Lewy body in Parkinson’s disease: 
molecules implicated in the formation and degradation of alpha-synuclein aggregates. Neuropa-
thology 27: 494-506.
Wakamatsu, M., Ishii, A., Iwata, S., Sakagami, J., Ukai, Y., Ono, M., et al. (2008). Selective loss of 
nigral dopamine neurons induced by overexpression of truncated human alpha-synuclein in mice. 
Neurobiol.Aging 29: 574-85.
Wang, J., Martin, E., Gonzales, V., Borchelt, D. R. & Lee, M. K. (2008). Differential regulation of 




Wang, Y., Zhang, Q. J., Liu, J., Ali, U., Gui, Z. H., Hui, Y. P., et al. (2010). Changes in fi ring rate and 
pattern of GABAergic neurons in subregions of the substantia nigra pars reticulata in rat models of 
Parkinson’s disease. Brain Res. 1324: 54-63.
Watanabe, Y., Tatebe, H., Taguchi, K., Endo, Y., Tokuda, T., Mizuno, T., et al. (2012). p62/SQSTM1-de-
pendent autophagy of Lewy body-like alpha-synuclein inclusions. PLoS One 7: e52868.
Webb, J.L., Ravikumar, B., Atkins, J., Skepper, J. N. & Rubinsztein, D. C. (2003). Alpha-Synuclein is 
degraded by both autophagy and the proteasome. J.Biol.Chem. 278: 25009-13.
Weinreb, P.H., Zhen, W., Poon, A. W., Conway, K. A. & Lansbury, P. T.,Jr (1996). NACP, a protein 
implicated in Alzheimer’s disease and learning, is natively unfolded. Biochemistry 35: 13709-15.
Wersinger, C., Prou, D., Vernier, P., Niznik, H. B. & Sidhu, A. (2003). Mutations in the lipid-binding 
domain of alpha-synuclein confer overlapping, yet distinct, functional properties in the regulation 
of dopamine transporter activity. Mol.Cell.Neurosci. 24: 91-105.
Wersinger, C., Sidhu, A. (2005). Disruption of the interaction of alpha-synuclein with microtubules 
enhances cell surface recruitment of the dopamine transporter. Biochemistry 44: 13612-24.
Williams, R.S., Eames, M., Ryves, W. J., Viggars, J. & Harwood, A. J. (1999). Loss of a prolyl oli-
gopeptidase confers resistance to lithium by elevation of inositol (1,4,5) trisphosphate. EMBO J. 
18: 2734-45.
Wills, J., Credle, J., Oaks, A. W., Duka, V., Lee, J. H., Jones, J., et al. (2012). Paraquat, but not maneb, 
induces synucleinopathy and tauopathy in striata of mice through inhibition of proteasomal and 
autophagic pathways. PLoS One 7: e30745.
Winner, B., Jappelli, R., Maji, S. K., Desplats, P. A., Boyer, L., Aigner, S., et al. (2011). In vivo 
demonstration that alpha-synuclein oligomers are toxic. Proc.Natl.Acad.Sci.U.S.A. 108: 4194-9.
Winslow, A.R., Chen, C. W., Corrochano, S., Acevedo-Arozena, A., Gordon, D. E., Peden, A. A., et 
al. (2010). Alpha-Synuclein impairs macroautophagy: implications for Parkinson’s disease. J.Cell 
Biol. 190: 1023-37.
Wirdefeldt, K., Adami, H. O., Cole, P., Trichopoulos, D. & Mandel, J. (2011). Epidemiology and eti-
ology of Parkinson’s disease: a review of the evidence. Eur.J.Epidemiol. 26 Suppl 1: S1-58.
Wood, S.J. (1999). Alpha-synuclein fi brillogenesis is nucleation-dependent. J.Biol.Chem. 274: 
19509-12.
Wu, J., Lou, H., Alerte, T. N., Stachowski, E. K., Chen, J., Singleton, A. B., et al. (2012). Lewy-like 
aggregation of alpha-synuclein reduces protein phosphatase 2A activity in vitro and in vivo. Neu-
roscience 207: 288-97.
Wu, N., Joshi, P. R., Cepeda, C., Masliah, E. & Levine, M. S. (2010). Alpha-synuclein overexpression 
in mice alters synaptic communication in the corticostriatal pathway. J.Neurosci.Res. 88: 1764-76.
Xilouri, M., Brekk, O. R., Kirik, D. & Stefanis, L. (2013). LAMP2A as a therapeutic target in Parkin-
son disease. Autophagy 9: 2166-8.
Xilouri, M., Vogiatzi, T., Vekrellis, K., Park, D. & Stefanis, L. (2009). Abberant alpha-synuclein 
confers toxicity to neurons in part through inhibition of chaperone-mediated autophagy. PLoS One 
4: e5515.
Yavich, L., Oksman, M., Tanila, H., Kerokoski, P., Hiltunen, M., van Groen, T., et al. (2005). Loco-
motor activity and evoked dopamine release are reduced in mice overexpressing A30P-mutated 
human alpha-synuclein. Neurobiol.Dis. 20: 303-13.
Yavich, L., Tanila, H., Vepsalainen, S. & Jäkälä, P. (2004). Role of alpha-synuclein in presynaptic 
dopamine recruitment. J.Neurosci. 24: 11165-70.
References
96
Yorimitsu, T., Klionsky, D. J. (2005). Autophagy: molecular machinery for self-eating. Cell Death 
Differ. 12 Suppl 2: 1542-52.
Zarranz, J.J., Alegre, J., Gomez-Esteban, J. C., Lezcano, E., Ros, R., Ampuero, I., et al. (2004). The 
new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann.Neurol. 
55: 164-73.
Zhang, X., Xie, W., Qu, S., Pan, T., Wang, X. & Le, W. (2005). Neuroprotection by iron chelator 
against proteasome inhibitor-induced nigral degeneration. Biochem.Biophys.Res.Commun. 333: 
544-9.
Zhou, R.M., Huang, Y. X., Li, X. L., Chen, C., Shi, Q., Wang, G. R., et al. (2010). Molecular interac-
tion of alpha-synuclein with tubulin infl uences on the polymerization of microtubule in vitro and 
structure of microtubule in cells. Mol.Biol.Rep. 37: 3183-92.
Zhu, W., Xie, W., Pan, T., Xu, P., Fridkin, M., Zheng, H., et al. (2007). Prevention and restoration 
of lactacystin-induced nigrostriatal dopamine neuron degeneration by novel brain-permeable iron 
chelators. FASEB J. 21: 3835-44.
 
References
The Effects of Prolyl Oligopeptidase Inhibition in 
α-Synuclein Based Mouse Models of Parkinson’s 
Disease
DIVISION OF PHARMACOLOGY AND PHARMACOTHERAPY
FACULTY OF PHARMACY
DOCTORAL PROGRAMME IN DRUG RESEARCH
UNIVERSITY OF HELSINKI
MARI SAVOLAINEN
DISSERTATIONES SCHOLAE DOCTORALIS AD SANITATEM INVESTIGANDAM
UNIVERSITATIS HELSINKIENSIS 80/2015
80/2015









































Recent Publications in this Series
60/2015 Chakravarthi Kanduri
Genomics Approaches to Study Music Perception and Performance
61/2015 Jussi Kupari
Studies on Peripheral Nervous System Development and Function in Mice Defi cient for the 
Neurturin Receptor GFRα2
62/2015 Anton Tokariev
Studying Connectivity in the Neonatal EEG
63/2015 Eva María del Amo Páez
Computational Prediction and Pharmacokinetic Simulations for Drug Discovery and 
Development
64/2015 Reija Silvennoinen
Physiological Modulation of the Reverse Cholesterol Transport Pathway in vivo
65/2015 Heli Venhoranta
Inherited Developmental Diseases Related to Reproductive Failures in Cattle
66/2015 Juhana Rautiola
Angiogenesis Inhibitors in Metastatic Renal Cancer with Emphasis on Prognostic Clinical and 
Molecular Factors
67/2015 Terhi Peuralinna
Genetics of Neurodegeneration: Alzheimer, Lewy Body and Motor Neuron Diseases in the 
Finnish Population
68/2015 Manuela Tumiati
Rad51c is a Tumor Suppressor in Mammary and Sebaceous Glands
69/2015 Mikko Helenius
Role of Purinergic Signaling in Pathological Pulmonary Vascular Remodeling
70/2015 Kaisa Rajakylä
The Nuclear Import Mechanism of SRF Co-Activator MKL1
71/2015 Johanna Lotsari-Salomaa
Epigenetic Characteristics of Lynch Syndrome-Associated and Sporadic Tumorigenesis
72/2015 Tea Pemovska
Individualized Chemical Systems Medicine of Acute and Chronic Myeloid Leukemia
73/2015 Simona Bramante
Oncolytic Adenovirus Coding for GM-CSF in Treatment of Cancer
74/2015 Alhadi Almangush
Histopathological Predictors of Early Stage Oral Tongue Cancer
75/2015 Otto Manninen
Imaging Studies in the Mouse Model of Progressive Myoclonus Epilepsy of Unverricht-Lundborg 
Type, EPM1
76/2015 Mordekhay Medvedovsky
Methodological and Clinical Aspects of Ictal and Interictal MEG
77/2015 Marika Melamies
Studies on Canine Lower Respiratory Tract with Special Reference to 
Inhaled Corticosteroids
78/2015 Elina Välimäki
Activation of Infl ammasome and Protein Secretion by Endogenous Danger 
and Microbe-Derived Signals in Human Macrophages
79/2015 Terhi Keltanen
Postmortem Biochemistry - Analysis of Metabolic Imbalance
